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Pancreatic cancer remains a major unsolved health problem, with conventional 
cancer treatments having little impact on disease course. The objective of this thesis is to 
create innovative tools to better understand and improve chemotherapeutic treatment of 
pancreatic cancer. Towards this end, nanosystems were designed with a dual purpose: to 
carry chemotherapeutic drugs and act as photoacoustic imaging contrast agents. The 
overarching hypothesis is that these nanosystems can provide enhanced therapy for 
pancreatic cancer and enable visualization of drug delivery. Demonstrated in this 
dissertation is the design, synthesis, and characterization of two such nanosystems built to 
carry the chemotherapeutic agent gemcitabine while acting as a photoacoustic imaging 
contrast agent. The nanosystems were also shown to be multifunctional with possible 
application as photothermal therapy agents and cellular functional sensors. Although 
future research is required to fully investigate the clinical potential of these systems for 
pancreatic cancer, the work presented in this dissertation is a step towards creation of 
multifunctional nanosystems that will enable non-invasive, in vivo photoacoustic imaging 
of drug delivery. 
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Chapter 1: Introduction 
Pancreatic cancer remains a major unsolved health problem, with conventional 
cancer treatments having little impact on disease course. In 2010 an estimated 43,100 
people will be diagnosed with pancreatic cancer.1 Tragically, 36,800 people are expected 
to die from pancreatic adenocarcinoma in 2010, putting the yearly death rate painfully 
close to its incidence.1, 2 In the United States, for men and women alike, pancreatic cancer 
represents the 4th leading cause of cancer-related deaths.2 In fact, for all stages of 
pancreatic cancer combined, the 5 year survival rate remains at a low 5%, making it 
arguably the most lethal of all solid tumors.3 In addition, the number of patients 
diagnosed with pancreatic cancer each year is rising;4 this increase is in contrast to other 
diseases such as colorectal cancer, where a decrease in incidences can be attributed to 
investments in early detection.5 It is clear that novel treatment and early detection 
methods are needed for pancreatic cancer.  
The overarching hypothesis of this work is that nanosystems designed to be dual 
drug delivery and imaging contrast vehicles can provide enhanced therapy for pancreatic 
cancer and enable visualization of that drug delivery. The nanosystems that are designed, 
synthesized, and discussed in this dissertation are novel and patented.6 Throughout this 
work, the prospect of using these nanosystems in conjunction with photoacoustic imaging 
techniques in pre-clinical settings is evaluated.   
This introductory chapter outlines the current clinical treatment and imaging 
strategies for pancreatic cancer, introduces how nanotechnology can be incorporated with 
existing and future treatment and imaging techniques, and finally provides overall 
research goals for this dissertation. 
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1.1 PANCREATIC CANCER: ANATOMY, RISK FACTORS, AND SYMPTOMS 
The pancreas is a gland that serves two main functions: it produces hormones, 
such as insulin, which are needed to use or store energy coming from food; and it 
produces enzymes, specifically digestive enzymes that are released through a system of 
ducts to the duodenum (the first part of the small intestine).  As shown in Fig. 1.1, the 
pancreas is shaped like a six-inch long flat pear where its widest section represents the 
head, the middle is the body, and the thinnest section is the tail.  The majority of 
pancreatic adenocarcinomas are 3 cm in diameter upon diagnosis7 and present in the head 
of the pancreas. 
Currently no routine screening for pancreatic cancer is performed in the United 
States, although several risk factors have been identified.8 As with many cancers, 
smoking and age are the major risk factors, with pancreatic cancer being much more 
likely after 60 years of age. Furthermore, race is a factor. Pancreatic cancer is more 
prevalent in the African American population than the white population; however, some 
of this increased risk may be due to socioeconomic factors and to cigarette smoking. 
Diseases involving the pancreas such as chronic pancreatitis and diabetes are also risk 
factors. Interestingly, patients who have had a partial gastrectomy (part of their stomach 
removed) are also at increased risk. Additionally, as many as 10% of pancreatic cancers 
may be related to inherited DNA mutations. Finally, diets high in meats, fried foods, and 
nitrosamines increase the risk for this cancer; while diets high in fruits and vegetables 
decrease the risk.  
Generally, pancreatic cancer symptoms do not present until late stages of disease 
progression. These symptoms are ambiguous at first and include weight loss, fatigue, loss 
of appetite, etc.  Unfortunately, most often it is not until patients present with symptoms 
of jaundice that clinicians are generally triggered to check for pancreatic cancer.  By this 
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time, only 10% of diagnosed patients have a localized tumor.9 The other 30-40% of 
patients have locally advanced disease progression, and the remaining 50-60% have a 
metastatic form.9   
1.1.1 Current Treatment Strategies for Pancreatic Cancer 
Generally, treatment options for pancreatic cancer are surgery, chemotherapy, and 
radiation. In the following paragraphs each treatment option is presented in detail. 
Surgery. Today surgical resection of pancreatic cancer offers the best chance for 
survival.10 Sadly, only 10% of patients diagnosed with localized pancreatic tumors are 
candidates for this procedure.11 Thus for the majority of patients who are diagnosed with 
inoperable tumors due to a locally advanced or metastic form of this disease, treatment 
options include chemotherapy followed by or in conjunction with radiation, if the patient 
is fit.11 Unfortunately, these treatment options only extend the 3-10 month median 
survival range12 by a few months. In some cases chemotherapy is used to shrink 
pancreatic tumors to an operable size,13 and this neoadjuvant therapy has met with 
success in select cases.   
Chemotherapy. Pancreatic carcinoma is inherently resistant to chemotherapeutic 
regimens, either alone or in combinations. The most effective drugs that have formed the 
basis of chemotherapeutic treatment for pancreatic cancer have been 5-fluorouracil (5-
FU) and the more recently approved gemcitabine.3 Current studies focus on biologic 
agents, such as antagonists to the epidermal growth factor receptor (EGFR), farnesyl 
transferase inhibitors, and antiangiogenic agents, and on newer chemotherapeutics. As 
with most chemotherapeutic regimens, treatment involves systemic intravenous 
injections. The concentrations of gemcitabine used per session is dose-limited by its 
cytotoxic effect on healthy bone marrow and epithelial tissue.14 Some hypothesize that 
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the systemic approach is ineffective for most patients because drug concentrations 
accumulated within the tumor itself are not high enough to realize their estimated 
therapeutic potential.15 In response to this issue several solutions have surfaced.  A few 
groups have studied the use of endoscopic ultrasound guided fine needle injections of 
immunotherapies or tumor necrosis factors with gemcitabine directly into inoperable 
pancreatic tumors.16 Shrinkage of the tumor to the point of resection was observed in 
14% of patients in one cross-sectional study.17 Other groups are employing different 
strategies altogether, such as gene therapy.18-20 Yet another strategy involves 
encapsulation of a gemcitabine prodrug in liposomes21 for targeted delivery strategies in 
the future.22   
Radiation therapy. The third conventional treatment, radiation therapy (or 
external beam therapy) has little impact on pancreatic carcinoma. Some advocate 
combining radiation therapy with the radiosensitizing agents and 5-FU or gemcitabine.23 
A number of major oncologic centers recommend using neoadjuvant chemoradiation 
therapy for either all patients with potentially operable disease or for patients with locally 
advanced disease. After finishing this therapy, the patient is restaged, and if the disease 
still appears resectable, pancreatic resection is undertaken.10 Some institutions use 
neoadjuvant chemotherapy and radiation therapy to try to improve the resectability 
potential of locally advanced cancers. Early results are promising10; however, no 
prospective, randomized, controlled trials have been conducted to offer support for this 
approach. 
1.1.2 Need for Imaging to Accurately Stage Pancreatic Cancer 
Diagnosis of pancreatic cancer in late developmental phases is very common as 
early-stage symptoms do not univocally indicate the cause.  Since resection is the 
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preferred first treatment strategy, imaging for staging purposes is equally critical. A 
number of continually evolving imaging modalities are available to help diagnose 
pancreatic carcinoma in patients in whom the disease is suggested clinically. These 
include computed tomography (CT), transcutaneous ultrasonography (TUS), endoscopic 
ultrasonography (EUS), magnetic resonance imaging (MRI), and positron emission 
tomography (PET).24  
Computed tomography (CT). Because of its ubiquitous availability and ability to 
image the whole abdomen and pelvis, abdominal CT scanning is usually the mainstay of 
initial diagnostic modalities used for assessing patients suspected to have pancreatic 
carcinoma. The quality of CT scanners has been rapidly evolving. Unfortunately, 40-50% 
of tumors smaller than 3 cm are missed, and these are the tumors most likely to be 
resectable. Newer models using spiral (i.e., helical) CT scanning with multiple detectors 
and dual-phase contrast enhancement have significantly improved the sensitivity and 
specificity of abdominal CT findings in patients with pancreatic carcinoma. Dual-phase 
spiral CT findings are approximately 80% accurate for helping determine the resectability 
potential of pancreatic carcinoma. However, small tumors can still be missed even with 
the most advanced CT scanning currently available.24  
Transcutaneous ultrasonography (TUS). Even though it is less expensive and 
generally more readily available than CT scanning, TUS has less utility in pancreatic 
carcinoma than CT scanning because the pancreas is often obscured by overlying gas. 
Additionally, the depth of the pancreas from the abdominal wall limits transcutaneous 
ultrasonic imaging to lower frequency (2-5 MHz), and thus, a lower-resolution 
ultrasonographic image is obtained. Therefore, TUS can help detect only 60-70% of 
pancreatic carcinomas, and similar to CT scanning, more than 40% of the lesions smaller 
than 3 cm are missed.  TUS is very useful as an initial screening test in evaluating 
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patients who present with possible obstructive jaundice. By helping to detect intrahepatic 
or extrahepatic bile duct dilation, abdominal ultrasonography can help rapidly and 
accurately assess whether or not a patient has a biliary obstruction. However, other 
studies, such as abdominal CT scanning, EUS, or magnetic resonance 
cholangiopancreatography (MRCP), usually should then be performed to definitively 
diagnose the source of biliary obstruction. 
Endoscopic ultrasonography (EUS). EUS obviates the physical limitations of 
TUS by placing a high-frequency ultrasonographic transducer on an endoscope, which is 
then positioned in the stomach or duodenum endoscopically to help visualize the head, 
body, and tail of the pancreas. Additionally, because of the proximity of the pancreas to 
the EUS transducer, high-frequency ultrasonography (7.5-12 MHz) can be used to 
produce very high-resolution (submillimeter) images. Where EUS is available, it has 
proven to be the most sensitive and specific diagnostic test for pancreatic cancer. In 
numerous series, EUS has detection rates of 99-100% for all pancreatic carcinomas, 
including those smaller than 3 cm. EUS is accurate for assessing the etiology of 
obstructive jaundice. An additional significant diagnostic advantage is EUS-guided fine-
needle aspiration, which allows for the simultaneous cytologic confirmation of pancreatic 
carcinoma at the time of EUS diagnosis. EUS appears to be equivalent to dual-phase 
spiral CT scanning for assessing tumor resectability potential. 
Magnetic resonance imaging (MRI). The role of MRI in pancreatic cancer has 
been less well studied than the role of CT scanning. It does not appear to be superior to 
spiral CT scanning. Because of the difficulty of working within intense magnetic fields, 
MRI is limited by the inability to perform MRI-directed needle aspirations; however, this 
technology is undergoing rapid change. 
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Positron emission tomography (PET). PET scanning uses 18F-
fluorodeoxyglucose (FDG) to image both the primary tumor and metastatic disease.  PET 
scanning can be especially useful in looking for occult metastatic disease. Its role in 
pancreatic cancer evaluation management is still under investigation. False-positive PET 
scans have been reported in patients with pancreatitis.25 
A combination of imaging techniques are generally used to identify, visualize, 
and stage pancreatic cancer. Details of imaging and staging procedures are given below. 
Imaging procedure. Most patients suspected of having pancreatic carcinoma are 
initially studied with TUS and/or spiral CT. If patients have obvious hepatic metastatic 
disease based on initial TUS or CT findings, they undergo an image-guided biopsy of one 
of the liver metastases and then proceed to palliative therapy. Patients with a suggested or 
definite pancreatic mass or those who are still considered to have pancreatic cancer but 
do not have an obvious pancreatic mass need to have more definitive imaging studies. 
These studies are most commonly done using endoscopic ultrasonography – EUS plays a 
central role in the definitive diagnosis and staging of patients with pancreatic carcinoma. 
If a pancreatic mass is observed on EUS images, the patient is staged using EUS to 
determine resectability potential. Patients thought to have resectable tumors based on 
EUS findings proceed directly to operative intervention. If tumors are deemed 
unresectable based on EUS findings, the patients proceed directly to chemotherapy, 
radiation therapy, or both.  
Staging: Once an imaging modality has helped establish a probable diagnosis of 
pancreatic cancer, the next issue is whether the lesion is amenable to surgical resection. 
Only 10% of all patients presenting with pancreatic cancer are ultimately found to have 
easily resectable tumors with no evidence of local advancement. No survival benefit is 
achieved for patients undergoing noncurative resections for pancreatic carcinoma. Thus, 
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to avoid operating on patients who cannot benefit from the operation, accurate 
preoperative staging is very important. Despite our best efforts, however, thousands of 
patients who were thought to be candidates for pancreatectomy, based on imaging results, 
were discovered to have unresectable tumors at surgery. Therefore, improving imaging of 
tumors is critical for clinicians to more accurately assess patient treatment options. 
1.1.3 Endoscopic Ultrasound Imaging of Pancreatic Cancer 
In most clinics a combination of imaging techniques are currently used to 
diagnose and stage pancreatic cancer. One preferred combination uses CT7 to detect the 
presence of a pancreatic cancer mass, and EUS to find and stage small lesions.26, 27 In 
fact, the role of EUS imaging for pancreatic cancer has increased dramatically in recent 
years due to its high sensitivity and ability to detect lesions as small as 2-3 mm.27 
Although EUS shows promise, the images produced by this modality remain difficult to 
read (Fig 1.2). In fact, only endosonographers who have completed over 100 
examinations are generally trusted to stage pancreatic cancer using EUS.28 EUS has only 
70-80% accuracy for correctly staging pancreatic carcinoma.  
Despite its limitations, EUS is a currently well-characterized and trusted clinical 
imaging modality. Part of our overall research goals is to further improve EUS by 
combining endoscopic ultrasound and photoacoustic (EUSPA) imaging to enhance 
imaging contrast which will improve tumor staging accuracy, and ultimately increase 
resectability prediction rates. 
1.2  PHOTOACOUSTIC IMAGING 
EUS currently uses the acoustic contrast between normal and abnormal tissue to 
differentiate between cancerous and normal masses. Optical absorption of tissue is 
another possible contrast mechanism to detect and stage pancreatic cancer. Malignant 
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tumors are associated with higher blood content due to enhanced microvascularization 
inside or around the tumor.29-32 The absorption coefficient of blood equals approximately 
1 to 10 cm-1 in the near-infrared spectral range depending on laser wavelength and the 
level of oxygen saturation in hemoglobin, while background absorption is only about 
0.03-0.05 cm-1 in normal tissue.33, 34 The increased concentration of strongly absorbing 
molecules (hemoglobin and other porphyrins) was shown to yield 2-8 fold optical 
contrast between tumors and normal tissues.35 Furthermore, malignant tumors have 
enhanced and noticeably hypoxic blood content.33, 34 In contrast, benign tumors have a 
normal level of blood oxygenation.36, 37   
Therefore, a technique for remote measurements of tissue optical absorption 
would be an optimal method for staging pancreatic tumors. Such a technique – named 
photo/opto/thermo-acoustic imaging – exists, and aims to remotely estimate the optical 
properties of tissue at high spatial and temporal resolution.38 Photoacoustic imaging was 
introduced for use in biomedical applications by Oraevsky39-42 and Kruger43-45 and then 
further developed by Wang46, 47 and others. Now, photoacoustic imaging applications 
range from microscopy to whole organ imaging.48  
During photoacoustic imaging the tissue is irradiated with short (5-10 ns) pulses 
of low energy laser light. The 15-20 mJ/cm2 laser fluence of near-infrared irradiation is 
sufficient to deliver optical energy to the pancreas and adjacent tissue – this laser fluence 
is well within the safe level of laser irradiation of tissue defined by the American 
National Standards and FDA.49 Therefore, a photoacoustic level of pulsed laser energy 
will not produce any thermal damage to the tissue, and will result in a negligible 
temperature increase.50, 51 Next, through the processes of optical absorption followed by 
thermoelastic expansion, broadband acoustic waves are generated within the irradiated 
volume. Using an ultrasound detector, these waves can be detected and spatially resolved. 
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The received ultrasound signal contains information about both position (time of flight) 
and strength of the optical absorber (amplitude of the photoacoustic signal).  
The amplitude of the thermoelastic response of the tissue is proportional to the 
optical absorption, i.e., the stronger the absorption, the stronger the signal. Putting these 
qualitative statements in terms of a mathematical expression, the change in acoustic 
pressure associated with the generation of photoacoustic pressure transients (ΔP) is equal 
to the Grüneisen parameter Γ (a dimensionless, temperature dependant factor 
representing the fraction of thermal energy converted into mechanical stress by the 
absorber) times the incident laser fluence (H) and the absorber’s absorption coefficient 
(μa), yielding the simplified expression40, 52: 
 
   
 
Equation (1) is valid only if the stress confinement condition is met, that is, if the 
heat diffusion time (τD) is significantly shorter than the stress relaxation time (τSR), i.e., 
the time for the acoustic waves to propagate through the irradiated volume.  This 
condition limits the duration of the laser pulse (τL), implying that it must also be much 
shorter than the stress relaxation time.  When the stress confinement condition is met, the 
input laser energy generates photoacoustic pressure with the greatest efficiency. 
Therefore, contrast in photoacoustic imaging is primarily determined by the μa of 
tissue components, most of which are shown in Fig. 1.3. For pancreatic cancer imaging, 
the contrast mechanism in photoacoustic imaging offers the prospect of identifying both 
anatomical features and different functional activities of the pancreas that are 




 The measurements of intrinsic optical properties of the pancreas and other 
relevant tissues are limited, quite variable and offer only an approximate guide to the 
optical behavior of tissues. However, several observations can be made from the typical 
absorption spectrum of tissue. In the near-infrared (2000-3000 nm) region, water is the 
dominant absorber; the light penetration depth (the distance through tissue over which 
diffuse light decreases in fluence to 1/e or 37% of its initial value) varies from about 
1 mm to 0.1 mm. In the ultraviolet region near and below 300 nm, the absorption depth is 
shallow, owing to absorption by cellular macromolecules. In the central region as shown 
in Fig. 1.3, tissue absorption is modest while contrast between tissue components remains 
high. Within 750-1300 nm wavelengths, the average optical penetration depth is on the 
order of tens of millimeters – therefore, this spectral range is very suitable for 
photoacoustic imaging of the pancreas. 
A simple form of photoacoustic imaging (i.e., without contrast agents) may 
already discriminate between cancer cells and surrounding healthy tissue by 
discriminating hypoxic regions in the pancreas. However, by using near infrared (NIR) 
laser light (700-1300 nm) and a targeted NIR absorbing nanosystem delivered to the 
tumor, the photoacoustic response will be further enhanced because healthy tissue will 
not absorb the NIR light strongly nor will they have any significant concentration of the 
absorber (nanoparticles). In contrast, nanoparticles accumulated in the tumor will 
efficiently convert light energy into acoustic pressure waves that can provide a large 
photoacoustic signal against the tissue background.  
1.3  NANOSYSTEMS AS CONTRAST AGENTS FOR TARGETED PHOTOACOUSTIC IMAGING 
A variety of metal nanoparticles including gold or silver nanospheres, rods, shells 
and crescents can be used as photoabsorbers (exogenous contrast agents).53-56 Compared 
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to conventional dyes such as indocyanine green, the absorption cross-section of metal 
nanoparticles can be six orders of magnitude higher,57 thus making them effective 
absorbers for photoacoustic imaging. In addition, gold and silver nanoparticles are 
nontoxic in certain formulations and have already been used in biological and some 
clinical applications.58-62 Mono-disperse metal nanoshells, for instance, are easy to 
synthesize, and their peak optical absorption can be synthetically tuned from 700 nm to 
1100 nm where light penetration in tissue is optimal.63 Indeed, by varying the shape and 
aspect ratio of nanostructures, the particles can be manufactured to absorb light at a 
desired wavelength across a wide spectrum including the near infrared spectrum.64, 65  
These nanoparticles can be administered intravenously and blood circulation 
transports them to the region of interest. When injected into the blood stream, 
hydrophobic particles get coated by plasma proteins and are rapidly removed from the 
circulation by the reticuloendothelial system. However, by grafting hydrophilic polymer 
chains such as polyethylene glycol (PEG), immunogenic responses can be suppressed and 
blood circulation time of the nanoparticles can be improved.66, 67 It has been 
demonstrated that small particles extravasate and accumulate in tumors due to the 
enhanced permeability and retention effect.68, 69 This effect is caused by the leaky nature 
of tumor vessels. Thus, by an injection of correctly sized photoabsorbers (metal 
nanoparticle contrast agents), passive accumulation in tumors can be achieved. 
Furthermore, the metal nanoparticles can be made tumor specific by bioconjugating them 
with monoclonal antibodies, antibody fragments, folates, aptamers, or integrins whose 
receptors on the surface of cancer cells are upregulated. These targeting moieties can be 
attached either directly to the nanoparticles or via linker segments. For example, gold 
nanoparticles have been specifically targeted to epidermal growth factor (EGFR), which 
is overexpressed in over 30% of all epithelial cancers.70-73  
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Therefore, using these metal nanoparticle contrast agents targeted to cancer cell 
surface receptors in conjunction with a photoacoustic and ultrasound imaging device will 
significantly enhance pancreatic cancer detection and staging. 
1.4  NANOSYSTEMS AS COMBINED CONTRAST AGENTS AND DRUG DELIVERY VEHICLES 
Research in nanotechnology has exponentially increased over the last decade.74 
Metal nanoparticles were discovered to be excellent optical contrast agents; and over the 
same time period, other types of nanoparticles, such as polymeric nanoparticles and 
liposomes, were proven as exceptional drug and therapeutic gene delivery vehicles.75-77 
These vehicles could also be targeted to cancer cell surface receptors similar to the metal 
nanoparticles described above. The overarching therapeutic scheme is for 
chemotherapeutic drugs to be packaged in the nanoparticles; the targeted nanoparticles 
are then delivered systemically, extravasate into the tumor area due to the EPR effect, and 
latch on preferentially to cancer cells. While latched on to cancer cells, the nanoparticles 
can either release their drug cargo in the extracellular space or be endocytosed into the 
cell where the drugs are released internally.78 Researchers hope to accomplish the 
following two main objectives by packing chemotherapeutics in nanoparticles targeted to 
cancer cells versus using traditional systemic injections of chemotherapy: (1) to limit the  
chemotherapeutic damage to healthy tissue (less patient suffering and side effects) and 
(2) to maximize  the drug dose delivered directly to the tumor, making the therapy more 
effective and subjecting the patient to a lower overall dose of drugs. These objectives 
have been accomplished by researchers with the chemotherapeutic drug doxorubicin, for 
instance, where it was encapsulated in either poly(lactic-co-glycolic) acid or liposomes 
and successfully delivered to cancer cells.79-83 Liposomal doxorubicin is currently in 
clinical trials.  
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As nanotechnology matures, sophisticated nanoparticles are surfacing in the form 
of multifunctional drug carriers. Several triggered drug delivery systems have been 
synthesized where light or some other form of electromagnetic energy is used to trigger 
drug release once the therapeutic nanoparticles have accumulated at the diseased site.84-86 
In addition to triggered release, researchers have begun to make combined imaging 
contrast and drug delivery nanoparticles. Interestingly, these new nanoparticles provide 
clinicians with an ability never before realized: the visualization of drug delivery. In 
current clinical settings, when a patient receives an injection or takes a pill, doctors 
“hope” the drug is properly delivered. Using a multifunctional nanoparticle, that delivery 
can be monitored and eventually even quantified at the diseased site.  
Some initial studies using nanoparticles as multifunctional carriers for drug 
delivery and MRI contrast enhancement have surfaced.87 Similarly, research in using 
photoacoustic imaging to visualize drug delivery is in its infancy. Initial strategies 
proposed to combine drug delivery with photoacoustic imaging involve using traditional, 
metallic photoacoustic contrast agents as multiplexed drug carriers.  
Gold nanorods are photoacoustic contrast agents that can be easily multiplexed by 
conjugating drugs, targeting moieties, or other molecules of interest to their surface.88 
Drugs can be chemically modified with a linker that allows for facile attachment to the 
gold surface. The linker can have a thiol group that readily attaches to the gold surface 
via thiolate bonds, or other photocleavable linkers are possible. For example, gold 
nanorods conjugated to Etanercept (a rheumatic drug) were intra-articularly injected into 
ex vivo rat tail joints, and photoacoustic tomography (PAT) was used to visualize the 
distribution of the conjugates. The sensitivity of photoacoustic imaging to detect the gold 
nanorods in this study was calculated to be at 10 pM concentrations in joint connective 
tissue.89 
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Other photoacoustic contrast agents with potential as drug carriers are hollow 
gold structures. Both hollow gold nanocages and nanoshells absorb NIR light and have 
the capacity to house large payloads of drugs in their interior while leaving their exterior 
available for surface functionalization with targeting moieties.59, 90 It was shown that 63% 
of doxorubicin (a breast and ovarian chemotherapeutic agent) could be loaded by weight 
in hollow gold nanospheres.86 NIR light was used to trigger release of the drug by using 
the light for heat conversion at the nanosphere surface. After heat triggered release, the 
doxorubicin exhibited cytotoxic effects on MDA-MB-231 breast cancer cells. Others 
demonstrated that the gold hollow nanospheres could double as photothermal agents, 
demonstrating an enhanced killing effect in vitro when both drugs and photothermal 
therapy were used in combination. These hollow gold structures have been used to 
enhance contrast in photoacoustic imaging91, but their use as a multifunctional carrier 
capable of photoacoustic image-guided drug delivery has not yet been published.  
Though using noble metal structures with drugs conjugated directly to their 
surface is a commonly used example of a multiplexed drug carrier, new hybrid carriers 
are also being explored. Traditionally, nano-forms of medicine involved encapsulation of 
drugs in polymers or liposomal complexes for delivery. Now hybrid polymer-silver or 
polymer-gold structures are being explored for this purpose where the drugs are housed 
in the polymer and the metal is used to heat the structure and trigger drug release.92-95 In 
one approach, hollow gold nanoshells were either encapsulated in the liposome with 
drugs or tethered to the lipid bilayer via a linker, and NIR light was used to disrupt the 
stability of the lipid membrane, causing the inner contents to be released.96 If the ratio of 
the noble metal content to the drugs and polymer or lipid system is known, photoacoustic 
imaging can be used to monitor drug release processes using these hybrid systems.   
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Very few studies on the topic of drug delivery monitored by photoacoustics exist 
since the field is young. However, the opportunity to visualize drug delivery and trigger 
drug release is exciting to researchers and clinicians alike. In the coming years, image-
guided drug delivery using a combination of photoacoustics with multiplexed 
nanoparticles will be a rapidly expanding research area. The research presented in this 
dissertation is part of this growing field. The focus here is on synthesis and initial testing 
of nanosystems specifically designed to enhance photoacoustic imaging while delivering 
drugs.  
1.5  COMBINED ENDOSCOPIC ULTRASOUND AND PHOTOACOUSTIC IMAGING OF 
PANCREATIC CANCER 
Using multifunctional nanoparticles in combination with ultrasound and 
photoacoustic (USPA) imaging to visualize drug delivery is a broad goal of this research 
project. For this goal to be realized for pancreatic cancer, the USPA imaging would need 
to be performed endoscopically to allow for the light source to get in close proximity to 
the pancreas, affording an effective photoacoustic response. Figure 1.4 provides an 
illustration of how endoscopic ultrasound and photoacoustic (EUSPA) imaging can be 
accomplished in vivo using an adapted EUS probe that can deliver light.  
The goal to combine EUS and photoacoustic imaging is based on several major 
factors. First, endoscopic ultrasound and photoacoustic imaging are complementary and 
can be transparently integrated since both photoacoustic and ultrasound imaging systems 
utilize the same ultrasound sensor and associated receiver electronics. Second, since both 
anatomical (morphology) and functional (activity) properties of the pancreatic tissue are 
expected to change with malignancy, it is anticipated that EUSPA imaging may detect 
and stage pathology earlier than EUS examination alone or even in combination with CT. 
Furthermore, compared to other imaging modalities such as microCT, MRI, PET/SPECT 
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and diffuse optical tomography (described in section 1.1.2 and also see Table 1), only 
USPA is a high-resolution, high-sensitivity real-time imaging capable of simultaneous 
morphological, functional and molecular imaging. Third, ultrasonic and optical access is 
enhanced by the location of the pancreas (typically within a few centimeters from the 
transducer). High frequency, and hence high spatial resolution ultrasound imaging is 
possible in most cases. Since the same ultrasound transducer will be used to detect 
photoacoustic transients, the photoacoustic signal can be resolved with spatial resolution 
akin to that in EUS imaging.  Fourth, based on current clinical criteria, EUS imaging is 
already widely used for staging of pancreatic cancer4, 27, 28 and, therefore, all necessary 
pre-requisites for EUSPA imaging of the pancreas are readily available. Patients will not 
be subjected to any additional biopsies, and the examination time will not increase to 
perform EUSPA imaging of the pancreas. Fifth, both ultrasound and photoacoustic 
imaging techniques are non-ionizing imaging methods and there are no safety concerns 
associated with low-fluence, non-ionizing laser irradiation. In addition, EUSPA imaging 
can be relatively inexpensive and portable. Finally, an urgent need exists for more 
sensitive and specific imaging to detect and stage pancreatic cancer – nanoparticle-
augmented EUSPA imaging may fill that need and become an important clinical tool for 
reliable staging of pancreatic cancer.  
1.6 OVERALL RESEARCH GOALS 
The overall hypothesis of the research is that (1) multifunctional nanoparticle 
contrast agents capable of combined therapeutic and imaging contrast components 
targeted to pancreatic cancer can be produced and (2) using these multifunctional 
nanoparticles in conjunction with a EUSPA imaging system will ultimately accomplish 
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visualization of drug delivery, more effective therapy, and more accurate staging of 
pancreatic cancer.  
Towards accomplishment of these overall goals, the research presented here 
evaluates the feasibility of (1) synthesizing multifunctional (imaging contrast + drug 
delivery) nanoparticles, (2) evaluating therapeutic efficacy of these nanoparticles in vitro, 
and (3) imaging these nanoparticles with lab prototype USPA systems. The building of an 
EUSPA probe and demonstration of EUSPA imaging augmented with nanoparticles will 
be the subject of future work meant to build on that presented here.   
The research presented in the following chapters is organized by nanosystem. 
Two multifunctional nanosystems are described in detail from design (Chapters 2 and 6), 
to preliminary synthesis and photoacoustic testing (Chapters 3 and 7), to complete 
synthesis of the designed nanosystems and in vitro characterization (Chapters 4/5 and 8). 
Finally, overall conclusions combined with insights for future work (Chapter 9) are 
presented that summarize the broad implications of the research relative to the biomedical 













Figure 1.1: The anatomy of the pancreas as shown in relation to surrounding organs97 
(top) and in relation to its duct structure98 (middle). Malignant tumor 









Figure 1.2: EUS image of a pancreatic cancer (blue and yellow dotted lines show the 
extent of the tumor). EUS image provided by Dr. Jeffrey Lee, M.D. 




Figure 1.3: Optical absorption (μa) or optical absorption plus scattering (μa+ μs) for 
various absorbers in tissue (HbO2 – oxygenated hemoglobin, Hb – 




Figure 1.4: An illustration of how endoscopic ultrasound and photoacoustic (EUSPA) 











Imaging depth Very good 

























Real-time No No No No Yes Yes 
Endogenous contrast  Poor Very good Poor Excellent Good Excellent 
Molecular contrast Good Poor Excellent Good Poor Excellent 
Safety No concerns Concerns Concerns No concerns No concerns No concerns 
Longitudinal studies Very good Poor Poor Good Excellent Excellent 
Blood perfusion Poor Poor Poor Excellent Good Excellent 
Oxygen saturation Poor Poor Poor Good Poor Excellent 
Portability Very good Poor Poor Poor Excellent Excellent 
Cost effectiveness Very good Poor Poor Poor Excellent Good 
Table 1.1: A comparison of properties of currently available imaging technologies that 
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Chapter 2: Design of the Combined Imaging and Therapy Nanocage 
System (CIT-NS) 
The objective of this research project is to design and synthesize new 
multifunctional nanoparticle systems capable of drug delivery and enhancing imaging 
contrast. The design of one such nanosystem termed the Combined Imaging and Therapy 
Nanocage System (CIT-NS) is explained in depth in this chapter (note that the CIT-NS is 
also referred to as the nanocage system in the text).  Each component of the CIT-NS and 
the reasons for its selection are discussed. Furthermore, synergistic elements in the 
overall design and its potential limitations are addressed.  
The CIT-NS design, illustrated in Fig. 2.1, was inspired by two existing 
nanoparticles. As mentioned in Section 1.4, polymeric nanoparticles have been developed 
as efficient chemotherapeutic drug carriers.1 The CIT-NS uses that design as the core of 
the system. Similarly, metal nanoshells have been designed as optical contrast agents 
possessing a core of silica and a noble metal outer shell.2 These metal nanoshells could be 
synthetically tuned to absorb near infrared light by adjusting the thickness of the gold 
layer deposited on the silica surface.3 Since these metal nanoshells have high absorption 
cross-sections in the near infrared (NIR) spectrum, they make excellent photoacoustic 
contrast agents. The CIT-NS design was born from the marriage of these two particles 
(Fig. 2.1). The core of the CIT-NS consists of drugs encapsulated in a polymeric matrix 
of poly(lactic-co-glycolic) (PLGA) acid surrounded by a silver “shell” that is instead 
named a cage since the metal layer may not be completely confluent in the CIT-NS 
design providing a metal “cage” for the polymer and drug components.  
 32 
2.1 CIT-NS COMPONENTS 
The various components of the CIT-NS are described in depth in this section, 
relating details about why they were chosen for inclusion in the design and which 
properties they impart to the CIT-NS as a whole.  
2.1.1 Chemotherapeutic Drugs 
Unfortunately, pancreatic adenocarcinoma is inherently resistant to 
chemotherapeutic regimens, either alone or in combinations. The most effective drugs 
that have formed the basis of chemotherapeutic treatment for pancreatic cancer have been 
5-fluorouracil (5-FU) and the more recently approved gemcitabine.4 As with most 
chemotherapeutic regimens, treatment involves systemic intravenous injections. The 
concentrations of gemcitabine and other drugs used per session is dose-limited by their 
cytotoxic effect on healthy bone marrow and epithelial tissue.5 Some hypothesize that the 
systemic approach is ineffective for most patients because drug concentrations 
accumulated within the tumor itself are not high enough to realize their estimated 
therapeutic potential.  In response to this issue several solutions involving packaging 
these chemotherapeutics in polymeric nanoparticles have surfaced.6-8 It is anticipated that 
packaging drugs in this way allows for a more lethal dose to be targeted and delivered 
directly to the cancerous site where its therapeutic potential will be realized.  
Since gemcitabine is the most effective and most highly prescribed 
chemotherapeutic drug to treat pancreatic cancer, it was chosen to be packaged in the 
CIT-NS. However, intrinsic properties of gemcitabine make it difficult to encapsulate in 
PLGA. For instance, gemcitabine is highly hydrophilic and PLGA is hydrophobic. 
Although hydrophilic molecules have previously been encapsulated in PLGA9, 
hydrophobic molecules encapsulate with higher efficiency and do not experience the 
burst release effect upon introduction in a solvent as strongly as hydrophilic molecules in 
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PLGA. Therefore, modifications to gemcitabine were necessary to make it more 
hydrophobic, allowing for better encapsulation in PLGA. Various prodrug forms of 
gemcitabine are covered in Chapter 5. 
The most significant restriction regarding what drugs the system can carry is 
dictated by the drugs’ ability to encapsulate in PLGA. Most hydrophobic molecules 
encapsulate well in PLGA, and PLGA as a carrier for drugs and myriad contrast agents or 
hydrophobic molecules of interest has been well documented.10-14 One example of a 
widely used chemotherapeutic agent that is naturally hydrophobic and encapsulates well 
in PLGA is Doxorubicin (DOX). Incorporation of DOX in the CIT-NS was tested and 
results can be found in Chaper 4.    
2.1.2 Poly(lactic-co-glycolic) Acid (PLGA) 
One of the most widely investigated materials in drug delivery is poly(lactic-co-
glycolic) acid (PLGA) due to its long history in the field, many advantageous properties, 
ease of use and wide availability.12, 15 PLGA makes up the bulk of the core of the CIT-
NS, entrapping drug molecules within its matrix.   
The PLGA used in the CIT-NS is an FDA-approved copolymer of 50:50 lactide 
and glycolide monomers (Fig. 2.2). PLGA is a bulk eroding, biodegradable polymer that 
is approved for use as suture material and in various drug delivery systems, including 
Lupron Depot®, ProLease® and Trelstar® Depot.12, 16 PLGA degrades into lactic acid and 
glycolic acid through hydrolysis of the ester bond, and the material bulk erodes as water 
diffuses into the matrix more quickly than the polymer degrades.17, 18 PLGA is 
biocompatible due to the uptake of lactide and glycolide post-degradation into the citric 
acid cycle, and this allows for the use of PLGA without the need for removal of the 
material after the intervention.  Of all possible copolymer blends of PLGA, the 50:50 
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lactide:glycolide PLGA degrades the fastest. PLGA microparticles injected 
intramuscularly in the legs of rats were shown to degrade by 70% in 3 weeks and be 
completely degraded in vivo at ~10 weeks.16 Nanoformulations of PLGA are expected to 
degrade even more quickly. PLGA particles have been formulated extensively for use in 
both oral and subcutaneously-injected delivery systems.19, 20 Furthermore, as discussed 
above, biodegradable PLGA nanoparticles have been utilized as successful delivery 
systems.12, 17, 21-23  
PLGA is also a popular material due to its intracellular trafficking. Some groups 
have shown that cellular internalization of PLGA nanoparticles is through both fluid 
phase pinocytosis and clathrin-coated pits in vascular smooth muscle cells (VSMCs). 
Within 10 min of incubation with cells in vitro, PLGA nanoparticles rapidly escape endo-
lysosomes and enter the cytoplasm.24 At neutral pH, PLGA nanoparticles exhibit a 
negatively charged surface due to the presence of the carboxylic acid end groups on the 
copolymer. Interestingly, following cellular internalization (via endocytosis) PLGA 
nanoparticles undergo surface charge reversal (anionic to cationic) in the acidic pH of 
endo-lysosomal compartments.24 The charge reversal facilitates an interaction of PLGA 
with the vesicular membranes, leading to transient and localized destabilization of the 
membrane, thereby resulting in the escape of nanoparticles into the cytosol.25 A 
significant fraction of the PLGA nanoparticles undergo exocytosis - only 15% of the 
internalized nanoparticles escape into the cytosolic compartment. However, the fraction 
of nanoparticles that escape the endosome seem to remain in the cytoplasm and release 
the encapsulated therapeutic in a sustained manner as the polymer degrades slowly. This 
intracellular trafficking pathway might explain why DOX-loaded PLGA nanoparticles 
exhibited greater cytotoxic effects relative to free drugs at low concentrations.26 Drugs 
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that require cytosolic delivery to have a therapeutic effect benefit from carriers like 
PLGA.  
Due to their size and shape, PLGA nanoparticles and microparticles are popular 
for the encapsulation and delivery of active agents. PLGA particles can travel through 
blood vessels or be injected into other physiological areas, such as the peritoneum, and 
protect the encapsulated agent until delivery. Particles of PLGA can be formulated in 
many ways,12, 27-29 yet emulsion and nanoprecipitation techniques30-33 are facile and can 
be used to encapsulate both hydrophilic and hydrophobic agents. The advantages of the 
emulsion techniques are simplicity, flexibility in nanoparticle size by adjusting chemical 
interactions between starting materials, and the ability to encapsulate an agent without 
chemically linking it to the carrier. The optimization31 and scale up production32 of 
PLGA particles up to 100 g per batch has been reported.  
To summarize, PLGA was chosen as the core of the CIT-NS due to its proven 
biocompatibility and biodegradation properties, its ability to sequester and protect active 
agents such as drugs, its intracellular cytosol trafficking, and the ease of using emulsion 
techniques to potentially produce large quantities of drug-loaded PLGA nanoparticles.  
2.1.3 Silver 
The core of the CIT-NS is surrounded by a silver studded or seeded cage. The 
function of silver in the CIT-NS is to increase the nanosystem’s light absorption in the 
NIR spectrum, making it a suitable photoacoustic contrast agent. Silver on the surface of 
PLGA will have similar optical properties to the metal nanoshell structures mentioned 
previously that can act as photoacoustic contrast agents.2  
The deposition of a thin layer of gold on the surface of a dielectric material 
(silica) to create a nanoshell allows for unique optical properties. At the nanoscale, as the 
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ratio of the silica core diameter to the thickness of the Au coating changes, the 
nanoshells’ scattering and absorption properties change. Since the layer of gold is so thin, 
and the mean free path of electrons on the surface of gold is tens of nanometers, light can 
excite the conduction band of electrons in the metal to oscillate almost in unison across 
the nanoshell surface in response to light. This collective oscillation is termed the surface 
plasmon resonance (SPR) of the nanoparticle and is akin to mechanical or acoustic 
resonance but at the electronic scale. In the case of nanoshells, as the ratio of the core to 
shell thickness is changed, the SPR peak can be tuned from the visible to the NIR 
spectrum of light.34  
Silver on the surface of PLGA yields similar plasmonic effects as gold nanoshells 
since PLGA is a dielectric similar to silica and the silver cage coating on the PLGA 
surface is comparable to a gold shell configuration. In fact, gold is used by the majority 
of researchers to impart photoacoustic contrast properties to nanosystems.35, 36 Silver was 
incorporated in the CIT-NS because it has slightly stronger and sharper plasmon 
resonance properties (by 10 to 15%)37, making it theoretically a better absorber and 
producer of photoacoustic transients. Furthermore, silver can be reduced onto the surface 
of PLGA in a cage-like, porous or semi-porous fashion so that controlled drug release 
through the silver cage is possible. 
  Currently, the use of silver in biomedical applications from nano to orthopedic is 
a controversial topic.38 Some clinicians and researchers believe silver is toxic, while 
others see it as benign. Thus, the next few sections are provided as background on the use 
of silver throughout history and in the biomedical realm.  
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2.1.3.1 History of Silver as a Preservative 
The use of silver in biomedical applications is far from new.  As early as 400 
B.C., Hippocrates wrote of the healing and anti-disease properties of silver.39 Ancient 
Egyptian writings also mention using silver for medical purposes.40 Throughout history, 
well before the mechanism behind silver’s germicidal and antibiotic properties were 
known, people had been using silver for its medical, preservative, and restorative powers.  
For instance, Herodotus recorded that to prevent sickness, the King of Persia carried with 
him boiled water in a silver flagon.41, 42 In ancient Roman and Greek societies, the 
wealthy would commonly store their water, wine, and food stuffs in silver vessels to 
prevent bacterial growth.  The known use of silver as a preservative in this way led to its 
incorporation in the making of utensils and goblets. Many, like the Chinese emperor and 
his court, would eat with silver chopsticks. In the Middle Ages, silver became the 
material of choice for the making of most tableware settings. This use of silver came to 
the upper class’ advantage since their daily employment of silver utensils helped shield 
them from experiencing the full brunt of the plague.40 In fact, the crude form of silver 
used to make early utensils contributed to the bluish skin discoloration seen in most 
wealthy folks at that time, resulting in their label as “royal blue bloods.”  Furthermore, it 
is possible that the phrase “born with a silver spoon” was coined during this time, and 
represented not only the wealth of the “royal blue bloods” class but also their good health 
and fortune.41 The use of silver as an anti-spoilage agent continued through the ages. The 
first Australian outback settlers suspended their silverware in water jugs to reduce 
spoilage. Early American pioneers traveling westward in search of good fortune did the 
same. Even in the early 1900’s, our grandparents and great-grandparents would place 
silver dollars in milk jugs to preserve freshness.40   
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Our use of silver as a preservative continues today. Switzerland now 
manufactures silver water purification tablets and filters employed in many international 
airlines.  Silver is also used in swimming pools in place of chlorine to reduce the growth 
of algae and bacteria. These progressive swimming pool owners use “electrical ionization 
units that impregnate the water with silver and copper ions” to help sanitize their pool 
water.43 Another current day application of silver is in toilets.44 Vitra started a line of 
toilets and plumbing that have silver ions embedded in the glaze that covers these fixtures 
in order to kill germs.  In February of 2006, Samsung introduced washing machines that 
expel silver ions during a final rinse cycle, which are supposed to provide anti-bacterial 
protection to clothes for up to several days.45 Lastly, silver nanoparticles are now being 
considered for use in chitosan bionanocomposite films which will be used in food 
packaging to preserve freshness and prevent bacterial adhesion.46   
2.1.3.2 History of Silver as a Therapeutic Agent 
In addition to its use as a preservative and germicide, silver enjoys a long history 
as a therapeutic agent for early medical applications.  Hippocrates specifically referenced 
it as a treatment for ulcers, saying that “the flowers of silver alone, in the finest powder” 
should be employed.39 Later in 78 A.D., Pliny the Elder mentions it in his survey of the 
world’s knowledge, saying that when silver is used as an ingredient in plasters, it 
enhances the quick closure of wounds.41 In Ayurvedic medicine, an old form of 
alternative medicine in India, small amounts of silver were used as an active ingredient in 
an elixir given to patients stricken with disease or old age as a restorative or rejuvenative 
agent. In the 1800’s, silver sutures were used with successful results.40 In addition, 
around that same time, the use of hardened silver nitrate in the treatment of ulcers became 
widespread. Silver nitrate pencils were becoming standard equipment for surgeons in the 
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19th century. Also in that same era, J. N. Rust was the first to treat third degree burns with 
a dilute solution of silver nitrate. Rust claimed that the application of silver nitrates 
immediately gave rise to an artificial epidermis. Early in the 20th century, silver foil was 
used to treat burns as well. Doctors appreciated the foil’s pain-killing effects, anti-
bacterial properties, and good cosmetic results.47 In 1884, German obstetrician C.S.F. 
Crede administered a 1% silver nitrate eye solution to infants to reduce cases of 
ophthalmia neonatorum. His treatment was so effective that the incidence of eye disease 
in infants dropped to 0.2%, almost preventing infant blindness.  Crede’s remedy is still 
used today.40, 41, 48 Before 1939, over 96 different silver medicinals were marketed in 
topical, intravenous, and oral applications.41 Silver compounds, like silver nitrate, were 
also used extensively during World War I and part of World War II to prevent infection.40 
In the late 1960’s a new compound, silver sulphadiazine, was introduced by Charles Fox 
Jr. and it eventually became the new gold standard in burn treatment.  It was originally 
thought that sulphadiazine itself imparted antimicrobial properties. However, when silver 
nitrate and sodium sulphadiazine were combined to form silver sulphadiazine, it was 
discovered that the sulphadiazine acted to keep silver ions in solution. Sulphadiazine 
allowed for slow release of silver ions into the wound at just high enough concentrations 
to still be an effective biocide.49, 50 Additionally, by keeping silver ions in solution, 
sulphadiazine prevented the skin blackening effects experienced with silver nitrate 
products.44 It is clear that the medicinal benefits of silver have been known for centuries 
and are being exploited to this day.      
2.1.3.3 Harmful Effects of Overexposure to Silver 
The use of silver was clearly on the rise in the 1900’s.  At about this time, harmful 
side effects from overexposure to silver were publicized. Excessive use of protein-bound 
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silver compounds was found to cause a notable discoloration of the skin called argyria.  A 
large number of the argyria cases observed were caused by improperly prepared and 
unstable silver present in many of the early silver medicines .40 The discoloration usually 
came after years of drinking colloidal silver formulations. Researchers subsequently 
learned that excess silver deposition in the form of silver granules (perhaps silver sulfide) 
precipitates in the dermis and mucous membranes, causing that irreversible blue-gray 
discoloration.51 Once deposited in skin, silver remains immobile and accumulates with 
age and use of the silver product.52 Argyria is rare and most sources site that other than 
discoloration, overexposure to silver is fairly innocuous, although some disagree.53, 54  
The US Food and Drug Administration has stated that over-the-counter products 
containing silver are frequently misbranded and are not always safe or effective.55 This 
debate has spawned many discussions, and an excellent summary of the health effects of 
silver has been prepared by the Committee for the Responsible Use of Silver in Health.  
The reader is directed to the Committee’s sponsored site at www.silverfacts.com for more 
information.   
As discussed above, silver has a long history of use as an antibacterial and 
therapeutic agent. Although its use in excess can have unwanted effects, many 
researchers have renewed interest in employing it for an amazing variety of different 
applications. Recent advances demonstrate the use of silver, silver alloys, conjugates, and 
complexes as dental biomaterials56, 57, anti-bacterial agents used in conjunction with 
biomedical implants58-61, therapeutic agents in the treatment of burns62, and anti-viral63, 64 
(even anti-HIV) agents. 
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2.1.3.4 Cytotoxicity of Silver 
Despite the widespread use of silver over the centuries and its resurgence for use 
in antibacterial applications, the use of silver in biomedical applications remains 
controversial as some in vitro studies have shown silver to exhibit cytotoxic effects.65, 66 
Despite these findings, silver continues to be used in myriad applications such as silver 
coated catheters, orthopedic implants, and many medical devices.61, 67, 68 Other studies 
have shown silver to be non-cytotoxic38, 69, 70 in these formulations in vitro, but no 
concrete finding or consensus has been reached in the community. Most probably, the 
surface properties of the silver compound being used and the form of silver (i.e. 
nanosilver, bulk silver, or silver salts) ultimately determine its impact on nearby cells. 
Therefore, whatever specific silver formulation that is proposed must be tested 
extensively in vitro and in vivo before it can be accepted as safe. In vitro cytoxicity 
results with the various silver nanosystems tested here can be found in Chapters 3, 4, and 
8.   
In conclusion, silver was incorporated into the CIT-NS design to impart light 
absorption properties in the NIR, making the nanocage system a photoacoustic contrast 
agent. Silver has other properties that can also be exploited. Silver is more reactive than 
gold, which is possibly why it has cytotoxic effects in some cases. But that same 
reactivity also leads to silver degradation in the body. Details of degradation are covered 
in Chapter 8; but it is possible that if silver degrades, the entire CIT-NS represents one of 
the first degradable photoacoustic contrast nanosystems. Furthermore, noble metals like 
silver and gold bind readily to free thiol groups in solution, making covalent thiolate 
bonds.71 Therefore, free thiol groups on a targeting moiety or polymer coating can be 
grafted to the surface of silver with ease. In summary, silver imparts photoacoustic 
contrast properties to the CIT-NS, it degrades in the body, and it provides a surface for 
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facile bioconjugation; furthermore, despite the controversy over its use, silver remains a 
viable solution to several biomedical problems.  
2.1.4 Exterior Coatings and Targeting Moieties  
In order to successfully navigate through the bloodstream and find its intended 
target cells, the CIT-NS must have exterior coatings and targeting moieties grafted 
directly on its surface. These exterior coatings help accomplish two goals: (1) to increase 
the circulation time of the nanosystem in the bloodstream by limiting recognition and 
clearance by the reticuloendothelial system (RES) and (2) to increase the likelihood of 
the nanosystem reaching and interacting with its intended target cells or diseased site.  
Grafting poly(ethylene glycol) (PEG) chains to the surface of a nanosystem is one 
of the most well characterized methods for increasing its circulation time in the 
bloodstream. Once the surface of a nanosystem is covered with a brush71 layer of 
hydrophilic PEG chains, the zeta potential of the system decreases to zero and thus, the 
nanoparticle surface is neutrally charged. This neutral, non-reactive surface helps repel 
proteins by steric repulsion forces, limiting opsonization in the bloodstream. 
Opsonization is the depositing of opsonin proteins on the surface of a foreign body. It is 
the first step in a long cascade of biological events that leads to recognition by the RES 
and clearance of the nanosystem out of the bloodstream by macrophages of the 
mononuclear phagocytic system. PEG chains in the molecular weight range above 2000 
Da are effective in limiting opsonization and increasing blood circulation time for various 
nanosystems.72, 73 As mentioned above, grafting PEG chains to the surface of the CIT-NS 
can be easily accomplished through using methyl-PEG-SH molecules that readily form 
thiolate bonds at the silver surface.  
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When designing nanoystems it is challenging to construct a nanoparticle that has 
both limited uptake by the RES in the bloodstream and yet excellent recognition and 
interaction with its intended target site (i.e. cancerous cells, angiogensis, etc.). 
Unfortunately, many targeting moieties, namely antibodies or antibody fragments, will 
induce a RES response in vivo. Therefore, most nanosystem designs aim to tightly control 
and limit the number of targeting moieties on the surface of the nanosystem so that large 
brush layers of PEG can still be incorporated on the surface. Combining the targeting 
moiety and PEG on the surface in this way strikes a balance between the long circulation 
time needed in the bloodstream and the molecular specificity required for the target. 
Several different targeting moieties have been proposed to make nanosystems 
molecularly sensitive to pancreatic cancer cells. This molecular sensitivity is usually 
accomplished by grafting a protein, antibody, or molecule to the nanosystem that can 
recognize and interact with receptors or upregulated proteins on the surface of cancer 
cells. Listed here are several cell surface molecules known to be upregulated by 
pancreatic cancer cell lines: Mucin 1 (a transmembrane glycoprotein)74,  F19 antigen (a 
cell surface glycoprotein called fibroblast activation protein that is highly expressed by 
the stromal tissue of pancreatic cancer)75, claudin-4 (a cell surface protein found in tight 
junctions that is overexpressed in both primary and metastatic pancreatic cancer cell 
lines)76-78, CD71 (transferrin receptors)77, gastrin receptors79, IGF-1R (an insulin-like 
growth factor receptor)80, and EGFR (epidermal growth factor receptor).6, 81 Because 
EGFR is overexpressed throughout the various stages of pancreatic cancer growth and 
metastasis, the antibody to the EGFR (anti-EGFR) was chosen as the first intended 
targeting moiety for the CIT-NS.   
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2.2  SYNERGISTIC ASPECTS OF THE CIT-NS DESIGN 
The combination of the CIT-NS with photoacoustic imaging provides several 
synergies that could be exploited to better treat cancer. These effects range from 
synergies resulting from integration with ultrasound technologies, lasers, and from the 
CIT-NS design itself.  
2.2.1 Combining the CIT-NS with Ultrasound  
 Ultrasound can sonoporate cell membranes, making them more permeable to 
drugs or nanoparticles. Studies have shown increased killing effects when 
chemotherapeutic drugs were delivered in the presence of ultrasound.82-84 To realize its 
full potential for imaging contrast enhancement, the CIT-NS must be used in conjunction 
with a photoacoustic imaging device which uses ultrasound transducers by design. 
Therefore, once the CIT-NS has accumulated in the tumor site, the cancer cells can be 
sensitized to nanoparticle and chemotherapeutic drug delivery using that same ultrasound 
system. Furthermore, high intensity, focused ultrasound (HIFU) can also be used to help 
enhance nanoparticle accumulation in the cancer region. HIFU creates cavitation, forcing 
holes to form between cells in the endothelial lining of blood vessels. However, HIFU 
treatment has also caused increased metastasis in vivo85, so its use with the CIT-NS 
should be approached with caution. Overall, combining the CIT-NS with ultrasound 
provides a means to increase the drug’s therapeutic effect and uptake in cancerous cells.  
2.2.2 Triggered Drug Release and other Photothermal Effects  
 The CIT-NS is designed to work in conjunction with a photoacousic imaging 
device that is reliant on laser light delivery. This laser light can have synergistic effects 
when combined with the CIT-NS. Interestingly, PLGA has a glass transition temperature 
(Tg) of ~40-45°C. This Tg is only several degrees above body temperature. When 
 45 
irradiated with laser light at the peak plasmon resonance of the CIT-NS, the temperature 
of the nanosystem is expected to instantaneously and temporarily rise to several hundred 
degrees Kelvin86, well above the Tg for PLGA. Therefore, this heating could cause the 
polymer to become glassy and release drugs from its matrix. Thus, drug delivery from the 
CIT-NS, which would usually be carried out by simple diffusion, could be enhanced and 
even triggered at the diseased site using light. Furthermore, the heat generated by the 
CIT-NS absorbing the laser light has other therapeutic benefits. For instance, a pulsed 
laser that only induces temporary changes in temperature could be replaced with a 
continuous wave (CW) laser. That CW laser can be used to make the CIT-NS heat up and 
cause hyperthermia in the cancer cells around them. This process of heating nanoparticles 
near cells to induce cell death is a well-known procedure called photothermal therapy. 
Photothermal therapy using gold nanoshells87 on patients with head and neck cancers is 
already in Phase I clinical trials. In short, laser light can be used to enhance cancer 
therapy in two ways: (1) to trigger drug delivery from the CIT-NS and (2) to use the CIT-
NS as a photothermal therapy agent, killing cancer cells via hyperthermia. 
2.2.3 Silver Nanoparticles and Ionizing Radiation 
 In addition to silver serving as a multifunctional imaging contrast and 
photothermal agent, silver nanoparticles can also sensitize cells to ionizing radiation (IR). 
When IR is incident upon cells labeled with silver nanoparticles, some hypothesize that 
silver ions elute from the nanoparticles and interact with ATP, causing production of 
reactive oxygen species that ultimately leads to cell death. Interestingly, silver 
nanoparticles sensitized cells to IR induced killing, while gold nanoparticles of similar 
size had no sensitizing effects.88 Therefore, if the CIT-NS was used in combination with 
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common radiation therapy techniques, silver labeled cancer cells would be sensitized, 
enhancing the IR’s therapeutic effect.  
2.2.4 Biodegradation of the CIT-NS 
 The CIT-NS was designed to degrade over time in the body. All of the organic 
components of the nanosystem from the drugs to the PLGA, anti-EGFR, and PEG will 
eventually break down and clear the body through natural mechanisms such as the citric 
acid cycle, RES or renal clearance, etc. However, silver’s degradation in vivo in nano 
form is not well characterized or understood. Once the CIT-NS enters a cell, lysosomes 
will likely tear the exterior coatings from the silver surface, creating a bare “naked” silver 
interface.89 This surface will likely oxidize and pit in the acidic lysosomal compartment 
and if the silver is not completely degraded in the cell, it will most likely get recycled out 
of the cell into the extracellular space. Interactions with other enzymes or proteins in that 
space will further degrade silver. Unlike gold, which is unreactive and known to not 
degrade in the body, silver is more reactive and is known to degrade in salt solutions. 
Degradation products of metallic nano silver formulations likely include silver oxides or 
Ag+ ions. Silver oxides can be cleared by the body, but Ag+ ions are very reactive and 
will interact with proteins and enzymes, possibly causing them to lose function – this is 
one of the suspected mechanisms of silver’s controversial cytotoxicity.90 However, the 
antibacterial properties of Ag+ ions have been well understood for centuries39, 42, which 
explains the extensive use of silver coated catheters, orthopedic implants, and many 
medical devices61, 67, 68. In fact, having silver in place in the pancreas following tumor 
resection could help fight bacterial infections should they arise. In short, the entire CIT-
NS is expected to degrade over weeks in the body, making this system one of the few 
degradable nanosystems that incorporate metal contrast agents.   
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2.3 LIMITATIONS OF THE CIT-NS DESIGN 
The CIT-NS is limited by two properties: size and drug diffusion. The size of the 
endothelial gap junctions through which nanoparticles must extravasate to reach cancer 
were reported to be between 300 nm to 700 nm.91 Therefore, the diameter of the CIT-NS 
should be designed to remain below this size range. PLGA core particles with entrapped 
drugs synthesized via emulsion techniques are generally between 150 nm and 250 nm in 
diameter. Adding a layer or silver and exterior coatings to the PLGA could increase the 
diameter by up to 100 nm. Therefore, keeping the nanosystem small by synthesizing 
smaller PLGA cores with thin silver layers is critical for this nanosystem to be viable in 
vivo. Even at these small sizes, large amounts of the CIT-NS are expected to accumulate 
in the liver and spleen, in addition to the tumor. Thus, organ specific toxicity will need to 
be assessed prior to in vivo application. Furthermore, the larger the nanosystem becomes, 
the more difficult it is to keep attractive forces between the particles from causing 
agglomeration or flocculation between nanoparticles in solution. 
The other limiting factor in the CIT-NS design is the mechanism of drug delivery. 
In the absence of triggering drug release using electromagnetic energy and heating, drug 
release will occur via diffusion out of the bulk eroding PLGA polymer matrix. This drug 
diffusion will start the instant the CIT-NS is suspended in an aqueous environment. 
Therefore, ways to control or to limit drug diffusion prior to the nanosystem reaching its 
intended disease site are critical. One way to limit drug release through the CIT-NS is to 
control the confluency of the silver on the surface of PLGA. In theory, if the silver were a 
completely confluent shell with no holes around PLGA, then no drug diffusion would 
take place. Therefore, if the silver seeds coating the PLGA core exterior are very close 
together, this design could help limit and considerably slow drug release out of the 
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nanosystem. Controlling the drug release will allow the nanosystem time to accumulate 
in the tumor before significant drug is lost.   
2.4 CONCLUSIONS 
The CIT-NS is a complex nanosystem inherently built for functionality and 
synergy between it and USPA imaging. The advantage of such a system clinically is the 
ability to visualize drug delivery to pancreatic cancer in vivo, non-invasively. 
Furthermore, the ability of the nanosystem to also act as both a photothermal agent and 
an IR-sensitizing agent gives clinicians even more therapeutic options using this 
nanosystem. The limitations of the nanosystem are its overall size and drug delivery 
method, but these obstacles can be mitigated if synthetic techniques are employed to keep 
the nanosystem small and its silver tightly packed on the surface (see Chapter 4 for more 




Figure 2.1: An illustration of the Combined Imaging and Therapy Nanocage System 








Figure 2.2: The chemical structure of poly(lactic-co-glycolic) acid where x represents 
the number of lactide units and y represents the number of glycolide units 
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Chapter 3: Preliminary Testing of the CIT-NS design for enhancing PA 
Imaging 
The CIT-NS introduced in Chapter 2 is a complex nanosystem requiring 
significant research to synthesize. Before such a complex nanosystem is built, it is 
prudent to first test aspects of the design with similar nanosystems that are easier to 
synthesize. This chapter is the result of one such test in which a silver cage is deposited 
on a silica core instead of a PLGA core. The purpose of this preliminary test is to prove 
that a silver-silica nanocage can (1) be biocompatible and (2) provide imaging contrast 
enhancement for photoacoustic imaging. If a large near infrared absorption cross-section 
is demonstrated for these silver-silica (cage-core) particles, and if they create strong 
photoacoustic transients in ex vivo studies without signs of cytotoxicity, then building the 
CIT-NS with all its complexity is warranted.    
3.1 INTRODUCTION 
Photoacoustic contrast agent development has grown with the adoption of the 
photoacoustic imaging technique over the last decade. The surge of research in the fields 
of nanoscience and nanotechnology has yielded inorganic nanoparticles of various shapes 
and forms including shells, rods, and crescents with tunable absorption properties.1-5 
These nanosystems absorb light strongly in the near infrared (NIR) spectrum, where 
absorption from native tissue is minimized.6 They are ideally suited as photoacoustic 
contrast agents since the absorption cross-section of myriad nanostructures can be 
multiples to orders of magnitude higher than the surrounding native tissue at NIR 
wavelengths. Reviews of the basic theory and principles of using nanotechnology in 
conjunction with photoacoustics are available7, 8 and were highlighted in Chapter 1.  
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Most often, nanoparticles for photoacoustic imaging contrast are administered 
intravenously. They accumulate at a diseased site via both “passive” and “active” 
mechanisms, as discussed in Chapter 1. In the case of using photoacoustic imaging to 
highlight cancerous tissue, passive accumulation of nanoparticles in a solid tumor occurs 
due to the enhanced permeability and retention (EPR) effect, where the nanoparticles get 
essentially trapped in the leaky and disorganized nature of the tumor vasculature and 
eventually extravasate through endothelial junctions into the cancerous vasculature.9, 10 
Active targeting is achieved by covalently attaching antibodies or other signaling 
molecules to the nanoparticles.10-12 In the active case, in addition to the passive EPR 
effect, the nanoparticles accumulate in diseased tissue due to the specific affinity of the 
antibody for its antigen: an upregulated cell-surface receptor on the diseased cells. 
Nanoparticles that accumulate directly at the site of disease can provide the necessary 
photoacoustic contrast with healthy tissue that is critical for disease detection and 
diagnosis.   
Photoacoustic contrast agents are naturally multifunctional since low NIR pulsed 
light can be used for detection and diagnosis, while continuous wave light delivery modes 
can be used to create photothermal tissue damage from nanoparticle heating.13, 14 The 
nanosystems can be functionalized further to expand their therapeutic capability beyond 
photothermal mechanisms. For instance, core-shell nanoparticles15 with tunable optical 
absorption properties are currently in clinical trials for photothermal therapy. These 
nanoshells possess an inert silica core. The CIT-NS introduced in Chapter 2 is a new 
multifunctional nanosystem that results from replacing the inert silica with a core capable 
of carrying drugs or other contrast agents (see Fig. 3.1 and note that Fig. 3.1 is a different 
illustration of the CIT-NS already depicted in Fig. 2.1 minus the targeting moiety 
 60 
depiction). The CIT-NS could have enhanced sensitivity to multimodal imaging or 
treatment strategies.  
The benefits of the CIT-NS could be profound; but first, a detailed analysis of the 
optical properties of a porous layer versus the traditional confluent noble metal shell must 
be performed. These preliminary experiments are necessary to prove that a silver 
nanocage coating similar to that in the CIT-NS design will provide near infrared 
absorption and hence photoacoustic contrast. Therefore, in this chapter, a porous silver 
“cage” coating was reduced onto a silica core and the feasibility of using this silver-silica 
nanosystem as a photoacoustic imaging contrast agent was evaluated. Furthermore, the 
biocompatibility of the silver nanosystem was explored by performing cytotoxicity tests 
in vitro. 
3.2 METHODS 
3.2.1 Coating Silica with a Porous Silver Layer 
Various sizes of the silver-silica nanosystem were produced by reducing silver 
onto silica spheres ranging in diameter from 180 nm to 520 nm. The procedures for 
coating the smallest (180 nm) and the largest (520 nm) spheres are presented along with 
generalized rules for scaling the synthesis to any size in between. The silica amine (-NH2 
surface groups) was purchased from two vendors: Corpuscular, Inc. or Bangs 
Laboratories, Inc.  A modified stoichiometrically controlled method16 was used to reduce 
silver onto silica in a porous, cage-like fashion. The silica spheres (20 µl of 2.5 wt% 180 
nm spheres or 1.5 mg of the 520 nm spheres) were suspended via sonication in 
polypropylene vials containing 30 ml of deionized ultra-filtered (18.2mΩ-cm) (DIUF) 
water (in all diameters of silica attempted, the total surface area of all spheres in solution 
was kept constant at 6.5×10-3 m2).  The 180 nm spheres were placed in a 15°C water bath, 
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while the 520 nm spheres were placed in a 11°C bath; both batches were stirred 
continuously at 500 rpm (the temperature was varied according to the diameter: 15°C for 
spheres roughly in the 100’s of nm, 14°C for spheres in the 200’s of nm, and so on). 
Silver in the form of 0.15 M silver nitrate was added to the stirring spheres in the amount 
of 0.4 ml for the 180 nm spheres and 0.8 ml for the 520 nm spheres. Note that the amount 
(mmol) of silver to add based on silica diameter, assuming constant surface area of 
6.5×10-3 m2, can be calculated as: 
    y = 0.000176x + 0.02824   (3.1) 
where y is the mmol of silver to add and x is the diameter of silica in nm. Lastly, 50 µl of 
36% glucose, and 50 µl of 3% NH4OH solutions were added.  Color changes from yellow 
to orange-brown, and finally to grey-black were noted between 2 and 13 min after adding 
NH4OH.  The pH of the solutions initially rose to 9 upon addition of the NH4OH, but then 
fell to 7 when the silver reduction was complete. To suppress aggregation, 200 µl of 50 
mM of poly(ethylene glycol) (mPEG-SH of 5000 g/mol from Laysan Bio) was added. 
The nanosystem was collected and cleaned 3 times using DIUF water and a 100 kDa 
Millipore centrifugal filter spun at 1500g for 4 min. The nanosystem can be suspended in 
DIUF water and stored in a plastic vial in the dark for several weeks.    
The silver-silica nanosystem was analyzed using a LEO 1530 scanning electron 
microscope.  The ultraviolet to visible (UV-vis) absorption spectrum of the as prepared 
nanosystem suspended in DIUF water was captured using a Shimadzu UV-1201 
spectrophotometer (the spectra obtained represent either ~2.0x109 180 nm core particles 
per ml or ~2.6x108 520 nm core particles per ml). 
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3.2.2 Photoacoustic and Ultrasound Imaging of the Silver-Silica Nanosystem 
To test the feasibility of using the silver-silica nanosystem as a contrast agent for 
combined ultrasound and photoacoustic (USPA) imaging, a custom-made imaging 
system was employed (Fig. 3.2). This system inherently contained two parts: a pulsed 
laser system with light delivery assembly interfaced with an ultrasound array-based 
transducer operated by an ultrasound system capable of capturing radio frequency (RF) 
signals. Pulsed light was generated by an optical parametric oscillator (OPO), tunable 
within a 680-950 nm range. For all studies, a wavelength of 800 nm with 7 ns laser pulse 
duration at 10 Hz pulse repetition rate was used.  The maximum laser energy per pulse 
was 15 mJ/cm2, which is well below the maximum permissible exposure standard set by 
the American National Standards Institute.17 From the OPO system, light was directed 
into a fiber optic bundle containing 18 individual fibers. These fibers surrounded the 
ultrasound transducer (7.5 MHz center frequency, 10.5 mm wide, 128 element linear 
array), and allowed light irradiation and sound delivery to overlap within the imaging 
plane. The ultrasound transducer was interfaced with a Cortex ultrasound imaging engine 
(Winprobe Corporation, North Palm Beach, FL, USA) capable of RF data acquisition. 
The pulsed laser system, integrated imaging probe, and ultrasound system with RF signal 
acquisition together made up the USPA system that could capture spatially co-registered 
photoacoustic and ultrasound RF signals needed to form both ultrasound and 
photoacoustic images. 
To evaluate the nanosystem as a contrast agent for photoacoustic imaging, the 
USPA system was employed to image the nanoparticles directly injected into an ex-vivo 
canine pancreas. Specifically, the pancreas was set in a gelatin mold (only for structural 
stability and ease of imaging). The 180 nm silica core, silver coated particles (50 µl of 
109 particles/ml suspended in a warm 8% gelatin solution) were injected via needle into 
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the chilled pancreas, approximately 8-10 mm below the pancreas surface. The solution 
with nanoparticles quickly gelled inside the organ, mimicking accumulation of the 
nanosystem in a small tumor. Spatially co-registered ultrasound and photoacoustic RF 
signals were captured using the USPA system. All RF data was then beamformed and the 
images were plotted using conventional logarithmic (ultrasound) and linear 
(photoacoustic) scales. 
3.2.3 Preparing Samples of Set Concentrations of the Nanosystem for Imaging 
Studies 
Samples of the silver-silica nanosystem were created by incorporating the 180 nm 
silica core, silver coated particles in poly(vinyl alcohol) (PVA) at concentrations of 
2×107, 2×108, and 2×109 particles per ml. Specifically, under continuous stirring, 8 wt% 
PVA (165 sf from Celvol) was dissolved in water at 70°C containing a colloidal 
suspension of nanoparticles. After 15 min, the solution was pulled into a 1 cc syringe.  
The syringes were put through four freeze-thaw cycles in which they were held at -20°C 
for 12 hr and then at room temperature for 12 hr.  During these cycles, the PVA formed 
physical cross-links with itself. At the conclusion of the four cycles, firm 5 mm diameter 
cylindrical samples of suspended nanoparticles were removed from the syringes.  Setting 
the nanoparticles in these PVA samples provided a physical construct that held the 
various concentrations of nanoparticles in place for imaging. 
3.2.4 Cytotoxicity Testing of the Nanosystem 
The breast cancer cell line MDA-MB-231 and the pancreatic cancer cell line 
MPanc96 were both incubated with nanoparticles and tested for cell viability. Both cell 
lines were cultured in vitro using Dulbecco’s Modified Eagle Medium (with 4500 mg 
glucose/L, L-glutamine, NaHCO3 and pyridoxine HCl) supplemented with 10% fetal 
 64 
bovine serum and 1% HEPES buffer and were maintained at 37°C under 5% CO2 in a 
humidified incubator. All cell culture products were purchased from Sigma. For cell 
viability studies, cells were seeded in a 96 well plate (each well had 5,000 cells per 100 
µl of media). The cells were allowed to attach and grow in the 96 well plate for 24 hr, 
after which the cell media was removed and replaced with suspensions of PEGylated, 
silver coated 180 nm silica spheres at various concentrations representing 2 mg/ml, 1 
mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, and 0 mg/ml of silver specifically (at least 
5 wells were seeded with each concentration). Note that the highest silver concentration 
at 2 mg/ml represented ~2×1010 particles per ml, while the lowest silver concentration at 
0.125 mg/ml represented ~1×109 particles per ml. After 24 hr of incubation, the media 
containing the silver-silica nanosystem was removed and replaced with fresh media 
containing no nanoparticles. The absorbance of each well in the plate was measured at 
490 nm using a Synergy HT Multimode Microplate Reader from BioTek.  Then, 20 µl of 
a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) and an electron coupling reagent (phenazine 
methosulfate) PMS from the CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay (a Promega product) was added to each well. Over a period of 1.5 hr in the 
incubator, the MTS was bioreduced by cells into a formazan product that had an 
absorbance peak at 490 nm. Dehydrogenase enzymes found in metabolically active cells 
were responsible for the conversion of MTS into the soluble formazan product. 
Therefore, the absorbance of each well at 490 nm was directly proportional to the number 
of viable cells. Values for the absorbance of each well at 490 nm taken before adding 
MTS were subtracted from the after MTS incubation values. Cell viability was 
determined by comparing the resulting absorbance of wells containing no nanoparticles 
to wells containing nanoparticles using an F test for a one-way ANOVA.  
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3.3 RESULTS AND DISCUSSION 
3.3.1 The Silver-Silica Nanosystem 
Porous, cage-like silver coatings built around sizes of silica cores ranging in 
diameter from 180-520 nm were produced. A scanning electron micrograph of a typical 
batch of 180 nm particles and its corresponding UV-vis spectrum are shown in Figs. 3.3a 
and 3.3b. The extinction spectrum is broad and extends into the near infrared wavelength 
region; this ultimate broadening is comparable to results from other researchers who 
created similar coatings with different methods.18, 19 To achieve this broad extinction, 
sufficient silver coverage of the silica core is required. Indeed, when only half of the 
recommended moles of silver were reacted with 180 nm silica cores, insufficient coating 
of the particles resulted as shown in Fig. 3.3c. The corresponding extinction spectrum for 
these sparsely coated particles is similar to solid silver spheres in solution as shown in 
Fig. 3.3d. These results suggest that the cage-like coatings of silver over silica must reach 
a minimal confluency on the surface of silica for plasmonic effects to be observed in near 
infrared (NIR) wavelengths of light. Previous research has suggested that particles on the 
surface must be no more than 3 radii apart for nanoparticle plasmonic coupling to 
happen, shifting extinction to the NIR spectrum.20-22  
Silica core sizes up to 520 nm were coated with silver as shown in Fig. 3.3e. 
Interestingly, the corresponding extinction spectrum (Fig. 3.3f) was similar to that of the 
coated 180 nm particles (Fig. 3.3b), despite the large difference in silica core size. 
Research from the West and Halas groups have shown that by changing the thickness of a 
confluent layer of metal over a silica core, the absorption peak of the resulting 
nanoparticles can be tuned.23 Since a rough layer of silver over silica was built, it follows 
that the silver-silica nanosystem consists of particles with varying silver coating 
thickness. Therefore, the nanosystem is made up of nanoparticles, each of which is 
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resonating at a slightly different wavelength. At a macroscopic level, this results in the 
ultimate broadening on the extinction spectra since the spectra represents the contribution 
from all these roughly coated nanoparticles. Adding to this resonance effect is the action 
of single silver spheres in close proximity. On the surface of many nanoparticles, the 
coating is semi-confluent, but on others there is evidence of single silver spheres all 
attached to the silica and packed closely together. As mentioned previously, plasmon 
coupling effects take place when metal nanoparticles are within several radii of each 
other.20-22 
The silver-silica nanosystems described here are large with core diameters 
ranging from 180 nm to 520 nm; Mie theory calculations show that the extinction spectra 
for traditional shell-core, silver-silica particles are dominated by scattering. In fact, Jain 
et al2 described that for core-shell particles of this size, the scattering cross section 
divided by the absorption cross section is expected to be much greater than 6. However, 
the principal requirement for an excellent photoacoustic contrast agent is high optical 
absorption, which is represented by the absorption coefficient µa. The absorption 
coefficient is defined as 
µa = N⋅σabs,     (3.2) 
where N is the number concentration of particles and σabs is the absorption cross section 
of one particle. Furthermore, σabs = Qabs⋅σg where Qabs is the absorption efficiency, and σg 
is the geometric cross section of one particle. The Qabs for a 30 nm gold sphere is 2 at 532 
nm24, and Qabs for a silica-silver core shell structure (180 nm core, 60 nm shell) at 800 nm 
as calculated from publicly available Miecoated software developed by Christian Matzler 
at the University of Bern25 is ~2 orders of magnitude lower at 0.018. The geometric cross 
section, however, of the silver-silica nanosystem is almost two orders of magnitude 
greater than the gold spheres. Therefore, as it follows from Eq. 3.2, for the same 
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concentration of the two nanosystems, the absorption coefficient µa is on the same order 
of magnitude. This simple comparison elucidates why larger nanosystems can enhance 
photoacoustic imaging contrast to the same degree as smaller nanosystems which 
inherently possess higher absorption efficiencies. Therefore, when comparing 
nanosystems for enhancement of photoacoustic contrast, a critical parameter to consider 
is the absorption cross section, σabs. It is important to note that these Mie theory 
calculations are limited to shell-core particles and do not adequately describe the rough 
coatings purposefully built here, but these sample calculations were provided to convey 
the significance of the σabs parameter in the design of photoacoustic contrast agents. 
3.3.2 Imaging of the Silver Nanosystem in Ex Vivo Pancreatic Tissue 
One of the advantages of photoacoustic imaging is its ability to detect 
nanoparticles deep in tissue. This capability was tested by performing USPA imaging ex-
vivo on a canine pancreas after injecting 50 µl of 180 nm silica core, silver coated 
particles at a concentration of 109 particles/ml. The ultrasound image (Fig. 3.4a) defines 
the pancreas area, the photoacoustic image (Fig. 3.4b) shows the signal received 
primarily from the nanosystem interrogated by the pulse of scattered laser light, and the 
combined image (Fig. 3.4c) clearly depicts the location of the nanosystem against the 
background ultrasonic image of the organ. This series of images demonstrates the ability 
of combined USPA imaging to locate accumulated nanoparticles inside tissue and 
spatially register their location relative to the anatomical structures of the background 
tissue. In this case, strong photoacoustic signal from nanoparticles located 1 cm deep in 
tissue was detected. By translating the USPA imaging probe across the tissue surface, a 
3-D rendering of the entire nanoparticle injection region in the tissue could be generated 
(Fig. 3.5). Thus, if the silver nanosystem were injected in the bloodstream systematically 
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and accumulated in a cancerous mass, then combined USPA imaging could be used to 
locate the nanoparticles inside tissue, helping clinicians to better define and characterize 
diseased areas.  
 
3.3.3 Imaging the Nanosystem Samples of Set Concentrations 
In addition to the imaging performed on the pancreas, some fundamental 
properties of the photoacoustic signal from these nanoparticles were analyzed using 
samples of silver coated silica suspended in poly(vinyl alcohol) (PVA). Before describing 
the results of these studies in detail, the following relationships are provided for 
completeness. First, the photoacoustic pressure (Ρ) generated from an absorbing source 
immediately following a laser pulse can be defined as follows,26 
 
         (3.3) 
where β is the thermal expansion coefficient, ν is the acoustic velocity in the medium, µa 
is the absorption coefficient (as defined in Eq. 3.2), F is the fluence of light reaching the 
absorber, and Cp is the specific heat at constant pressure. Note that absorption from native 
tissue and/or PVA was assumed to be constant in our calculations, so changes in µa 
should solely reflect changes in nanoparticle concentration. Given these relationships and 
minimal temperature increases during PAUS imaging,13, 14, 27 a plot of P/F versus N 
should be linear. To test this hypothesis, PVA samples with different concentrations of 
nanoparticles were imaged and analyzed.   
The PVA samples, set in a gelatin mold for structural stability during 
photoacoustic imaging trials, were imaged using the USPA imaging setup similar to that 
shown in Fig. 3.2, except that samples were irradiated using a diffuse air beam outputted 
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directly from the OPO (i.e., no optical fibers were used). Furthermore, the air beam and 
ultrasound imaging plane were perpendicular to each other, not co-axial as shown in Fig. 
3.2. Specifically, an 800 nm, 4 mJ per pulse laser beam, diffused over an ~ 1 cm2 spot 
size, was directed at the circular end of the cylindrical nanoparticle samples. The 7.5 
MHz, 128 elements linear array transducer was set to image a traverse plane about ~2.5 
mm away from the circular end of the cylindrical samples. Such an imaging setup was 
needed to ensure homogeneous irradiation of the samples with known laser fluence (4 
mJ/cm2), thus allowing the analysis of the photoacoustic pressure dependence on the 
concentration of nanoparticles. 
Photoacoustic imaging of the samples resulted in a visible increase in signal as the 
concentration of nanoparticles increased, as shown in Fig. 3.6. To measure the changes in 
photoacoustic pressure quantitatively, areas inside the white circular regions of interest 
labeled in the inset images on Fig. 3.6 were set into grids of 60 by 50 pixels, inside 
which, a box of 30 by 30 pixels was defined.  The mean photoacoustic signal value of the 
30 by 30 pixel area was calculated for 21 different positions inside the 60 by 50 grid. The 
average of those different means was taken as the relative photoacoustic pressure for each 
sample. The relative fluence-compensated pressure values (per Eq. 3.3) versus 
concentration for each sample was linear (R2 = 0.999). This result confirms the 
fundamental relationship that for a reasonable range of concentration of absorbers 
(nanoparticles), the photoacoustic signal from the nanosystem increases linearly with the 
concentration of nanoparticles.  
Imaging the silver-silica nanosystem with set concentrations of particles not only 
allowed for testing this linear relationship, but also allowed for testing the sensitivity of 
our photoacoustic imaging system. Sensitivity was accessed by comparing the lowest 
concentration sample at 2x107 particles per ml to the control containing no particles. 
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Using a balanced one-way ANOVA test, the means of the signals gathered per the 21 box 
positions were compared between the control sample (no particles) and the lowest 
concentration sample tested (2x107 particles per ml). With a p value < 0.000001, the 
means of the two signal sets were statistically significantly different. Therefore, our 
photoacoustic imaging system is sensitive to concentrations at least as low as 2x107 
particles per ml. This detection limit is more than one order of magnitude lower than that 
reported for gold nanorods (7.5x108 nanorods per ml as reported by Eghtedari et al28). 
However, a direct comparison of these two sensitivity figures is not fully meaningful 
since the experimental conditions (i.e., the medium and distance traveled by light) were 
different in the two experimental set-ups. Nonetheless, the comparison does indicate that 
the silver-silica nanosystem was able to enhance photoacoustic signal at low 
concentrations similar to a well-known standard such as gold nanorods.   
In future in vivo experiments, the linear relationship between photoacoustic 
pressure and concentration of nanoparticles can be used to quantify the accumulation of 
the nanoparticles inside the tissue. If these nanoparticles were carrying drugs or other 
molecules of interest, performing photoacoustic imaging over time could provide 
noninvasive, quantifiable, image-guided monitoring of delivery and therapy. 
3.3.4 Cytotoxicity Tests Using the Silver-Silica Nanosystem 
There is much debate in the literature over the toxicity of silver.29 Its use in burn 
wound treatment and as an antimicrobial in general are well known and characterized, but 
questions over toxicity still remain.30-32 Due to these debates, it was critical for 
cytotoxicity tests to be performed using the silver-silica nanosystem. According to testing 
on two different cell lines (MDA-MB-231 and MPanc96), concentrations of silver in the 
silver coated silica particles up to 2 mg/ml (~2×1010 particles per ml in media) were not 
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exhibiting toxic effects. As shown in Fig. 3.7, cells exposed to no nanoparticles and cells 
exposed to concentrations of up to 2 mg/ml silver content showed no statistically 
significant variation in cell viability. The ANOVA tests on these populations showed p-
values of 0.6 and 0.4 with the MDA-MB-231 and MPanc96 cells lines, respectively. 
These p-values suggest that there is no reason to reject the null hypothesis that the means 
of the populations (absorbance values) tested were different. Thus, the cell viability of all 
the wells are the same, and the silver nanosystem did not exhibit cytotoxic effects, even 
at concentrations as high as 2 mg/ml content of silver. 
This work represents the first demonstration of photoacoustic imaging using a 
contrast agent incorporating silver in biological tissue. Further biodistribution and 
biocompatibility studies should be performed to evaluate the use of nanosilver in the 
body,33 but this work clearly demonstrates its potential as a photoacoustic contrast agent. 
The developed silver-silica nanosystem also has potential in image-guided 
therapy approaches. Once a diseased tissue or tumor is identified with traditional imaging 
techniques and the need for therapy is established, the delivery of these nanoparticles to 
the diseased site of interest could be image-guided to assist different therapy approaches. 
For example, photoacoustic imaging could be used to detect the presence and 
concentration of the particles in the tumor while they are simultaneously used for 
photothermal therapy. Furthermore, different types of therapy can be employed. Indeed, 
the particles could be used for guidance and monitoring of cavitation therapy  in which 
nanoparticles are used to create nanobubbles. These bubbles can act alone or they can be 
further exploited in ultrasound therapy. Moreover, when the particles contain 
chemotherapeutic drugs in their core (the CIT-NS design),34 then drug release could be 
controlled or monitored using this nanosystem augmented by USPA imaging. By 
tailoring the silver coating and the properties of the polymeric core used to make the 
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nanosystem, light may be used to induce a shape change in the structure of the 
nanosystem. This shape change should cause extensive release of the drug only where 
light interrogates the tissue with accumulated nanoparticles. Thus, the CIT-NS can serve 
simultaneously as an imaging contrast agent and therapeutic delivery and release device, 
enhancing our capabilities to effectively treat patients.    
3.4 CONCLUSIONS 
Rough silver coatings around silica nanospheres can be built and their optical 
extinction at near infrared wavelengths is high and broad. The breadth of the spectrum 
allows for a multitude of near infrared wavelengths to be used in photoacoustic imaging 
of these agents. Using 800 nm light, the silver-silica nanosystem was detected at least 1 
cm deep in ex vivo pancreatic tissue using combined ultrasound and photoacoustic 
imaging. Furthermore, the photoacoustic signal from the nanosystem was found to 
increase linearly with nanoparticle concentration, as theory suggested. Therefore, since 
(1) the silver-silica nanosystem was found to be non-toxic and (2) strong photoacoustic 
transients were generated by the silver-silica nanosystem and detected deep in ex vivo 
tissue, then the preliminary results suggest that the CIT-NS has the potential to provide 
image-guided therapy monitoring, opening up a host of applications in which imaging 














Figure 3.1: An illustration of the Combined Imaging and Therapy Nanocage System 




Figure 3.2.    Schematic of the combined ultrasound and photoacoustic (USPA) imaging 
system incorporating the array-based ultrasound transducer integrated with 




Figure 3.3.    Scanning electron micrograph (SEM) of the silver-silica nanosystem with 
silica core diameter of 180 nm (a), and corresponding coated 180 nm UV-
vis spectrograph (b); a batch of sparsely coated 180 nm nanoparticles (c), 
and corresponding UV-vis spectrograph (d); a silver coated 520 nm silica 
core batch (d), and corresponding UV-vis spectrograph (e).  All scale bars 
are 200 nm. 
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Figure 3.4.   Ultrasound (a), photoacoustic (b), and combined (c) images of nanoparticles 
injected directly into an ex-vivo canine pancreas. All images were acquired 
from the same position as determined by the location of the ultrasound 




Figure 3.5.    Several views of a 3-D rendering of USPA imaging from the silver 
nanosystem injected directly into an ex-vivo canine pancreas. All images are 
20 mm by 10.5 mm by 12 mm. For clarity, ultrasound signal from gelatin 





Figure 3.6.    Plot of fluence-normalized photoacoustic signal versus nanoparticle 
concentration for the four samples shown in the inset.  Inset: photoacoustic 
images of gelatin phantom with PVA samples containing 0, 2×107, 2×108, 
2×109 particles per ml from left to right where the white circle outlines the 
boundaries of the samples as determined by ultrasound imaging. All inset 
images are 12.5 mm by 10.5 mm. 
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Figure 3.7.   Cell viability data after 24 hr exposure to the silver-silica nanosystem at 
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Chapter 4: Synthesis and Characterization of the CIT-NS incorporating 
Doxorubicin 
Preliminary testing in Chapter 3 showed that a silver cage-like coating over a 
dielectric core, a structure optically similar to the CIT-NS, could provide photoacoustic 
imaging contrast, thus indicating that synthesis of the CIT-NS is indeed warranted. 
However, building the CIT-NS incorporating the drug gemcitabine is especially 
challenging since the native drug is hydrophilic and difficult to encapsulate in poly(lactic-
co-glycolic) acid (PLGA) (see Chapter 5 for details). For that reason, the CIT-NS was 
first built incorporating a model hydrophobic drug, namely the chemotherapeutic agent 
doxorubicin (DOX); which is known to encapsulate well in PLGA using oil in water 
emulsion techniques.1 This chapter details the experimental steps in synthesis and 
characterization of the CIT-NS incorporating DOX. The basic understanding of 
properties and synthesis techniques gained from making the CIT-NS with DOX proved 
that the design of the CIT-NS system is valid and producible, and provided the insight 
required for preparation of the ideal CIT-NS incorporating gemcitabine (Chapter 5).   
4.1 INTRODUCTION 
Since its discovery in 1971, the use of DOX as a chemotherapeutic agent has been 
rapidly expanding.2 DOX is currently FDA approved to treat lymphoma, acute leukemia, 
soft-tissue carcinoma and breast, ovarian, testicular, lung, bladder and gastric cancers.1 It 
is an anthracyline antibiotic that intercalates with DNA, blocking synthesis and 
transcription by sterically disturbing DNA nucleotides and inhibiting the enzyme 
topoisomerase II.1  
Because of DOX’s well characterized cardiotoxicity and nephrotoxicity2, 3, the 
maximum lifetime dose limit for this drug is 550 mg/m2 (note that m2 is the body surface 
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area of the patient).1 The damage to healthy cells caused by DOX has led to research by 
numerous groups on methods to encapsulate DOX in nanocarriers or make conjugates of 
DOX that can target the diseased site directly.1, 2, 4-14 In previous work from our group1, 
PLGA was used as a biodegradable carrier for DOX. Other groups have also proposed 
similar strategies for a combination of PLA or PLGA with DOX for cancer treatment.3, 15  
DOX is a popular model drug in nanocarrier research for several reasons: (1) it is 
FDA approved to treat numerous cancers, (2) it is hydrophobic (soluble in methanol and 
minimally soluble in aqueous salt solutions), (3) it is orange-red in color (absorbs light at 
480 nm), and (4) it is inherently fluorescent. All of these factors make it a suitable model 
drug for the CIT-NS system. Its hydrophobic nature should facilitate DOX’s 
incorporation into the CIT-NS system.  Once incorporated, DOX’s fluorescence and light 
absorption properties should enable drug release profile characterization by spectroscopy 
and studies of DOX’s interaction with cells by microscopy. This chapter covers the 
experimental methods and results of incorporating DOX as a model drug into the CIT-NS 
without a targeting antibody (Fig 4.1). Understanding how this model drug performs in 
the CIT-NS represents a significant step towards synthesis and understanding of the ideal 
CIT-NS incorporating the drug gemcitabine.  
4.2  METHODS 
Each step in the synthesis and characterization of a DOX loaded CIT-NS are 
described separately below. For reader clarity, the sources for all materials are 
consolidated here. 
4.2.1 Materials 
All chemicals were used without further purification and were at minimum ACS 
grade.  PLGA 50:50DL 2A was purchased from Lakeshore Biomaterials (Birmingham, 
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AL, USA) and Medisorb (Cincinnati, OH, Mn = 11 kD).  ACS grade L(+) ascorbic acid 
and ultrapure silver nitrate were products of Acros (Morris Plains, NJ, USA). Polyvinyl 
alcohol (PVA) was purchased from Sigma-Aldrich (St. Louis, MO, USA, ~30 kDa).  
Dimethyl sulfoxide (DMSO) and acetone were purchased from Fisher Scientific (Fair 
Lawn, NJ, USA).  Slide mounting media, Vectashield with DAPI stain, was from Vector 
Laboratories (Burlingame, CA, USA).  Sodium hydroxide was purchased from J.T. Baker 
(Phillipsburg, NJ, USA).  Dulbecco’s phosphate buffered saline (DPBS) came from 
Mediatech, Inc. (Herndon, VA, USA). Doxorubicin hydrochloride was purchased from 
Fisher Scientific (Fair Lawn, NJ, USA).  All cell culture products were purchased from 
Invitrogen (Carlsbad, CA, USA) unless otherwise specified. The MTT assay (Toxicology 
Assay Kit TOX-1) and the bovine serum albumin (BSA) were from Sigma (St. Louis, 
MO, USA). Finally, the methyl-poly(ethylene glycol)-thiol (mPEG-SH of 5 kDa) was 
from Laysan Bio (Arab, AL, USA). 
4.2.2 Nanocage Synthesis with Doxorubicin  
 The CIT-NS was built in a step-wise, bottom up approach. An overall schematic 
describing the steps in synthesis required for the CIT-NS incorporating DOX are shown 
in Fig 4.2 and are described in sequence below. 
 Step 1: Synthesizing the PLGA Core with Encapsulated DOX: An oil in water 
nanoprecipitation method, modified from that reported by Betancourt et al.1, was 
employed.  Briefly, 10 mg of DOX was dissolved in 2 ml methanol.  Separately, 100 mg 
of poly(lactic-co-glycolic) acid (PLGA) (50:50 DL, MW~12 kDa) was dissolved in 3 ml 
acetone. The co-solvent oil phase was created by mixing 1 ml of the DOX solution with 
all of the PLGA solution.  The water phase consisted of a 10 ml surfactant solution of 1 
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mg/ml poly(vinyl alcohol) (PVA) and 10 mg/ml bovine serum albumin (BSA) in 
deionized and ultrafiltrated to 18.2 MΩ-cm (DIUF) water.   
The oil phase was pipetted quickly into the water phase and sonicated briefly for 
15 seconds.  The resulting nanoprecipitation was stirred rigorously under slight vacuum 
for 30 min to remove the organic solvents. The resulting DOX loaded PLGA 
nanoparticles were collected via centrifugation at 48,000xg in a Beckman J2-21 
refrigerated centrifuge running at 4°C for 15 min.  The particles were washed once with a 
10 mg/ml PVA solution and then resuspended in 20 ml DIUF water. The supernatants 
from all washes were retained for spectrophotometry analysis.  
 Step 2: Nucleating Ag on the Surface of PLGA: The DOX-loaded PLGA 
nanoparticles from step 1 (250 μl of the total 20 ml) were placed in a round shallow glass 
dish with 30 ml DIUF water (the water level was no greater than 3 mm high in the 
shallow dish).  While stirring at 400 rpm, 300 μl of 0.15 M silver nitrate was added.  The 
entire dish was then subjected to 254 nm light from an 8 W source for 15 min. During 
that 15 min, the light activated the PVA to act as a photoreducing agent for silver, 
nucleating silver on the surface of PLGA. 
Step 3: Ag Nanocage Formation Around PLGA: Following from Step 2, the UV 
light was removed and the solution was transferred to a 50 ml polyethylene beaker.  
While stirring, 100 μL of 18wt% ascorbic acid was added.  Within 30 seconds the 
solution turned from pink (native color of DOX-loaded PLGA) to tan-brown and finally 
grey-black, indicating that the silver had been reduced. Directly following reduction, 0.1 
ml of a 30 mg/ml solution of methyl-poly(ethylene glycol)–thiol (mPEG-SH) was added 
and allowed to stir for 15 min. The resulting nanocages were collected via centrifugation 
at 48,000xg in a Beckman J2-21 refrigerated centrifuge running at 4°C for 15 min. The 
supernatant was retained for spectrophotometry analysis. 
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4.2.3 Nanocage Characterization with Doxorubicin  
Several methods were used to characterize the nanocages: scanning electron 
microscopy (SEM), ultraviolet to visible (UV-vis) spectrophotometry, zeta potential, and 
dynamic light scattering.  For all stages of CIT-NS development, preparation for SEM 
involved aliquoting the nanosystem directly from the reaction vessel and placing a drop 
on carbon conductive tape attached directly to an SEM platform tab.  The drop was 
allowed to dry prior to examination using a 10 kV accelerating voltage on a LEO 1530 
scanning electron microscope.  Note that to observe the DOX loaded PLGA cores using 
SEM, the sample was sputter coated with a 20 nm thick layer of gold.  Observation of the 
CIT-NS after any level of reduction of silver no longer required sputter coating for SEM 
preparation. 
The optical properties of the CIT-NS were examined using a Shimadzu UV-1201 
spectrophotometer. The CIT-NS was suspended in DI water in a plastic 10 mm 
pathlength cuvette.  The spectrophotometer was used in absorbance mode to read the 
attenuation of light passing through the sample at wavelengths from 300 to 1100 nm.   
The surface charge and size distribution of DOX loaded PLGA particles produced 
using the nanoprecipitation technique were characterized using a ZetaPlus instrument 
with accompanying software (Brookhaven Instruments Corp., Holtsville, NY) on 
suspensions of 1 mg/mL nanoparticles in water.  
4.2.4 In Vitro DOX Release Studies 
 To perform DOX release studies, the entire procedure described in 4.2.2 had to be 
scaled up in order have enough DOX released from nanocages to allow for proper 
spectrophotometry measurements over long time periods. Specifically, the procedure was 
modified as follows. In Step 1 directly after the oil-in-water emulsion, 5 ml of 0.15 M 
silver nitrate was added and 254 nm light from an 8 W source irradiated the mixture 
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while stirring during the vacuum distillation of the organic phases (the acetone and 
methanol). Following vacuum distillation, the Ag nucleated DOX-PLGA nanoparticles 
were collected via centrifugation at 48,000xg in a Beckman J2-21 refrigerated centrifuge 
running at 4°C for 15 min.  The resulting pellet of particles was resuspended in 20 ml 
DIUF water and the supernatant was retained for spectrophotometric analysis. Then 5 ml 
of the particle solution was added to each of four large beakers prefilled with 300 ml of 
DIUF water each. With vigorous stirring, 2.5 ml of 0.15 M silver nitrate was added to 
each beaker. To reduce the silver into cages over the DOX-PLGA, 0.3 ml of 18wt% 
ascorbic acid was added to each beaker. Over the course of 30 s, the solution turned from 
pink (native color of DOX-loaded PLGA) to tan-brown and finally grey-black, indicating 
that the silver had been reduced. Directly following reduction, 0.25 ml of a 30 mg/ml 
mPEG-SH solution was added. The resulting nanocages were collected via centrifugation 
at 48,000xg in a Beckman J2-21 refrigerated centrifuge running at 4°C for 15 min. The 
pellet was resuspended in 15 ml of DIUF water and equal aliquots of the suspension  
were loaded into 3 centrifuge tubes. These tubes were kept in a 37°C water bath over a 
period of 1 week. During that week, the tubes were periodically spun down at 48,000xg 
in a Beckman J2-21 refrigerated centrifuge running at 4°C for 15 min. After each 
centrifugation, the pellet was resuspended via sonication in 5 ml of fresh DIUF water and 
placed back in the warm water bath. The supernatants from each round of centrifugation 
were kept and analyzed to determine how much DOX was releasing into the water over 
time.  
4.2.5 Cytotoxicity Studies 
Cell Maintenance and Preparation: The in vitro therapeutic efficacy of the various 
PLGA-DOX nanoparticles were tested against human mammary gland epithelial 
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adenocarcinoma cells (MDA-MB-231). The breast cancer cells were maintained in 
Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum, 1% 
HEPES buffer, 1% L-glutamine, and 1% sodium pyruvate. They were kept at 37°C in a 
humidified 5% CO2 incubator. For cell studies, 4500 cells per well were seeded in a 96 
well plate and allowed to attach and grow for 1 day in media prior to the cytotoxicity 
experiment.  
Nanoparticle Preparation: Three types of nanoparticles were tested for toxicity: 
the CIT-NS with DOX, the CIT-NS without DOX, and the DOX loaded PLGA 
nanoparticles. Following Step 3 explained in 4.2.2, the nanocages (CIT-NS with DOX) 
were suspended in 3.1 ml of MDA-MB-231 cell media and sterilized by sending the 
entire solution with nanocages through a 0.45 µm syringe filter. This suspension of 
nanocages in media represented a 12 µg/ml concentration of DOX. To get the other 
concentrations of 1.2 and 0.12 µg/ml DOX that were tested, the nanocages were diluted 
1:10 in media. To test nanocages with no drugs (CIT-NS without DOX), the exact same 
procedures were followed, but DOX was not included during the formulation. Finally, to 
obtain a similar concentration of DOX in the DOX-PLGA nanoparticles (with no 
nanocage), 80 µl of the 20 ml suspension of DOX-PLGA nanoparticles (after Step 1 in 
4.2.2) were suspended in 1 ml of MDA-MB-231 media. The DOX-PLGA particles were 
also diluted 1:10 in media as appropriate to obtain the 1.2 and 0.12 µg/ml DOX 
concentrations for cell testing.  
MTT Assay: After cells were allowed to grow for 24 hr in the 96 well plate, their 
media was aspirated off and media containing the prepared nanoparticles was added. The 
media containing nanoparticles was allowed to interact with the cells for 4 hrs, after 
which the media with nanoparticles was removed and replaced with fresh, unadulterated 
media. Each condition was repeated in 4 separate wells, each containing 100 µl of media. 
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To assess the therapeutic efficacy of the interaction between the nanoparticles and the 
cells, the cells were allowed to incubate and grow for another 48 hr after the 
nanoparticles were removed. At 48 hr the activity of the mitochondria in each well was 
tested by adding 10 µl of the MTT product (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide). This MTT product was incubated with the cells for 4 hr, at which 
time the yellow tetrazole product was reduced by active mitochondria into insoluble 
purple formazan crystals. After adding 100 µl of the isopropanol/HCl mixture provided in 
the kit to each well in the 96 well plate and pipetting extensively, the formazan product 
dissolved. The absorbance of the formazan product at 570 nm could be determined for 
each well using a spectrophotometer, and a comparison with control wells provided a 
measure of therapeutic efficacy of the nanoparticles. To test whether conditions (wells 
with nanoparticles) were statistically significantly different from controls, an F test for a 
one-way analysis of variance (ANOVA) was used.   
Microscopy Studies: MDA-MB-231 cells were grown on microscope slide 
coverslips. The highest concentration of nanocages (representing 12 µg/ml DOX in cell 
media) were incubated with these cells on the coverslips for 18 hr. After 18 hr, the media 
containing nanocages was removed and the coverslip was washed 3x with 2 ml of DPBS. 
Then a solution of 1% formalin in DPBS was incubated for 20 min with the cells on the 
coverslips. Finally the formalin-DPBS was aspirated away and the coverslips were 
mounted on slides using Vectashield with DAPI nuclear stain and sealed on the edges 
with nail polish. Images of the cells were captured using a Leica Inverted Microscope at 
40X equipped with epi-fluorescence, brightfield, and phase contrast modes.   
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4.3 RESULTS AND DISCUSSION 
 The CIT-NS incorporating the model drug DOX is an important first step in 
building a prototype of the CIT-NS design and proving that it can be functional in vitro. 
In this section, results of the DOX loaded CIT-NS are presented and described from 
synthesis through characterization with breast cancer cells.   
4.3.1 CIT-NS incorporating Doxorubicin 
The synthesis of the CIT-NS started with an oil in water emulsion to load DOX in 
PLGA nanospheres (Step 1 in Section 4.2.2). A typical scanning electron microscope 
(SEM) micrograph of DOX loaded PLGA cores is shown in Fig 4.3.  These particles 
averaged 210 nm in mean diameter with a polydispersity index of 0.09 and a zeta 
potential of -7 mV as measured using a ZetaPlus instrument. The negative zeta potential 
of these particles indicates their propensity to repel each other in solution, leading to a 
stable colloid. Furthermore, 65% encapsulation efficiency (mg of DOX encapsulated per 
mg of DOX in the preparation) was observed. In this case, we attempted to load 5 mg of 
DOX in 100 mg of PLGA and the encapsulation of 3.25 mg was observed and is 
comparable to previous studies.1  
The next step in building the CIT-NS is to form nucleation sites for Ag on the 
surface of PLGA (Step 2 in Section 4.2.2). To nucleate silver on PLGA cores, a 
photoreduction method was employed. A diluted solution of the as prepared DOX-loaded 
PLGA nanospheres was placed in a round shallow dish and irradiated with 254 nm light. 
During this time, the PVA surfactant, still present on the surface of the PLGA 
nanospheres from the emulsion, acted as a reducing agent for Ag+ in solution, as shown 
mechanistically in Fig 4.4, while also serving as macroscopic support for the forming 
silver seeds. An image of these PLGA cores with silver nucleation sites is shown on the 
right side of Fig 4.4. Recall that preparation of these samples for SEM involved drop 
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casting them on a SEM tab with no metal sputter coating. Therefore, as the SEM image in 
Fig. 4.4 was acquired, the PLGA cores were ballooning in response to the electron beam, 
and thus, the sizes shown in the image are up to 100% greater than actual size and 
degradation of some silver nucleated cores is evident.  
The final step in building the CIT-NS involved the reduction of a silver cage 
around PLGA (Step 3 in Section 4.2.2). The photoreduction step (Step 2) only reduced a 
small percentage of the total Ag+ to Ag0 on the surface of PLGA, and therefore a final 
step using a stronger reducing agent was required to reduce all the Ag+ and produce a 
cage layer of silver around PLGA. The final reducing agent, ascorbic acid, was added 
under continued vigorous stirring at room temperature. Examples of two different cage 
morphologies produced after ascorbic acid reduction around PLGA are shown in Fig 4.5. 
Interestingly, the cages in Fig 4.5a were produced when half of the silver was used (only 
150 µl of 0.15 M silver nitrate) and the temperature was 1°C, whereas the almost fully 
confluent layer of silver in Fig 4.5b was produced at room temperature with 300 µl of 
0.15 M silver nitrate. From SEM analysis, the size of the silver cage varied in thickness 
from 20 nm to 60 nm.  
An ultraviolet to visible (UV-vis) spectrum of these nanocages was taken directly 
after synthesis and is shown in Fig 4.6. Interestingly, unlike nanoshells, the absorbance 
spectrum for the CIT-NS is broad and relatively uniform across the 400-1100 nm 
wavelength range.  This extinction pattern is different from other nanoparticles, such as 
nanoshells, defined by a confluent layer of metal over a dielectric core. The light 
absorbance properties, specifically the longitudinal surface plasmon resonance peak, of 
these nanoshells can be tuned by changing the thickness of their metallic layer.16 It could 
follow that since our metallic layer is, by design, not confluent or of uniform thickness 
and there is polydispersity in the size of the PLGA cores, an ultimate broadening or 
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flattening of the spectrum results. Furthermore, plasmon coupling between adjacent silver 
nanostructures on the PLGA surface can further broaden the spectrum.17, 18 Thus, the 
CIT-NS absorbs and scatters light strongly across a wide range of the wavelengths. The 
extinction spectrum of the nanocage system confers two important properties: (1) the 
nanocages can be used as a photoacoustic contrast agent since they absorb light in the 
near infrared spectrum where tissue absorption is minimal (Fig 1.3) and (2) a pulsed laser 
of any near infrared wavelength can be used for photoacoustic imaging with the nanocage 
system. 
The successful synthesis of the silver cage around a DOX loaded PLGA core 
represents the first known prototype of the novel CIT-NS. Post synthesis, an analysis of 
the in vitro functionality of the nanocage system was conducted and that discussion is 
provided in the next two sections.  
4.3.2 Doxorubicin Release Study 
The CIT-NS system was designed with the intent that the silver cage built 
surrounding the PLGA core should slow the release of drug by limiting its diffusion out 
of the core. The DOX release study shown in Fig 4.7 addresses this hypothesis. DOX 
release from DOX-PLGA nanospheres and the CIT-NS are compared. Both nanosystems 
show a characteristic burst release profile19, 20, but the profile was significantly delayed 
for the nanocage system. In the first 5 hours, the nanocage system released less than 10% 
of DOX, while the DOX-PLGA system had released over 50% of its contents. Since the 
nanocage system being tested was the system with the most confluent layer of silver (Fig 
4.5b), then the release profile shown in Fig 4.7 represents the slowest release profile 
achievable with the CIT-NS for the model drug DOX. The delayed drug release obtained 
with the CIT-NS is significant since maximum accumulation of nanosystems in tumors 
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using mouse models have been observed at ~5 hr (see Chapter 7). Therefore, if the CIT-
NS were systemically injected, it would elute less than 10% of its drug into the 
bloodstream in the first five hours while its circulating and accumulating at a cancer site. 
In comparison, the DOX-PLGA nanospheres would release greater than 50% into the 
blood stream, making that nanosystem hardly more effective than systemic injections of 
free drug as is currently performed in the clinic.  
4.3.3 Cytotoxicity Studies 
The cytotoxicity results obtained by mixing the CIT-NS and its various 
components with breast cancer cells were highly encouraging. As shown in Fig 4.8, the 
formulation with only PLGA and silver showed no statistically significant loss of cell 
viability relative to control. These results are contrary to literature reporting on the 
cytotoxicity of silver.21 The highest concentration tested here was 1.3 mg/ml of silver 
mixed with the cells – a high concentration. Therefore, silver in this form as part of the 
CIT-NS with a PLGA core and surrounding PEG layer was not cytotoxic. My hypothesis 
is that a size and surface property dependence on the toxicity of silver exists. Specifically, 
the silver ion is the most reactive form of silver and is likely responsible for its toxicity 
(see Chapter 2). When silver is in the form of small (5-10 nm), unstable seeds or in the 
form of a salt, the likelihood of silver ion release into the cellular environment is higher 
than that for the CIT-NS structure that has a much larger, more passivated silver surface. 
Therefore, since all the reports in the literature tested silver nanoseeds or silver salts22-24, 
it is feasible that larger, more stable silver nanostructures present an exception. Since 
they are more stable and less reactive, the basal level of silver ions eluted into the cellular 
space is low – low enough not to induce toxicity. Further work would be required to 
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address this hypothesis directly, but the hypothesis is provided as a possible explanation 
for the lack of toxicity observed here.  
In addition to the lack of toxicity from silver, other encouraging results are shown 
in Fig 4.8. For instance, in every formulation involving DOX, a corresponding loss of cell 
viability was observed. This loss of viability was concentration dependent and 
statistically significant with a p < 0.02 in the conditions with higher DOX concentrations. 
Therefore, encapsulating the drug in the CIT-NS is not hurting the in vitro efficacy of the 
drug and losses in cell viability are comparable to free drug. These results prove that the 
CIT-NS can function as designed and exhibit cytotoxic effects in a concentration 
dependent manner as expected.  
To further prove that DOX can be delivered to cells using the CIT-NS, 
microscopy studies with cells grown on coverslips was performed. Fig 4.9 shows co-
location of DOX fluorescence in the nucleus of breast cancer cells after 18 hr of 
incubation with the CIT-NS. The red DOX fluorescence was also seen in the cytoplasm 
near the nuclei. These results indicate that DOX can be delivered to cells by the CIT-NS 
and DOX does traffic through the cell, reaching the nucleus where it intercalates with 
DNA and exhibits its cytotoxic effect.  
4.4 CONCLUSIONS 
The CIT-NS incorporating the model drug DOX was successfully synthesized. 
Analysis of the in vitro properties of the system, such as control over the drug release 
profile and broad extinction in the near infrared spectrum, indicate that the nanosystem is 
viable for in vivo applications. Relating to the goals of the overall thesis, the results 
detailed in this chapter indicate that: (1) the design of the CIT-NS is valid and (2) that a 
prototype of the CIT-NS incorporating DOX can be synthesized with the expected 
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functional properties of drug delivery and light absorbance in the near infrared spectrum. 
Since the CIT-NS was successfully built with the model drug DOX, the ideal CIT-NS 





























Figure 4.1. An illustration of the Combined Imaging and Therapy Nanoplate System 





Figure 4.2.    A schematic illustrating the steps required to synthesize the CIT-NS 





Figure 4.3.    Doxorubicin loaded PLGA nanosphere (a) under scanning electron 






Figure 4.4.    Reaction schematic depicting how poly (vinyl alcohol) acts as a reducing 
agent in the presence of UV light (left). Scanning electron micrograph of 





Figure 4.5.   Different morphologies of the silver cage structure that was reduced on top 
of a PLGA core.  
 
 
Figure 4.6.    The extinction spectrum of the tightly packed silver nanocages directly after 




Figure 4.7.    A comparison of in vitro DOX release from DOX loaded PLGA 
nanospheres1 (orange curve) versus DOX loaded PLGA nanospheres coated 




Figure 4.8.   Results of the MTT assay with four different conditions mixed in media 
relative to controls. Values lower than 1 indicate therapeutic efficacy (lower 
cell viability).  
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Figure 4.9.    MDA-MB-231 breast cancer cells after 18 hr incubation with the CIT-NS 
incorporating DOX. (a) fluorescence image showing blue DAPI stained 
nuclei, (b) fluorescence image of the same cells in (a) showing red DOX 
flourescence, (c) a phase contrast image, and (d) a composite image of the 
three previous images showing purple nuclei – this indicates the co-location 
of DOX in the nucleus of these cells. Red DOX is also visible in the 
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Chapter 5: Synthesis and Characterization of the CIT-NS incorporating 
Gemcitabine 
At this point in the dissertation, all preliminary steps towards creating the CIT-NS 
have been described. Chapter 3 showed proof of concept for photoacoustic imaging using 
an optically similar nanosystem. Chapter 4 provided in vitro characterization of the CIT-
NS, incorporating the model drug doxorubicin. This chapter details attempts to 
incorporate gemcitabine, the pancreatic cancer chemotherapeutic agent, into the CIT-NS 
(Fig 5.1).  
5.1 INTRODUCTION 
Gemcitabine (Gem) remains the gold standard in chemotherapeutic treatment of 
pancreatic cancer.1 Gem (2’,2’-diflourodeoxycytidine) is a pyrimidine antimetabolite 
whose structure is an analogue to deoxycytidine (Fig 5.2). The two fluorine atoms on 
Gem that differentiate it from deoxycytidine make it a potent analogue base.  
Once in the cell, Gem must undergo phosphorylation to the active 5’-triphosphate; 
this conversion is mediated by deoxycytidine kinase. Once in this active form, 
gemcitabine triphosphate gets incorporated in an elongating DNA strand. Once it is 
added, however, no further bases can attach, DNA synthesis halts, and there is further 
inhibition of ribonucleoside reductase.2 Thus, Gem’s mode of action is to mimic the C-
base of DNA, use the cell’s native enzymes to put it in an active 5’-triphosphate form, 
and halt DNA synthesis, leading to cell death via apoptosis.  
Unfortunately, Gem could not be incorporated in poly(lactic-co-glycolic) acid 
(PLGA), which is the core of the desired CIT-NS system.  Like all DNA bases, Gem is 
hydrophilic. This hydrophilic property makes it difficult to entrap in hydrophobic carriers 
such as poly(lactic-co-glycolic) acid (PLGA).  Thus, a prodrug form of Gem was sought.   
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Another reason for seeking a prodrug form of Gem is that Gem has a short half 
life in plasma (on the order of minutes). Therefore large doses of the drug are required to 
achieve therapeutic levels.  Gem’s short half life is caused by cytidine deaminase in the 
blood, liver, and other tissues. Cytidine deaminase converts Gem to the inactive 
metabolite 2’,2’-diflourodeoxyuridine, which is excreted in the urine.2  
Synthesizing prodrug forms of Gem can solve both the solubility and deamination 
challenges. Making 4-(N)-acyl derivative prodrug forms of Gem can (1) make the drug 
more hydrophobic and (2) provide enough stability of the amine to significantly increase 
its half life in vivo.2, 3 Researchers have shown that acyl derivative of Gem are just as 
active or more active than the native drug since cathepsin enzymes B and D do cleave the 
amide bond on the prodrug, recovering native Gem in the intracellular space.2 Therefore, 
Gem prodrugs represent a viable option for incorporation in the desired CIT-NS.  
In this chapter, encapsulation of native gemcitabine and a prodrug form of 
gemcitabine in PLGA using emulsion techniques is presented. Furthermore, the 
implications of incorporating these gemcitabine derivatives in the CIT-NS design is 
broadly addressed.  
5.2  METHODS 
Each step in the synthesis and characterization of gemcitabine derivatives loaded 
in PLGA are described separately below. For reader clarity, the sources for all materials 
are consolidated here. 
5.2.1 Materials  
All chemicals were used without further purification and were at minimum ACS 
grade.  PLGA 50:50DL 2A was purchased from Lakeshore Biomaterials (Birmingham, 
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AL, USA, ~12 kDa) and Medisorb (Cincinnati, OH, Mn = 11 kD). Bovine serum albumin, 
polyvinyl alcohol (PVA, ~30 kDa), mineral oil, oleoyl chloride, pyridine, and methanol 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Dimethyl sulfoxide 
(DMSO) and acetone were purchased from Fisher Scientific (Fair Lawn, NJ, USA). 
Dulbecco’s phosphate buffered saline (DPBS) came from Mediatech, Inc. (Herndon, VA, 
USA). Lecithin was a product of Acros (Morris Plains, NJ, USA). Gemcitabine 
hydrochloride was purchased from Chemiceuticals LLC (Research Triangle Park, NC, 
USA).  All cell culture products, including the MTS assay, were purchased from 
Invitrogen (Carlsbad, CA, USA) unless otherwise specified. 
5.2.2 Gemcitabine Encapsulation in PLGA 
In spite of its hydrophilic properties, encapsulation of Gem in PLGA was 
achieved. A water-in-oil-in-oil double emulsion method was used, similar to that 
previously described.4, 5 An inner aqueous phase was created by dissolving 24 mg of Gem 
in 500 µl of a 10 mg/ml polyvinyl alcohol (PVA) solution.  This phase was slowly added 
onto an organic phase (inner oil) containing 100 mg of PLGA in 1.25 ml of acetone, and 
the system was sonicated for 1 min.  This first emulsion was poured into 35 ml of the 
external oil phase which contained mineral oil with dissolved lecithin (1.25 mg/ml) and 
sonicated again for 1 min.  Organic solvent was removed while stirring under vacuum, 
the particles were collected by centrifugation at 45,000xg for 15 min, and the supernatant 
was removed.  Gem loaded PLGA particles were washed repeatedly by suspension in 
hexane containing lecithin (1.25 mg/ml) to remove mineral oil. Storage of the particles 
involved adding 120 mg of trehalose (cryoprotectant) to the particle pellet and freezing 
overnight in a -80˚C freezer.  The resulting solution was then lyophilized in a Freeze 
Dryer 4.5 (Labconco, Kansas City, MO, USA) and the particles stored at -20˚C. For Gem 
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release studies, the particles were suspended in 40 ml of Dulbecco’s phosphate buffered 
saline (DPBS) and allowed to sit in a 37°C water bath. At various times, the particles 
were spun down at 45,000xg for 15 min and their supernatants collected. Drug release 
was quantified using spectrophotometric analysis of the supernatants at the peak 
absorbance of Gem (269 nm).  
5.2.3 Synthesis of a Gemcitabine Prodrug  
Many methods were used in attempts to make Gemcitabine-N4 Oleoyl Amide (see 
Section 5.3.2.2). The greatest yield was achieved by a method adapted from a 
gemcitabine derivatives patent which described a similar procedure using elaidic acid 
chloride.3 The reaction schematic is shown in Fig 5.3. Specifically, Oleoyl Chloride (OC) 
was reacted in 2.5 molar excess to Gem by the following method. Gem (100 mg, 0.333 
mmol) was dissolved in 3.0 ml of pyridine and placed under an Ar environment with 
vigorous stirring. Then 55 µl of OC (0.167 mmol) was added using a microneedle at 
successive time points of 0, 1, 2, 3, and 4 hr into the reaction. The reaction was 
characterized using electrospray ionization mass spectroscopy at the time points of 1, 2, 
3, 4, and 5 hr into the reaction. To separate unreacted OC from the PD, the entire crude 
reaction mixture was rotovaped until only an orange gooey precipitant remained. The 
precipitant was then suspended in 10 ml methanol. Remaining unreacted OC and oleic 
acid collected as a clear/white pellet at the bottom of the flask. The methanol containing 
PD was collected and rotovaped 3x with methanol suspensions to remove any excess 
pyridine. The final product was characterized by rotovaping again, drying overnight in a 
vacuum oven, and resuspending in deuterated pyridine for H1 Nuclear Magnetic 
Resonance (NMR) analysis at 600 MHz. Spiking the mixture for NMR with a known 
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amount of dioxane allowed for quantification of the amount of PD present, and thus the 
yield of this synthesis method.  
5.2.4 Cytotoxicity Studies with the Gemcitabine Prodrug 
The human pancreatic cancer cell line L3.6pl (a generous gift from the Pancreatic 
Cancer Group at M.D. Anderson Cancer Center) was incubated with both Gem and the 
PD in cell media to test the therapeutic efficacy (cell viability) of both drugs relative to 
each other and relative to control conditions with no drugs. The L3.6pl cells were 
cultured using Dulbecco’s Modified Eagle Medium (DMEM) (with 4500 mg glucose/L, 
L-glutamine, NaHCO3 and pyridoxine HCl) supplemented with 10% fetal bovine serum 
(FBS) and 1% Penicillin-Streptomycin (Pen/Strep) while maintained at 37°C and 5% CO2 
in a humidified incubator. For cell viability studies, cells were seeded in a 96 well plate 
(each well had 5,000 cells per 100 µl of media). The cells were allowed to attach and 
grow in the 96 well plate for 24 hr, after which the cell media was removed and replaced 
with suspensions of Gem and PD in media at various concentrations (300 nM, 30 nM, 3 
nM and 0 nM). Note that to get the PD suspended properly in media, Tween 20 was 
added as a biocompatible surfactant. After 48 hr of incubation, 20 µl of a tetrazolium 
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) and an electron coupling reagent (phenazine methosulfate) PMS 
from the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (a Promega 
product) was added to each well. Over a period of 1.5 hr in the incubator, the MTS was 
bioreduced by cells into a formazan product that had an absorbance peak at 490 nm. After 
1.5 hr, the absorbance of each well in the plate was measured at 490 nm using a Synergy 
HT Multimode Microplate Reader from BioTek. Dehydrogenase enzymes found in 
metabolically active cells were responsible for the conversion of MTS into the soluble 
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formazan product. Therefore, the absorbance of each well at 490 nm was directly 
proportional to the number of viable cells (at least 6 wells were tested per condition). Cell 
viability was determined by comparing the resulting absorbance of wells containing no 
drugs to wells containing Gem and PDs using an F test for a one-way ANOVA. 
5.2.5 Gemcitabine Prodrug Encapsulation in PLGA 
An oil in water emulsion technique was used to entrap the PD in PLGA similar to 
that previously described6 and used for Doxorubicin encapsulation in Chapter 4. This 
technique is appropriate since the PD is soluble in methanol. The steps in this technique 
are described below and shown in Fig 5.4.  
Briefly, 100 mg of PLGA was dissolved in 2 ml acetone. Then 225 µl of an 11.11 
mg/ml solution of the PD in methanol was added to the PLGA solution in acetone to form 
the oil phase. The water phase consisted of a 10 ml surfactant solution of 5 mg/ml 
poly(vinyl alcohol) (PVA) and 5 mg/ml bovine serum albumin (BSA) in deionized and 
ultrafiltrated to 18.2 MΩ-cm (DIUF) water.   
The oil phase was pipetted quickly into the water phase and sonicated for 15 
seconds.  The resulting white cloudy nanoprecipitation was stirred vigorously under 
slight vacuum for 30 min to remove the organic solvents. The resulting PD loaded PLGA 
nanoparticles were collected via centrifugation at 48,000xg in a Beckman J2-21 
refrigerated centrifuge running at 4°C for 15 min. The supernatants from all washes were 
retained for spectrophotometric analysis. 
5.3 RESULTS AND DISCUSSION 
The first step in synthesizing the CIT-NS system with Gem is to encapsulate Gem 
in PLGA. The results of several methods to entrap Gem and a PD of Gem in PLGA are 
detailed below.  
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5.3.1 Gemcitabine loaded PLGA Microparticles 
Gem was successfully loaded in PLGA using a water-in-oil-in-oil emulsion was 
successful. Encapsulation efficiencies (percent of Gem loaded versus that used in 
preparation) of up to 70% with loadings of up to 17 mg Gem per 100 mg PLGA, as 
determined by spectrophotometric assay, were observed. Unfortunately, the Gem loaded 
PLGA particles were larger than desired; they were actually microparticles (Fig 5.5). 
Furthermore, release studies showed all of the Gem releasing from the microparticles 
within the first half hour of being in an aqueous PBS solution. The water-in-oil-in-oil 
technique tends to produce larger particles, such as these Gem loaded PLGA 
microparticles.4 Smaller particles can be synthesized if high sonication powers (up to 120 
W probe sonicators) are used during the emulsion, but ultimately the Gem release profile 
is too fast for in vivo applications. Therefore, synthesis of a prodrug form of Gem that 
allows for better encapsulation in nanoparticles and slower release from PLGA, as 
detailed in the next section, was necessary.  
5.3.2 Synthesis of a Gemcitabine Prodrug 
This section describes three important results: (1) the successful synthesis of 
Gemcitabine-N4 Oleoyl Amide, (2) many failed attempts to synthesize and purify various 
gemcitabine prodrugs, and (3) characterization of the PD’s toxicity to a pancreatic cancer 
cell line in vitro.  
5.3.2.1 Synthesis and Characterization of Gemcitabine-N4 Oleoyl Amide 
Gemcitabine-N4 Oleoyl Amide (PD) was successfully synthesized using acyl 
halide chemistry. As reaction time increased, formation of the PD at 528 m/z in the mass 
spectroscopy results (Fig 5.6) was evident, along with a corresponding decrease in Gem 
at 264 m/z. A peak absorbance shift was also noted in the ultraviolet spectrum from the 
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peak for Gem (269 nm) to a peak for the PD (251 nm). Note that lower yields of the PD 
were obtained when OC was not added in succession during the reaction. Successive 
additions of OC may have helped maintain the activity of the very reactive OC species, 
reducing unwanted side reactions and increasing PD yield.  
The Gem-OC reaction proceeded by a standard SN2 mechanism. Again, OC is a 
very reactive species, with its Cl being an excellent leaving group. The excellent leaving 
group on OC helped facilitate a reaction with the nucleophilic primary amine on Gem, 
forming an amide bond. Fortunately, this synthesis involved a benign reactant, OC, that 
readily forms biocompatible oleic acid derivatives in the presence of methanol or water. 
Therefore, the synthesis worked as expected where the only toxic agent left in the final 
formulation was the PD itself.    
The purification and yield of the PD was determined by NMR. Most peaks in the 
NMR spectrum correspond with those cited for the Gemcitabine-N4 Elaidic Amide 
described elsewhere.3 The NMR spectra for Gem and the PD are shown in Fig 5.7. Shifts 
in the CH6, CH5, and CH1 positions are seen in the PD spectrum; no peaks associated 
with the Gem control are seen in the PD spectrum. Since a liquid separation/precipitation 
method was used to separate the PD from the initial reactants, the retention of small 
impurities from the initial two reactants was expected (small unexplained peaks in the PD 
NMR in Fig 5.7). More rigorous methods of purification such as preparative liquid 
chromatography (LC) using a silica column with a mobile phase of 10% methanol in 
chloroform was attempted, but the separation was poor and overall yield suffered greatly. 
Note that yields of other processes to make and purify gemcitabine prodrugs with these 
LC techniques have been reported between 15-50%.2, 3 The benefit of the simple 
separation method presented here is high yield. Using just liquid separation, yields as 
high as 90% were obtained. Yields were determined by spiking the NMR sample with a 
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known amount of dioxane and comparing the area under the dioxane peak at 3.61 ppm 
with that of CH6 on the PD at 8.51 ppm (this procedure was repeated with several 
controls and the experimental error between the NMR machine and the dioxane spiking 
was 13%). High yield is important because Gem is expensive. Furthermore, since our 
ultimate goal is to encapsulate the PD in PLGA, any Gem impurities left in the PD 
formulation will be expelled in the water phase during processing. The rare oleic acid 
derivatives left might encapsulate in PLGA, but they will have no cytotoxic effects and 
will not preclude a solid preliminary study on the synthesis of the CIT-NS.  
5.3.2.2 Failed Attempts to Synthesize Gemcitabine Prodrugs 
Synthesis of a Gem prodrug took 3.5 years of effort and resulted in numerous 
failed attempts. The methods attempted fall into two categories: synthetic methods in wet 
phase and synthetic methods involving solid phase organic chemistry. 
Wet Chemistry Methods: Using techniques described by Immordino et al2, the 
synthesis of 4-N-stearoyl-gemcitabine was attempted. The reaction was performed in 
dioxane with the reactant stearic anhydride. The reaction was monitored with 
spectrophotometry, thin layer chromatography, and mass spectroscopy; and none of these 
characterization tools indicated the presence of 4-N-stearoyl-gemcitabine. Aside from the 
reaction conditions specified by Immordino et al, reaction times for up to 63 hr at 
elevated temperatures up to 60°C were attempted, and still no prodrug was formed. The 
main difference between our experimental conditions and that of Immordino et al was the 
Gem used. They synthesized Gem in house, while we were using Gem that was packed as 
a salt with HCl as purchased from Chemiceuticals LLC. It is possible that the added HCl 
in our formulation inhibited the reaction by lowering the overall pH and making 
conditions unfavorable for 4-N-stearoyl-gemcitabine to be formed.   
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Solid Phase Chemistry Methods: Long polypeptide chains and libraries of DNA 
can now be synthesized using solid phase organic chemistry.7-9 Solid phase organic 
chemistry takes place in solution on the surface of polystyrene beads (~150 to 400 µm in 
diameter).8 Generally these polystyrene beads, also called resin, are surface 
functionalized with linker molecules that can react with functional groups on a molecule 
of interest. Once a molecule is attached to the resin, further organic chemistry reactions 
can be performed on the molecule at the bead surface. The beauty of solid phase organic 
synthesis is the ability to perform repeated washes while the product is immobilized on 
the resin, and then easily recover the reacted compound. For instance, using a Teflon 
fritted syringe, the beads can be trapped and cleaned with multiple solvents ad infinitum. 
Usually, detaching a product from the bead is simple since most linkers are acid labile. 
Therefore, placing a small amount of triflouroacetic (TFA) acid (1%) in dichloromethane 
(DCM) could cleave any supported compound from the bead, and that product would 
then be easily collected and separated from the beads. Since conventional LC methods 
were proving challenging for recovering large yields of pure PD, these solid phase 
organic synthesis methods were attempted in the hopes of retrieving high yields of 
purified prodrug. 
The first solid phase organic chemistry strategy attempted was to couple 
dihydropyran-functionalized (DHP) resin to the primary alcohol on Gem. This strategy 
involved immobilizing Gem through its primary alchohol, leaving Gem’s primary amine 
free for acylation in subsequent steps. Two preliminary steps were taken towards this 
strategy: (1) since Gem must be cleaved off the resin using TFA (a strong acid), Gem 
degradation in the presence of TFA was tested and (2) since high yield, high purity 
synthesis was the goal of this strategy, the loading and release of just Gem was tested 
prior to performing the acylation step. In the first test, Gem was incubated with a 5% 
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TFA solution in water for 5 min. After evaporating off the TFA and water, mass 
spectroscopy and NMR results showed no appreciable differences between Gem 
incubated with TFA and control Gem. Therefore, the second preliminary test was 
initiated using methods described by Thompson et al.10 Briefly, 489.1 mg of DHP resin 
was placed in a round bottom flask with 5 ml of dichloroethane (DCE). The beads were 
allowed to swell for 15 min while heating in an 80°C oil bath under reflux. Finally, 230.6 
mg of pyridinium p-toluenesulfonate PPTS (a 2.7 fold molar excess greater than the 
available linker sites on the resin surface) and 50.6 mg of Gem were added and the 
solution was stirred under reflux for 48 hr at 80°C. After the reaction, the beads were 
transferred to a fritted syringe where they were washed with DCM (1x), 1:1 
dimethylformamide (DMF):water (4x), DMF (3x), DCM (3x), and lastly 95:5 TFA:water 
for bead cleavage and collection. Mass spectroscopy confirmed the presence of intact 
Gem cleaved from the beads, but spectrophotometric analysis only showed a 13% yield. 
Furthermore, a ninhydrin test was used to look for the presence of the primary amine on 
Gem after cleavage. The ninhydrin compound should turn blue in the presence of a 
primary amine, but in both the test sample and Gem controls, the ninhydrin never 
exhibited a blue color. It is possible that the ninhydrin test works better with less hindered 
primary amines. Overall, after varying many parameters (amount of resin vs PPTS, 
temperature, etc) the highest loading and release yield of Gem was only 13%. This yield 
wasn’t high enough to warrant further exploration of coupling Gem to DHP resin. The 
next strategy was to try a more nucleoside friendly resin.  
After the DHP resin failed to load Gem in high yield, a resin used commonly in 
DNA synthesis was attempted, the dimethoxytrityl (DMT) resin. It is known that primary 
amines readily attach to DMT-functionalized resins.11 Therefore, the strategy here was to 
block the primary amine site by performing the acyl halide reaction (Section 5.3.2.1), and 
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then use the beads to sift out the Gemcitabine-N4 Oleoyl Amide prodrug from its reactant 
mixture by coupling to DMT through its primary alcohol. If higher resin loading could be 
achieved with this method, then cleaning and purification of the PD could be facilitated 
by using the resin. Briefly, Gemcitabine-N4 Oleoyl Amide was synthesized using the 
methods described in Section 5.3.2.1. Then 1 g of DMT resin was placed in the reaction 
vessel with 8.5 ml of dry DMF, 45.46 mg of imidazole, 43.36 µl of methanesulfonic acid, 
and 116.32 µl of diisopropylethylamine. Under an Ar environment, the mixture was 
shaken on an orbital shaker for 24 hr. This method of coupling nucleosides to DMT using 
mesylates had been previously reported.12 The resin was then transferred to a fritted 
syringe and cleaned using DMF (3x) and DCM (2x) before cleaving using a 0.5vol% 
TFA in DCM solution. Unfortunately, the yield of the PD was so low that it was 
immeasurable with spectrophotometers, although it was detected with mass spectrometry. 
Furthermore, even though the resin product manufacturers claim that the DMT cleaves 
from the nucleotide, we observed significant amounts of DMT eluting off the beads and 
into the cleavage solution, creating impurities in our final product. Even worse, however, 
was that the OC reactant had formed oleic acid and the oleic acid coupled to the beads in 
large quantities. Therefore, using DMT beads to clean unreacted OC away from the PD 
was simply not possible and the strategy of using solid phase chemistry was abandoned.  
5.3.2.3 Gemcitabine-N4 Oleoyl Amide Toxicity Compared to Native Gemcitabine 
Even though many strategies for prodrug synthesis had failed, the acyl halide 
approach creating Gemcitabine-N4 Oleoyl Amide as described in Section 5.3.2.1 was 
successful. Using that synthesis, a PD was created that could be characterized and tested. 
One such in vitro test was the cytotoxicity studies with pancreatic cancer cells detailed 
below.  
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The available literature reports the cytotoxic activity of Gem prodrugs to be 
between two- and five-fold better than native gemcitabine.2 Most references site the 
stability of the prodrug forms in plasma as the main reason for increased therapeutic 
efficacy.2, 3 The tests performed in the literature were with different cells lines than those 
used here and measured inhibition of protein synthesis. In comparison, the MTS assay 
presented here (Fig 5.8) is a cell viability study only, measuring the function of active 
mitochondria. The results shown in Fig 5.8 indicate that the PD and Gem have toxic 
effects proportionate to concentration. However, this MTS assay performed on L3.6pl 
pancreatic cancer cells demonstrated no evidence of enhanced cytotoxicity with the PD. 
Instead, these results indicated that the PD and Gem are equally effective. The 
contradiction between these results and the literature might stem from either the type of 
cytotoxicity tests performed or the differences between individual cells lines. Protein 
inhibition testing would need to be performed on the L3.6pl cell line to further elucidate 
the reason for this difference.  
5.3.3 Gemcitabine-N4 Oleoyl Amide Encapsulation in PLGA 
Unfortunately, encapsulation of the PD Gemcitabine-N4 Oleoyl Amide in PLGA 
via the oil in water emulsion technique was unsuccessful. Immediately after the oil phase 
was added to the water phase, the white milky solution began to aggregate. Two solutions 
are shown in Fig 5.9 – the left one was PD loaded PLGA and the right was a control with 
no drug loading. Aggregation is clear in the PD loaded PLGA sample. Encapsulation 
efficiencies were only 50% for PD loaded PLGA and the resulting PLGA particles were 
non-spherical in shape with a large polydispersity (Fig 5.10). Different combinations of 
surfactants ranging from 1 to 10 mg/ml of BSA and 1 to 10 mg/ml PVA combinations 
were attempted, but all trials suffered from similar microparticle results with low 
 118 
encapsulation efficiencies. While these hydrophobic forms of Gem load well in carriers 
such as liposomes2, in the case of PLGA they might be acting as a plasticizer. Recall 
from Chapter 2 that the Tg of PLGA is 40-45°C. If Gem and/or Gem prodrugs are acting 
as a plasticizer and lowering the Tg significantly, then amorphous shapes of PLGA, as 
shown in Fig 5.10, would result. Further work using either differential scanning 
calorimetry or thermo-mechanical analysis could be used to test the plasticizer 
hypothesis. The fact that a stable colloidal suspension of PD loaded PLGA nanoparticles 
could not be produced with the methods tested, meant that further progress towards 
building the CIT-NS incorporating Gem was simply not feasible or that further research 
incorporating Gem or PD into other polymeric carriers would need to be investigated.  
5.4 CONCLUSIONS 
In its native form, Gem did encapsulate in PLGA, but the resulting PLGA 
particles exhibited a large polydispersity in size from 200 nm to 20 µm; and all of the 
Gem released from these particles after just 30 min in aqueous solution. Thus, Gem 
prodrugs that might encapsulate in PLGA and release slowly were considered as a viable 
alternative. Furthermore, prodrugs, being more stable in plasma than native Gem, might 
also provide a therapeutic benefit. A prodrug of Gem, Gemcitabine-N4 Oleoyl Amide, 
was successfully synthesized; but contrary to the literature, it showed no enhanced 
therapeutic efficacy over the free native Gem and did not encapsulate well in PLGA. 
Using oil in water emulsion techniques, only 50% encapsulation efficiencies were 
achieved, and the PLGA particles aggregated extensively. These findings might indicate 
that synthesizing the CIT-NS incorporating Gem is not feasible. Solutions to this problem 
could involve updating the CIT-NS design. For instance, the polymer used for 
encapsulation could be changed to one unaffected by Gem, or liposomes could be used as 
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the core of the CIT-NS. One could also consider completely new designs for the CIT-NS 
that incorporate silver and Gem without the polymer. The design of such a system is the 



















Figure 5.2:   The chemical structure of gemcitabine.  In deoxycytidine the two fluorines 









Figure 5.4:   A schematic depicting the steps in the oil in water emulsion method required 










Figure 5.6: Progressive mass spectroscopy results as time continues in the reaction to 




Figure 5.7: NMR of Gem (top) and the PD (bottom). The H shifts that are most 
noteworthy with the acylation of Gem are the CH6, CH5, and CH1 as 
labeled in blue, green, and purple, respectively. The PD spectrum shows 
major shifts in the doublet and triplet peaks associated with these positions, 





Figure 5.8:   MTS assay results showing the relative cell viability to control when L3.6pl 
pancreatic cancer cells were mixed with different concentrations of the 
native Gemcitabine (Gem) drug versus the Gemcitabine-N4 Oleoyl Amide 
prodrug (PD).  
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Figure 5.9: Gemcitabine loaded PLGA microparticles (left) and control PLGA 
nanoparticles with no drug loading (right). 
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Chapter 6: Design of the Combined Imaging and Therapy Nanoplate 
System (CIT-NpS) 
Since the CIT-NS proved challenging to synthesize using gemcitabine, a design is 
presented here for a different multifunctional nanosystem with gemcitabine. The new 
nanosystem is called the Combined Imaging and Therapy Nanoplate System (CIT-NpS) 
and will be referred to as the CIT-NpS or the nanoplate system in this text.  
6.1 CIT-NPS COMPONENTS 
The design of the CIT-NpS is illustrated in Fig. 6.1. The CIT-NpS is a triangular 
silver nanoplate with three components attached to its exterior (1) gemcitabine, (2) 
antibodies that target upregulated cancer cell surface receptors, and (3) poly(ethylene 
glycol) (PEG) chains. The antibody and the PEG chains serve the same purposes in the 
CIT-NpS as they did in the CIT-NS of targeting and limiting immune system recognition, 
respectively, as outlined in Chapter 2. Gemcitabine continues to serve as chemotherapy, 
but in the new design it is attached to the nanoplate surface instead of being entrapped 
inside of a polymer core.  
6.2  COMPARISON OF THE CIT-NPS AND THE CIT-NS 
The CIT-NpS provides both advantages and disadvantages when compared to the 
CIT-NS in terms of optical properties, size and synthesis, drug loading, and stability. All 
of these various properties and characteristics are compared in this section.   
6.2.1 Optical Properties, Size, and Imaging Contrast  
 The shape of the nanoplate system (CIT-NpS) and the nanocage system (CIT-NS) 
are vastly different. In general, shape and size differences of the noble metal component 
in the nanosystem will dictate both its optical properties and the cellular response.  
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 The optical properties of plasmonic noble metals like silver and gold are highly 
dependent on size and shape. For instance, the longitudinal surface plasmon resonance 
(LSPR) peak of gold nanorods depends on the aspect ratio of the longitudinal (length of 
the rod) versus the transverse (diameter of the rod) dimensions. For example, gold 
nanorods with an aspect ratio, R (defined as the length/diameter of the rod), of 3.1 will 
have a LSPR peak at a wavelength of 740 nm, while an R of 3.9 yields a LSPR peak at 
800 nm.1 The phenomena of red-shifting, or right-shifting, of the LSPR to longer 
wavelengths as R increases is also true for other anisotropic shapes of noble metals, such 
as silver. In the case of silver nanoplates, the aspect ratio, calculated by the side length 
(longitudinal dimension) of the plate divided by the plate width (transverse dimension) 
will determine the LSPR of the nanosystem.2 These noble metal anisotropic shapes of 
particular aspect ratios yield sharp, well-defined extinction spectra peaks with 
wavelength when measured using a spectrophotometer.  
 Nanocages of silver, in contrast to nanoplates or nanorods, have much broader 
extinction spectra since a mixture of aspect ratios inherently exists in the sample. For a 
nanoshell or nanocage the R is defined as the core diameter divided by the metal 
thickness. The broadened extinction spectra result from inherent lack of size control 
during synthesis. When the nanocage system is built, silver is reduced onto cores of 
PLGA. The PLGA is not completely monodispersed, so a variation in core diameters is 
already present in the sample. Furthermore, the silver thickness around those PLGA cores 
is not uniform within each individual nanoparticle and particle to particle variation also 
exists, thus adding to the diversity of aspect ratios in the sample. The polydispersity of 
R’s in the sample ultimately led to very broad extinction spectra for the CIT-NS as 
demonstrated in Chapter 4.  
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 The difference in optical properties between the CIT-NpS that has a sharp LSPR 
peak, and the CIT-NS that has a broad LSPR, will cause these systems to behave slightly 
differently as imaging contrast agents for photoacoustic imaging. An important property 
of a nanosystem for photoacoustic imaging contrast is the absorption cross-section. 
Nanosystems with high absorption cross-sections, and thus high μa, as defined in Eq. 1.1, 
will create high amplitude photoacoustic transients. Per nanoparticle, the nanoplate 
system will have higher individual absorption cross-sections at the LSPR peak 
wavelength; and therefore, per particle, the nanoplate system is a superior contrast agent. 
However, the geometric size also plays a role in the probability of light absorption in an 
in vivo situation (see Chapter 3). Even though the absorption cross-section of the 
nanocage system is lower per particle, the probability of light absorption events is 
increased due to their greater geometric size.  Thus, the photoacoustic contrast created by 
these drastically different systems can be similar.3 Therefore, enhancement of 
photoacoustic imaging from nanoparticles depends on both geometric size and absorption 
cross-section.  
 While geometric size and absorption cross-section are the important factors in the 
physics of photoacoustic signal generation, the concentration of the nanosystem that 
accumulates in the diseased area ultimately determines its applicability in vivo. 
Photoacoustic signal is linearly proportional to nanoparticle concentration3, so high 
accumulation of the nanosystem at the diseased site is critical for detection and high 
signal to noise imaging.  
The biology of the diseased site or tumor determines the uptake of nanoparticles 
into both the extracellular and intracellular spaces. Since both the nanoplate and the 
nanocage systems are designed for systemic delivery, the structure of the tumor 
vasculature must allow for extravasation of the nanoparticles into the tumor area. 
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Extravasation is dependent on the size of the gap junctions between endothelial cells in 
the lining of the tumor vasculature (generally between 300 nm and 700 nm for most 
tumors).4 Smaller particles have a greater chance of navigating through these junctions, 
and therefore the nanoplate system with an overall size less that 200 nm has a greater 
change of accumulating in high concentrations. Furthermore, nanoparticle interactions 
with cells are size and shape dependent;5, 6 generally smaller particles get internalized to a 
greater extent. Therefore, the nanoplate system is advantageous to the nanocage system 
because (1) per particle it has a higher absorption cross section and (2) its smaller size 
allows it to accumulate in a tumor and interact with cancer cells to a greater extent.    
6.2.2 Synthesis Techniques  
 The CIT-NS is a complex structure requiring several individual steps for synthesis 
(see Chapters 4 and 5). Synthesis of the CIT-NpS is simpler since silver nanoplate 
synthesis techniques are readily available2, 7-10, and since conjugation of moieties to the 
surface of silver can be easily accomplished using thiol-mediated chemistries.11, 12 In 
order to encapsulate gemcitabine in a polymer matrix for the CIT-NS, a prodrug form of 
gemcitabine is required (see Chapter 5). Similarly, a prodrug form of gemcitabine 
containing a thiol is required for the CIT-NpS to enable covalent bonding of gemcitabine 
to the surface of silver. In both cases, the prodrug form needs to be tested to ensure it is 
as active as the native drug. Overall, the nanoplate system is more facile because it has  
fewer components and fewer steps in its synthesis.  
6.2.3 Drug Loading  
 The methods of drug loading/release and the drug loading capacities of the CIT-
NS versus the CIT-NpS systems are disparate. The method of drug loading in the CIT-NS 
is via entrapment in a polymer matrix core, whereas drug loading in the CIT-NpS is via 
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covalent bonds to the surface of silver. Each of these methods presents advantages and 
disadvantages. The distinct advantage of the CIT-NS is that large payloads of drug can be 
encapsulated in the polymer core. The disadvantage is that drug release from the 
nanocage system will happen by diffusion. Therefore, once the nanocage system is 
suspended in any aqueous fluid, it will release drugs slowly. The drug release profile can 
be controlled by varying the silver cage confluency (Chapter 4), but ultimately the 
polymer will experience bulk erosion and elution of the drug. The advantage of the CIT-
NpS is that drugs are attached to the nanoplates via covalent bonds. As long as silver 
remains stable in solution (i.e. it doesn’t erode into AgO or A+ ions), then the drugs will 
remain conjugated to the surface and will not diffuse out during systemic delivery or 
while in storage in a buffered solution. In summary, the nanocage system offers high drug 
loading capacity, but poor control over release; whereas, the nanoplate system has low 
drug loading capacity, but great control over release.  
6.2.4 Stability 
As with most noble metals, silver is most stable as a spherical nanoparticle; it is 
the lowest energy configuration. Making anisotropic shapes of metals, like nanoplates, 
requires specific capping agents and reaction conditions since those shapes have higher 
surface energies.13 Therefore, from a surface energy perspective, the silver nanoplate 
system is much less stable than the silver nanocage system; because the nanoplate is a 
highly anisotropic shape and the nanocage is built from nanospheres of silver packed 
closely around a polymer core. Silver nanoplates that are not passivated on the surface 
will dissolve in salt solutions and react readily with proteins and enzymes. Thus, one of 
the challenges for both systems, but even more so for the nanoplate system, is to 
passivate the surface of silver to make it more biocompatible and less reactive. The best 
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way to accomplish this goal is to conjugate polymers such as PEG to the surface. 
Additionally, allowing the surface to oxidize will also reduce reactivity. In the CIT-NS 
these conjugations are not challenging since the surface will only contain a few 
antibodies and mostly PEG. However, since drug molecules, that will not inherently 
stabilize the silver surface, are occupying the same sites that stabilizing molecules would 
normally bind, the CIT-NpS is more difficult to stabilize. Therefore, to stabilize the 
nanoplate system, the design must incorporate an optimized balance between the ratio of 
drugs and antibodies attached to the surface versus the coverage of passivating PEG 
molecules.   
6.3 CONCLUSIONS 
The CIT-NpS may be a superior combined imaging and therapy nanosystem since 
it has the advantages of higher absorption cross section per particle, sharper and more 
defined LSPR peaks, simplified synthesis, and smaller size that allows for better 
accumulation and intracellular trafficking at a tumor site. However, the large 
disadvantage of the nanoplate system is its reduced drug loading capacity compared to 
the CIT-NS. Furthermore, the CIT-NpS is more difficult to stabilize since it inherently 
has a high energy surface that is prone to dissolution and side reactions if not properly 
passivated. All of the advantages and challenges of the CIT-NpS are explored 














Figure 6.1: An illustration of the Combined Imaging and Therapy Nanoplate System 
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Chapter 7: In Vivo Testing of the CIT-NpS Design for Enhanced 
Photoacoustic Imaging 
Since the CIT-NS proved challenging to synthesize using gemcitabine, a new 
design was presented in Chapter 6 called the Combined Imaging and Therapy Nanoplate 
System (CIT-NpS). The CIT-NpS consists of silver nanoplate carriers with gemcitabine, 
poly(ethylene glycol) (PEG), and targeting antibodies grafted to its surface (Fig 6.1). 
Analogous to how the CIT-NS was explored, the intention of this chapter is to first prove 
the feasibility of using silver nanoplates as imaging contrast agents for photoacoustic 
imaging. Therefore, this chapter details all aspects of the CIT-NpS design and synthesis 
except the attachment of drugs to the nanoplates’ surface, while Chapter 8 covers drug 
conjugation to the plates.   
7.1 INTRODUCTION 
Noble metal nanoparticles have garnered particular interest from researchers in 
recent years because of their unique and tunable surface plasmon resonance properties.1 
As discussed in Chapters 1 and 6, confinement of the surface electrons in these metals 
when synthesized on the nanoscale leads to interesting light absorption and scattering 
properties within the visible to near infrared (NIR) wavelength ranges. Both the size and 
shape of metallic nanoparticles contribute strongly to this plasmon resonance effect.2-4 In 
many cases, as the aspect ratio in the dimensions of a nanoparticle is increased, the 
longitudinal surface plasmon resonance peak (LSPR) shifts to higher wavelengths across 
the visible to NIR wavelength spectrum.3, 5, 6  
Silver nanoplates represent one such nanoparticle where large aspect ratios are 
readily achievable and therefore the LSPR is easily tuned from the visible to the NIR. 
Particles like silver nanoplates whose resonance can be tuned into the NIR are of 
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particular interest for biomedical sensing applications, since absorption of light from 
tissue is minimized at NIR wavelengths.7 Another advantage of using silver over other 
common noble metals such as gold is that silver has at least 10% sharper and stronger 
resonances.8 The large disadvantage to using silver nanoparticles is their lack of stability 
in nanoform. Silver is inherently more reactive than gold and this activity leads to shape 
deformation of anisotropic nano-colloidal silver solutions (see Chapter 8 for details 
concerning silver nanoplate stability). 
 Applications using metallic nanoparticles as contrast agents depend on the 
stability of the nanoparticles’ LSPR to provide meaningful, interpretable signals. Some of 
these applications include two-photon microscopy, surface enhanced Raman scattering 
(SERS), and a myriad of other optical based techniques. Another emerging technique 
with the same restriction is photoacoustic (PA) imaging.9, 10 As discussed in Chapter 1, 
PA imaging is based on the principle of sound generation following light absorption. In 
short, PA imaging can detect nanoparticles in tissue by shining pulsed light on the 
nanoparticle-laden tissue, and measuring the resulting sound transients using an 
ultrasound (US) transducer.11 The US transducer can also then be used to capture a co-
registered US image of the interrogated area. When the US and PA images are combined, 
the location of nanoparticles can be displayed relative to the anatomical information 
provided by US. This PA technique is powerful because it only requires that light travel 
in one direction, and therefore the penetration depths at which PA imaging can detect 
nanoparticles is at least three times that of purely optical imaging methods. Since the 
absorption cross sections of metallic nanoparticles can be orders of magnitude higher 
than the surrounding native tissue, these nanoparticles are excellent photoacoustic 
imaging contrast agents.12-15  
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Since silver has exceptional optical properties suitable for many biomedical 
applications from sensors to contrast agents, it was chosen as the basic carrier in the CIT-
NpS. While silver is known to have these exceptional optical properties, no one has 
attempted to use silver, in any form, as a PA contrast agent. The silver-silica nanosystem 
presented in Chapter 3 was the first use of silver for PA imaging enhancement.16 In this 
chapter, silver nanoplates are presented as a different, and potentially better, nanosystem 
for enhancing PA imaging. The synthesis of silver nanoplates and methods of 
bioconjugation are presented along with studies testing the molecular sensitivity of these 
agents in vitro against pancreatic cancer cells. Furthermore, the cytotoxicity of these 
silver nanoplates is explored. Finally, the efficacy of silver nanoplates as contrast agents 
for USPA imaging in an in vivo mouse xenograft cancer model is evaluated. Therefore, 
the entire CIT-NpS is synthesized and characterized without drugs in this chapter. These 
initial tests prove that silver nanoplates are excellent PA contrast agents; the building of 
the entire CIT-NpS with attached drugs is described in Chapter 8.   
7.2  METHODS 
Each step in the synthesis and characterization of silver nanoplates is described 
separately below. For reader clarity, the sources for all materials are consolidated here. 
Materials: All chemicals were used without further purification and were at 
minimum ACS grade.  Silver nitrate (>99%), trisodium citrate (TSC), sodium periodate, 
the antibody to Epidermal Growth Factor Receptor (EGFR) clone C225, poly(ethylene 
glycol) bisphenol A epichlorohydrin Mn = 14 kDa, and Bis (p-sulfonatophenyl) 
phenylphosphine dihydrate dipotassium salt (BSPP) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). ACS grade L(+) ascorbic acid was a product of Acros (Morris 
Plains, NJ, USA). Dulbecco’s phosphate buffered saline (DPBS) came from Mediatech, 
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Inc. (Herndon, VA, USA). The methyl-poly(ethylene glycol)-thiol (mPEG-SH of 5 kDa) 
was from Laysan Bio (Arab, AL, USA). All cell culture products, including the MTS 
assay, were purchased from Invitrogen (Carlsbad, CA, USA) unless otherwise specified. 
Slide mounting media, Vectashield with DAPI stain, was from Vector Laboratories 
(Burlingame, CA, USA). The linker hydrazide-polyethylene glycol-dithiol (SPT-014B) 
was a product of Sensopath (Bozeman, MT, USA).  
7.2.1 Finite Difference Time Domain (FDTD) Modeling   
An effective PA contrast agent will have a high absorption cross-section. Recall 
that PA imaging contrast is generated by differences in the optical absorption map of the 
interrogated tissue. Further, Eqn 1 in Chapter 1 shows that photoacoustic pressure is 
directly proportional to the absorption coefficient of the tissue. To generate PA imaging 
contrast that is greater than the native tissue, an exogenous contrast agent must have a 
large absorption coefficient. Since the absorption coefficient is equal to the number of 
absorbers times the absorption cross-section of a single absorber, then it follows that 
absorption cross-section is a critical parameter for a PA contrast agent. Before 
synthesizing a new photoacoustic contrast agent such as a silver nanoplate, it is prudent 
to first model the absorption cross-section of a silver nanoplate and compare it to the 
absorption cross-sections of other existing photoacoustic contrast agents, such as gold 
nanospheres and nanocages.  
Modeling of the extinction, scattering, and absorption cross-sections of triangular 
silver nanoplates with uniform thickness of 12 nm and triangle edge lengths of 25 nm, 60 
nm, 90 nm, 128 nm, and 218 nm was accomplished using the commercially available 
program Lumerical Solutions. Lumerical FDTD uses finite difference time domain 
(FDTD) modeling to solve Maxwell’s equations for each point in a simulation space with 
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a user defined, non-uniform mesh. In the simulation space, a silver triangular nanoplate 
was situated in water (index of refraction for water was taken as 1.33 with no imaginary 
component simulated). Silver dielectric data were based on Johnson and Christy and 
fitted by a multi-Lorentzian sum. A wave packet of light with a Gaussian distribution of 
the field amplitude of light frequencies in a wavelength range of 300 nm to 1400 nm was 
simulated. The light source was chosen to be a total-field/scattered-field source (TFSF), 
defined as a volume where the light is injected on one face, and the total field is 
determined at every mesh point inside the TFSF volume, while outside the TFSF volume 
only the scattered filed is calculated. Such a light source reduces calculation noise and 
prevents artifacts of diffraction due to a finite source (aperture effect).  Monitors were set 
up inside and outside of the TFSF volume to measure optical cross-sections. To obtain 
final total optical cross-sections, the results from all directions were added, and then 
three separate simulations using light polarized along three directions (two longitudinal 
directions and one transverse direction) were averaged. 
7.2.2 Silver Nanoplate Synthesis 
 Silver nanoplates were formed via a seed-mediated growth process. Silver seeds 
were synthesized via procedures previously described by Xue et al.17 Specifically, a 250 
ml flask was placed in an ice bath and filled with 95 ml of deionized and ultrafiltrated (up 
to 18.2 MΩ-cm) (DIUF) water. In an Ar environment, 1 ml of 30 mM TSC and 0.5 ml of 
20 mM AgNO3 were added. The mixture was stirred at 500 rpm for 20 min. To reduce 
the silver, 1 ml of ice cold 50 mM NaBH4 was added quickly and the solution 
immediately turned bright yellow. One more ml of the 50 mM NaBH4 was then added 
over the following 15 min at a rate of 0.067 ml/min. In a separate ice cold vial, a solution 
of 1 ml of 50 mM NaBH4 was added to 1 ml of 5 mM Bis(p-
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sulfanatophenyl)phenylphosphine dehydrate dipotassium salt (BSPP). That 2 ml mixture 
of NaBH4 and BSPP was slowly dropped into the vigorously stirring silver seed solution 
over a period of 5 min (Ar environment was maintained throughout the procedure and the 
flask was wrapped in foil to minimize light exposure). The Ag seeds were then stirred at 
350 rpm and kept at 0°C for 5 hr. Finally, the seeds were transferred to a 4°C refrigerator 
in their original flask and allowed to age undisturbed in a sealed Ar environment 
overnight. 
The seeds were used to grow nanoplates within 14 days after synthesis, with the 
peak efficacy (largest translation to plates) obtained on the very next day after seed 
synthesis. Growing nanoplates of sizes up to 250 nm involved 4 separate growth steps in 
which the product of one step was used as the starting material for the subsequent step, as 
modified from that described by Zou et al.18 Table 7.1 provides a consolidated chart 
describing materials needed and observations for the separate growth steps described 
below.  
Sample S1: First, a 20 ml vial was filled with 8.0 ml of DIUF water, 50 µl of 40 
:mM trisodium citrate (TSC), and 150 µl of 40 mM L+ascorbic acid. The seeds prepared 
previously were diluted in water to an optical density (OD) of 0.65 at their peak 
resonance of 400 nm. Then 1.8 ml of the diluted silver seeds were added to the vial. The 
mixture was vigorously stirred at room temperature while 5.05 ml of 584 µM AgNO3 was 
dripped in over 10 min. During the 10 min, the solution turned from bright yellow to 
orange, red, and maroon. After the AgNO3 addition was complete, the solution was 
allowed to stir for an additional 10 min and the ultraviolet to visible (UV-vis) spectrum 
was taken using a DU Series 640 Spectrophotometer (Beckman Coulter).  This first 
solution was called S1.  
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Sample S2: Second, for the next Ag nanoplate growth step, another 20 ml vial 
was filled with 4.8 ml of DIUF water, 50 µl of 40 mM TSC, 150 µl of 40 mM L+ascorbic 
acid, and 5 ml of S1. Again, the mixture was vigorously stirred at room temperature 
while 5.05 ml of 584 µM AgNO3 was dripped in over 10 min. During the 10 min, the 
solution turned from maroon to purple to blue to teal. After the AgNO3 addition was 
complete, the solution was allowed to stir for an additional 10 min and the ultraviolet to 
visible (UV-vis) spectrum was taken. This second solution was called S2.  
Sample S3: Third, for the next Ag nanoplate growth step, another 20 ml vial was 
filled with 4.8 ml of DIUF water, 50 µl of 40 mM TSC, 150 µl of 40 mM L+ascorbic 
acid, and 5 ml of S2. Again, the mixture was vigorously stirred at room temperature 
while 5.05 ml of 584 µM AgNO3 was dripped in over 10 min. During the 10 min, the 
solution turned from teal to forest green to light forest green with a purple hue. After the 
AgNO3 addition was complete, the solution was allowed to stir for an additional 10 min 
and the ultraviolet to visible (UV-vis) spectrum was taken. This third solution was called 
S3.  
Sample S4: For the fourth and final growth step, another 20 ml vial was filled 
with 4.8 ml of DIUF water, 50 µl of 40 mM TSC, 150 µl of 40 mM L+ascorbic acid, and 
5 ml of S3. Again, the mixture was vigorously stirred at room temperature while 5.05 ml 
of 584 µM AgNO3 was dripped in over 10 min. During the 10 min, the solution turned 
from forest green/purple to pastel blue/silver. After the AgNO3 addition was complete, 
the solution was allowed to stir for an additional 10 min and the ultraviolet to visible 
(UV-vis) spectrum was taken. This fourth and final solution was called S4. All nanoplate 
solutions were analyzed using a LEO S5500 scanning transmission electron microscope 
(STEM). A custom designed program was built using the functionality provided by 
ImageJ to size all of the nanoplate and seed batches.  
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7.2.3 Silver Nanoplate Bioconjugation 
Functionalizing silver nanoplates with antibodies and PEG, a process called 
bioconjugation, is mediated using thiol chemistries and shown schematically in Fig 7.1. 
Free primary thiols are known to readily react to form covalent thiolate bonds with noble 
metals such as silver and gold.19, 20 Since PEG and antibodies do not naturally have an 
abundance of free thiol groups, preparation steps are required to “thiolate” these 
compounds in order to bioconjugate them to silver nanoplates. The steps towards 
thiolation of the antibody are described in detail below. The PEG, however, was 
purchased as a bifunctional molecule having a methyl terminus and a thiol terminus on 
each molecule.  
7.2.3.1 Antibody-Linker Synthesis 
Preparation, or more specifically “thiolation”, of the antibody was the most 
complicated synthetic step. For optimal antibody activity (interaction between the FV 
region with its receptor), the antibody must be bound to the nanoplate in a directional 
fashion. Therefore, a directional conjugation of the C225 anti-epidermal growth factor 
receptor antibody (a-EGFR) from Sigma-Aldrich (product number E2156) to nanoplates 
was performed. Directional procedures were adapted from those previously described for 
antibody conjugation to gold nanoparticles by Kumar et al.20 A linker molecule was 
employed to achieve directionality, meaning that only the Fc region, or nonbinding part 
of the antibody, attached to the silver. The particular linker used, a hydrazide-
polyethylene glycol-dithiol (bottom of Fig 7.1), covalently bound to the glycosylated 
portion of the antibody (found in the Fc region) through its hydrazide group, while the 
dithiol groups bound to silver.  
For directional conjugation of a-EGFR to Ag nanoplates, the linker molecule was 
first attached to the antibody. As previously described20, the antibody was prepped by 
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changing the buffer to a mono/dibasic sodium phosphate buffer (pH = 7.5) using two 
wash steps in a 50 kDa molecular weight cut off (MWCO) centrifugal filter from 
Millipore (centrifuge at 3600 rpm for 15 min at 4°C). The antibody was reconstituted in 
1.3 ml of the sodium phosphate buffer and placed in a sterile 2 ml tube. To create an 
aldehyde group on the glycosylated portion of the antibody, 80 µl of fresh 100 mM 
NaIO4 was added to the antibody solution and allowed to shake in the dark for 30 min at 
room temperature. The reaction was quenched by adding 500 µl of 1x phosphate buffered 
saline. Then, 6 µl of 427.4 mM linker in anhydrous ethanol (kept at -80°C prior to use) 
was added to the antibody solution and allowed to react for 1 hr while shaking at room 
temperature. Finally the antibody-linker (AB-linker) conjugate was cleaned using HEPES 
buffer in the same 50 kDa MWCO Millipore filters described above and then 
reconstituted in 300 µl HEPES buffer (pH = 8.0) for storage. The AB-linker conjugate 
can be stored at 4°C and will remain viable for the life of the antibody. A 75% to 85% 
yield of the AB-linker conjugate can be expected using this technique if strict and clean 
pipeting techniques are employed throughout the process. 
7.2.3.2 Antibody and PEG Conjugation to Nanoplates  
Once the AB-linker conjugate was built, further conjugation to the Ag nanoplates 
was facile. Briefly, any desired batch (S1 through S4) of nanoplates was placed in a 50 
kDa MWCO Millipore centrifugal filter directly after synthesis and spun at 1500 rcf for 5 
min at 20°C. The nanoplates were then resuspended in 1 ml of DIUF water, placed in a 2 
ml tube, wrapped in foil, and allowed to sit overnight at room temperature. Then, enough 
of the AB-linker solution was added to account for 0.05 mg of antibody-linker (the exact 
volume of the AB-linker solution varied based on the final concentration of the AB-linker 
in HEPES as determined by a Thermo Scientific Nanodrop measurement at a wavelength 
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of 280 nm with an assumed extinction coefficient of 210,000 M-1cm-1). The AB-linker 
and nanoplates were allowed to shake at room temperature in the dark for 20 min. Slight 
red shifts (5-10 nm) in peak resonance of the nanoplates was observed after conjugation 
of the AB-linker to the nanoplates. 
To limit opsonization in the bloodstream, the surface area of the silver not 
covered by antibody was passivated by attachment of mPEG-SH. Specifically, after 
allowing the AB-linker and Ag nanoplate solution to shake for 20 min, 50 µl of a 2 wt% 
PEG (Mn = 14 kDa) was added to enhance stability, and 40 µl of 50 mM mPEG-SH (5 
kDa) was also added to react with the Ag nanoplates. After shaking in the dark for 20 
min, the nanoplates were cleaned using 50 kDa MWCO Millipore centrifugal filters spun 
at 1500 rcf for 5 min at 4°C. The nanoplates were then resuspended in 500 µl of PBS and 
sent through a 0.22 µm filter into a sterile 2 ml tube for future use. The antibody 
conjugated Ag nanoplates can be stored at 4°C for the life of the antibody. A 40 to 60 nm 
red shift in the peak resonance of the nanoplates was observed directly after the mPEG-
SH passivating step. 
7.2.4 In Vitro Characterization with Pancreatic Cancer Cells 
Several different human pancreatic cancer cell lines were exposed to the 
bioconjugated silver nanoplates. In vitro tests from cell labeling to cytotoxicity were 
performed.  
7.2.4.1 Cell Labeling 
The human pancreatic cancer cell line MPanc96 was mixed in media with two 
types of Ag nanoplates: nanoplates conjugated to a-EGFR and mPEG-SH, and nanoplates 
conjugated only to mPEG-SH. Briefly, approximately 300,000 MPanc96 cells were 
suspended in 500 µl of media in two separate sterile 2 ml tubes. To each respective tube, 
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50 µl of the as prepared a-EGFR and mPEG-SH conjugated nanoplates, and the mPEG-
SH conjugated nanoplates were added. The tubes were shaken every 30 min over a 4 hr 
period while in the incubator. After 4 hours, the tubes were centrifuged at 125 rcf for 5 
min at 4°C. After the supernatant was removed, the cells were resuspended in 2 wt% 
formalin in DPBS, allowed to sit for 20 min, and then washed 2x with the 2 wt% 
formalin in DPBS solution. The cells were fixed on a microscope slide using Vectashield 
with Dapi mounting solution and imaged in fluorescence and darkfield modes of a Leica 
DMI3000 B inverted microscope with a Leica DFC 290 kit and a 3 mega pixel color 
camera. 
7.2.4.2 Cytotoxicity 
The human pancreatic cancer cell lines L3.6pl and MPanc96, and the non-
cancerous pancreatic line HPNE were incubated with bioconjugated silver nanoplates and 
tested for cell viability. Both cancer cell lines were cultured in vitro using Dulbecco’s 
Modified Eagle Medium (DMEM) (with 4500 mg glucose/L, L-glutamine, NaHCO3 and 
pyridoxine HCl) supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin-
Streptomycin (Pen/Strep) while maintained at 37°C and 5% CO2 in a humidified 
incubator. For the pancreatic cancer cell lines, the DMEM and the FBS were purchased 
from Sigma, while the Pen/Strep was purchased from Invitrogen. The non-cancerous 
pancreatic cell line, HPNE, was cultured in vitro using Medium D that contained one 
volume of medium M3, three volumes of glucose-free DMEM (with L-glutamine, phenol 
red, and pyridoxine HCl), 5% FBS, 5.5 mM glucose, 10 ng/ml EGF, and 50 µg/ml 
gentamycin. Medium M3 is a proprietary formulation optimized for the growth of 
neuroendocrine cells (InCell Corp., San Antonio, TX, USA). For cell viability studies, 
cells were seeded in a 96 well plate (each well had 5,000 cells per 100 µl of media for the 
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cancer lines and 10,000 cells per 100 µl of media for the non-cancerous line). The cells 
were allowed to attach and grow in the 96 well plate for 48 hr, after which the cell media 
was removed and replaced with suspensions of a-EGFR and mPEG-SH conjugated S4 
batches of Ag nanoplates at various concentrations representing 1 mg/ml, 0.5 mg/ml, 0.25 
mg/ml, 0.125 mg/ml, 0.0625 mg/ml and 0 mg/ml of silver (at least 5 wells were seeded 
with each concentration). Note that the highest silver concentration at 1 mg/ml 
represented ~1.2×1012 nanoplates per ml, while the lowest silver concentration at 0.0625 
mg/ml represented ~7.3×1010 nanoplates per ml. After 24 hr of incubation, the media was 
removed and replaced with fresh media containing no nanoplates. The absorbance of 
each well in the plate was measured at 490 nm using a Synergy HT Multimode 
Microplate Reader from BioTek.  To perform the assay, 20 µl of a tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) and an electron coupling reagent (phenazine methosulfate) PMS from 
the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (a Promega product) 
was added to each well. Over a period of 1 hr in the incubator, the MTS was bioreduced 
by cells into a formazan product that had an absorbance peak at 490 nm. Dehydrogenase 
enzymes found in metabolically active cells were responsible for the conversion of MTS 
into the soluble formazan product. Therefore, the absorbance of each well at 490 nm was 
directly proportional to the number of viable cells. The absorbance of each well at 490 
nm taken before adding MTS was subtracted from the post MTS incubation value. Cell 
viability was determined by comparing the resulting absorbance of wells containing no 
nanoplates to wells containing nanoplates using an F test for a one-way ANOVA. 
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7.2.5 Animal Model 
Xenograft tumors were grown subcutaneously in Nu/Nu mice to test the in vivo 
targeting and imaging capabilities of the a-EGFR conjugated nanoplates (the nanoplates 
were also passivated with mPEG-SH as described above). Specifically, after 
administering anesthesia (avertin) to the mouse, the mouse was injected on the back 
subcutaneously with 50,000 L3.6pl cells suspended in 100 µl of DPBS. After about two 
weeks of growth, the tumor was mature and the combined ultrasound and photoacoustic 
imaging experiment was conducted with the mouse situated on a heated eletrocardiogram 
pad where temperature and heart rate could be monitored while the animal was under 
anesthesia (isoflurane). After collecting ultrasound and photoacoustic data on the tumor 
area in what is termed “before” frames, the mouse was injected with ~1012 a-EGFR 
conjugated, mPEG-SH passivated S3 Ag nanoplates in 200 µl of PBS. Ultrasound and 
photoacoustic data was then collected every hour for the first 6 hr after injection and then 
again at 24 hr after injection. All procedures were conducted in accordance with the 
protocols approved by the Institutional Animal Care and Use Committee at the University 
of Texas at Austin. 
7.2.6 Biodistribution and Histology 
At 112 hr after the mouse was systemically injected with nanoplates, it was 
sacrificed for histological analysis of the tumor as well as biodistribution of silver 
throughout the organs. Upon sacrifice, the organs were excavated, weighed, and then 
dissolved in 5 ml of 70% nitric acid while stirring for 24 hr. The digested organs were 
diluted by a factor of 10 in water and sent through a 200 nm filter. For analysis, all 
samples were introduced with a standard glass nebulizer into a GBC Optimass 8000 
(GBC Scientific, Hampshire, IL, USA) inductively coupled plasma - time of flight mass 
spectrometer (ICP-TOFMS). Exact parameters for the ICP-TOFMS measurements can be 
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found in Table 1 of an article from Rowland et al.21 Each sample was monitored for Ag 
content against freshly made standards using silver nitrate.  
Histological slices of the tumor were taken after embedding the tumor section in 
paraffin. Individual tumor slices were mounted on slides and stained with hematoxylin 
and/or nuclear fast red. Then silver staining was performed to highlight the presence of 
silver nanoparticles in the tumor. Images of the slides were obtained using a Leica 
DMI3000 B inverted microscope with a Leica DFC 290 kit and 3 mega pixel color 
camera using a 1.25X objective.  
7.2.7 Combined Ultrasound and Photoacoustic (USPA) Imaging Set-up 
To perform in vivo imaging experiments, a custom designed combined ultrasound 
and photoacoustic (USPA) imaging system was used as previously described.7 Briefly, 
the setup for the combined USPA imaging system was shown in Fig 3.2 in Chapter 3. 
Pulsed light in the range of wavelengths between 680 nm and 1064 nm was generated by 
an optical parametric oscillator (OPO) laser system operating at 10 Hz with a 4-6 ns pulse 
duration. This light was focused onto a 18-fiber bundle that surrounded an array 
transducer (7.5 MHz center frequency, 14 mm wide, 128 element linear array). To collect 
radiofrequency (RF) data, the transducer was interfaced with a Cortex ultrasound imaging 
engine (Winprobe Corp) capable of RF data acquisition for spatially co-registered 
ultrasound and photoacoustic RF signals. To form the images, RF data was beamformed, 
and then US images (dB scale) and fluence-compensated PA images (linear scale) were 
plotted. Three dimensional renderings were obtained by stacking 2D slices using Amira 
software. 
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7.3 RESULTS AND DISCUSSION 
The purpose of the work presented in this chapter is to prove that silver 
nanoplates can be used as photoacoustic contrast agents. The following sections describe 
in detail: (1) modeling showing that nanoplates have the high absorption cross-sections 
required for photoacoustic imaging, (2) silver nanoplate synthesis and bioconjugation, (3) 
in vitro characterization of the nanoplates with pancreatic cancer cells, (4) in vivo results 
showing USPA imaging of nanoplate accumulation in a xenograft tumor mouse model, 
and (5) the biodistribution of silver in the mouse organs following systemic injection.  
7.3.1 FDTD Simulations of the Absorption and Scattering from Silver Nanoplates 
Figure 7.2 shows the calculated light extinction, absorption, and scattering cross-
sections for three silver nanoplates of increasing size. Recall that the extinction cross-
section is an additive composite of the absorption and scattering cross-sections. Since 
higher absorption cross-section leads to higher photoacoustic signal generation (see 
Chapter 1), the absorption cross-section is the key parameter for photoacoustic imaging 
contrast agent evaluation. As shown in Fig 7.2, as the edge length of the nanoplate 
increases, the contribution of the absorption cross-section to the overall extinction cross-
section decreases. However, the absorption cross-section absolute value remains fairly 
constant for the three sizes shown. A quantitative assessment of the absorption cross-
section for various silver nanoplates in comparison to gold nanospheres22 and 
nanocages12 is provided in Table 7.2. The absorption cross-section of silver nanoplates is 
comparable to or better than these other well-established photoacoustic contrast agents. 
Therefore, modeling results indicate that silver nanoplates have significant potential as 
photoacoustic contrast agents.  
 153 
7.3.2 Silver Nanoplate “green” Synthesis and Bioconjugation 
Researchers have designed numerous methods to synthesize Ag nanoplates.23-26 
Most are accomplished through seed mediated growth mechanisms that can include 
reducing agents such as hydrazine18, increases in temperature27, or even ingenious light 
mediated methods.28, 29 Interestingly, even microbes have been shown to produce silver 
nanoplates upon incubation with Ag+ in solution. Since the silver nanoplates developed 
here are intended for use in a biological context, the synthesis method was particularly 
“green”. Only biocompatible chemicals were used, such as ascorbic acid (vitamin C) and 
sodium citrate (a well known preservative). After exploring several different methods of 
preparing Ag seeds18, 30, the seeds proposed by Xue et al17, 28 were found to be the most 
reproducible; they provided the twinned plane and fault defects necessary for Ag 
nanoplates synthesis. To grow the Ag nanoplates from these seeds, procedures introduced 
by Zou et al.18 were slightly modified. The plates were grown in a step-wise process from 
5 nm seeds to large, > 200 nm edge length plates. Figure 7.2 shows the evolution of the 
synthesis from seeds to large nanoplates in four steps. First, the yellow seeds were grown 
into 25 nm nanoplates (S1) as shown in Fig 7.2a. Subsequent growth steps increased the 
edge length of the plates successively (Figs 7.2b-d representing samples S2-S4, 
respectively). The colors of the resulting solutions changed with their optical extinction 
properties as depicted in Figs 7.2e and 7.2f. This synthesis method produced mostly 
nanoplates with edge lengths as shown in Table 7.3, but a small population (< 20%) of 
Ag nanospheres or other oblong shapes were also synthesized. 
7.3.3 In Vitro Characterization with Pancreatic Cancer Cells 
A commonly overexpressed receptor on the surface of cancer cells is the 
epidermal growth factor receptor (EGFR). The antibody to EGFR (a-EGFR) was used as 
a model to target Ag nanoplates to pancreatic cancer cells. The directional conjugation 
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method used for binding a-EGFR to nanoplates was previously described by Kumar et 
al.20 This directional method employs linker molecules that bind the Fc portion of the 
antibody directly to the Ag surface, leaving the entire variable region free to interact with 
cells. To confirm that the antibody conjugated Ag nanoplates would target pancreatic 
cancer cells, while PEGylated Ag nanoplates would have limited interaction, pancreatic 
cancer cells were mixed with both types of particles in vitro for 4 hr. The resulting cells 
imaged using darkfield microscopy are shown in Fig 7.4. The control cells with no 
nanoplate incubation are seen as blue in darkfield microscopy (Fig 7.4a). The cells 
incubated with PEGylated Ag nanoplates appear to have no significant accumulation of 
silver (Fig 7.4b), but the cells incubated with a-EGFR conjugated nanoplates show 
significant interaction. These in vitro results demonstrated the ability of a-EGFR 
conjugated nanoplate to specifically interact with pancreatic cancer cells. 
To determine whether this interaction of a-EGFR conjugated nanoplates with 
cancer cells induced cytotoxicity, various amounts of a-EGFR conjugated nanoplates 
were mixed with three different cell lines in vitro: MPanc96 and L3.6pl (both pancreatic 
cancer cell lines shown to overexpress EGFR), and HPNE (a non-cancerous pancreatic 
cell line). The viability of the cells was tested after incubation with the a-EGFR 
conjugated nanoplates for 24 hr using the MTS assay. As shown in Fig 7.5, even up to 
concentrations of 1 mg/ml Ag, no statistically significant cytotoxicity was found with any 
of the three cells lines. These results were surprising since the cytotoxicity of 5 nm to 10 
nm Ag nanospheres has been characterized.31, 32 The lack of toxicity of these large 
nanoplates suggests that the cytotoxicity of silver may be size dependent or coating 
dependent.  
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7.3.4 In Vivo Ultrasound and Photoacoustic (USPA) Imaging 
All in vivo imaging was conducted on Nu/Nu transgenic mice with xenograft 
human pancreatic cancer subcutaneously grown on their back. Before injection of 
nanoplates, ultrasound (US) and photoacoustic (PA) imaging was performed across 2D 
transverse sections of the tumor area by translating the array transducer and fiber optic 
source across the length of the tumor. Combined ultrasound and photoacoustic USPA 
imaging of three cross-sections of the tumor region are shown in Fig 7.6. These images 
provide a basis for the expected endogenous contrast provided by blood and other natural 
absorbers in tissue (Fig 1.3). Then a-EGFR, mPEG-SH passivated Ag nanoplates were 
injected (~1012 nanoplates in 200 µl of PBS) into the tail vein. Imaging was performed 
every hour after injection up to 6 hr post injection. At 5 hr post injection, peak 
accumulation of nanoplates in the tumor was observed as determined by monitoring the 
photoacoustic signal intensity with time post injection. Individual ultrasound, 
photoacoustic, and combined USPA images are shown in Fig 7.7. The tumor is clearly 
outlined in the ultrasound image as the hypoechoic region on top circled in blue (Fig 
7.7a). Photoacoustic images captured using the wavelengths of 760 nm, 800 nm, and 900 
nm are shown as Figs 7.7b-d, respectively, and the corresponding combined USPA 
images of these frames are shown in Figs 7.7f-h. The UV-vis extinction spectrum of the 
nanoplates injected is shown in Fig 7.7e. As expected, the PA signal inside the tumor is 
strongest at 760 nm since that wavelength matches the LSPR peak of the Ag nanoplates. 
The PA signal decreased with increasing wavelength corresponding with the UV-vis 
absorption spectrum of the nanoplates. Also, the distribution of nanoplates in the tumor is 
heterogeneous. This uneven distribution of nanoplates in the tumor is also depicted in the 
3D USPA rendering of the tumor (Fig 7.8). Interestingly, the PA signal is highest at the 
base of the tumor where large blood vessels appear to be feeding the tumor. These large 
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blood vessels were confirmed upon tissue dissection. As the nanoplates injected 
intravenously rely on the bloodstream for transport to the tumor, areas of the tumor with 
insufficient blood circulation will tend to have minimal nanoplate accumulation. This 
incomplete distribution of nanoplates in the tumor represents a major challenge for all 
nanoparticle contrast agents and nanomedicine approaches aimed at imaging or treatment 
of cancer. 
7.3.5 Biodistribution of Silver 
Systemic injection of any foreign substance in the body will have 
pharmacological implications. Therefore, it is important to first determine the distribution 
of the injected agent throughout the body at various time points post injection. For this in 
vivo case study, the mouse was sacrificed at 112 hr post nanoplate injection. The 
biodistribution of silver throughout the various filtering organs within the body was 
determined using ICP-MS. The amount of silver per gram of tissue in various organs is 
displayed in Fig 7.9. As expected and seen in other studies with gold nanoparticles33, 34, 
the liver and spleen have high accumulation rates of silver, while the tumor has modest 
accumulation. Interestingly, the accumulation in the fecal matter is high, indicating that 
silver clearance from the body via the digestive system might be possible.  
Distribution of silver throughout the tumor was also investigated using histology. 
Histological slices of the tumor stained with silver stain and hematoxylin (Fig 7.10a) or 
silver stain and nuclear fast red (Fig 7.10b), also confirmed a heterogeneous nanoplate 
distribution within the tumor. The largest concentration of silver was present at the base 
of the tumor as indicated by the black arrow in Fig 7.10a. This accumulation was also 
seen in the PA images of the tumor in which the strongest PA signals were present at the 
base of the tumor (Fig 7.7).  
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Since silver nanoplates are carried by the bloodstream, and tumor vasculature is 
inherently disordered, a nonhomogeneous distribution of nanoparticles within the tumor 
space is always expected and represents a challenge for all nanoparticle-based medicine. 
Because nanoparticles cannot reach all areas of a tumor, successful therapeutic outcome 
may require multiple dosing and/or treatment strategies. Furthermore, in addition to 
accumulation in the tumor, filtering organs such as the liver and spleen are the most 
likely sites for silver distribution. Organ specific toxicity studies of the nanoplates in the 
liver and spleen are needed to determine the safety of using silver nanoplates in vivo.  
7.4 CONCLUSIONS 
The results presented indicate that silver nanoplates have excellent potential as a 
photoacoustic imaging contrast agent. They can be easily synthesized to absorb light 
from the visible to the near infrared spectrum. FDTD modeling confirmed that they have 
absorption cross-sections comparable to, and in some cases greater than, conventional 
gold contrast agents. Silver nanoplates bioconjugated to antibodies showed effective cell 
labeling and uptake in a tumor model of pancreatic cancer in vivo. Organ specific toxicity 
associated with silver in the liver and spleen must be addressed prior to widespread 
adoption as a photoacoustic imaging contrast agent, and clearance through the feces after 
systemic injection is possible. Overall, this work has solidly demonstrated the feasibility 
of using silver nanoplates as imaging contrasting agents. Chapter 8 will explore the 
feasibility of using nanoplates as drug carriers.  
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Figure 7.1: Surface grafting of directionally conjugated antibodies and PEG to the 











Table 7.1:     Chart showing the growth solutions required for various growth stages of 
the stepwise nanoplate growth with their associated color changes and 
resulting longitudinal surface plasmon resonance (LSPR) peaks. Amounts of 
trisodium citrate (TSC) are from a 40 mM solution, and amounts of ascorbic 
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Figure 7.2: FDTD modeling of the extinction, scattering, and absorption cross-section 


















Table 7.2:     A comparison of absorbance cross section values for various nanoparticles 
at their longitudinal surface plasmon resonance. Data for the silver 
nanoplates and Au nanorods were simulated using FDTD modeling while 
data for the Au nanospheres and Au nanocages were previously reported.12, 
16, 22 
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Figure 7.3:   Silver nanoplates directly after step-wise growth adding edge length from S1 
to S4 (a-d) with their corresponding extinction spectra (e) and color change 








Table 7.3:     Size chart of Ag nanoplate edge length and thickness for each growth step 
along with the percent population of spheres grown alongside the nanoplates 




































Figure 7.4:   Darkfield microscopy of pancreatic cancer cells after incubation with no 
nanoplates (a), PEGylated nanoplates (b), and a-EGFR conjugated 





Figure 7.5:   Results of the MTS assay for cell viability on three cell lines after incubation 


















Figure 7.6:   Blue circles highlight the position of the tumor in three different 2D cross-
sectional planes in vivo prior to the silver nanoplate injection. Ultrasound (a-
c) and photoacoustic images taken using 760 nm (d-f), 800 nm (g-i), and 
900 nm (j-l) wavelengths of light are shown for each cross-section. All 
images are 17.5 mm by 10.5 mm. 
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Figure 7.7:   Ultrasound (a), photoacoustic (b-d), and combined PAUS (f-h) images of a 
2D cross-section of the tumor at 5 hr post injection of a-EGFR and mPEG-
SH conjugated Ag nanoplates. The tumor area is circled in blue. All images 
are 17.5 mm by 10.5 mm. (e) shows the optical extinction spectrum for the 
Ag nanoplates injected. 
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Figure 7.8:   A 3D rendering of the entire mouse tumor and the accumulation of a-EGFR 
conjugated Ag nanoplates within the tumor volume. The image is 17.5 mm 
by 10.5mm by 12 mm. 
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Figure 7.9:   The biodistribution of silver in particular mouse organs 112 hr after silver 
nanoplate injection. Only ~15% of the initial injected dose was accounted 




Figure 7.10:  Histological slices of the tumor stained with silver stain and hematoxylin (a) 
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Chapter 8: Synthesis of the CIT-NpS and In Vitro Characterization 
The objective of this research is to create nanosystems with the ability to provide 
both imaging contrast and therapy for pancreatic cancer. In Chapters 2-5 the CIT-NS 
design was discussed. In Chapter 6, a new and potentially better nanosystem, the CIT-
NpS, was proposed. Chapter 7 showed that this nanoplate system could enhance 
photoacoustic imaging in vivo. Finally, this chapter explores synthesis methods and 
preliminary in vitro characterization for the entire CIT-NpS, complete with drugs as 
depicted in Fig 6.1.  
8.1 INTRODUCTION 
This chapter explores the feasibility of using silver nanoplates as drug carriers, 
thus completing the CIT-NpS design. As discussed in Chapters 2 and 5, Gemcitabine 
(Gem) remains the chemotherapeutic standard of care for pancreatic cancer patients;1-4 
therefore, attachment of Gem to the silver nanoplate system is the ultimate goal (Fig 6.1). 
Towards this end, several facets of synthesis and characterization of the CIT-NpS must 
be addressed: (1) methods of Gem conjugation to the nanoplate, (2) chemical 
modifications of Gem necessary for the chosen conjugation strategy, and (3) testing of 
the chemically modified drug (Gem prodrug) for therapeutic efficacy.  
Conjugating drugs to metal surfaces can be accomplished through several 
strategies. Electrostatic interactions, chemisorption, hydrogen bonding, and covalent 
bonding are some of the ways that drugs can be attached to nanoparticle carriers. 
Covalent bonds are desired since they form a strong connection between the drug and the 
metal that is not easily broken or displaced by interactions with molecules in the 
bloodstream. Primary amine groups, such as those found on Gem (Fig 5.2), can 
chemically adsorb to silver and gold surfaces. Some argue that the amine-gold connection 
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is covalent5, 6, but not as strong as the covalent bond between free thiol groups and silver 
or gold (a.k.a. thiolate bonds). The nanoplate system was designed to be a systemically 
injected platform. Therefore, thiolate bonds between the drug and the metal represent the 
tightest junction with the least likelihood of degrading in the bloodstream. For this 
thiolate bonding strategy to work, a free sulfhydryl residue (primary thiol) must be 
present on Gem.  
Introduction of sulfhydryl residues to molecules, also called thiolation, is well 
known. Hermanson describes at least 11 different methods for thiolation of proteins.7 
Seven of these techniques are for modification of amine groups to thiol groups. 
Following Hermanson’s protocols, Gem was thiolated using N-succinimidyl S-
acetylthioacetate (SATA) at its primary amine site. Described in this chapter are methods 
of synthesis and characterization for a Gemcitabine thioamide prodrug formed using 
SATA. Furthermore, prodrug therapeutic efficacy is tested in comparison to native Gem, 
and the effect that drug attachment has on the structural stability, drug delivery 
mechanisms, and imaging contrast potential of the nanoplate system is investigated.   
8.2  METHODS 
This methods section is divided into three major segments: (1) prodrug synthesis, 
(2) CIT-NpS synthesis, and (3) in vitro characterization of the CIT-NpS with pancreatic 
cancer cells. For reader clarity, the sources for all materials are consolidated here. 
Materials: All chemicals were used without further purification and were at 
minimum ACS grade.  Silver nitrate (>99%), pyridine, hydroxylamine, the antibody to 
Epidermal Growth Factor Receptor (EGFR) clone C225, poly(ethylene glycol) bisphenol 
A epichlorohydrin Mn = 14 kDa, and Bis (p-sulfonatophenyl) phenylphosphine dihydrate 
dipotassium salt (BSPP) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
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ACS grade L(+) ascorbic acid was a product of Acros (Morris Plains, NJ, USA). 
Dulbecco’s phosphate buffered saline (DPBS) came from Mediatech, Inc. (Herndon, VA, 
USA). The methyl-poly(ethylene glycol)-thiol (mPEG-SH of 5 kDa) was from Laysan 
Bio (Arab, AL, USA). All cell culture products, the MTS assay, and N-succinimidyl S-
acetylthioacetate (SATA) were purchased from Invitrogen (Carlsbad, CA, USA) unless 
otherwise specified. Slide mounting media, Vectashield with DAPI stain, was from 
Vector Laboratories (Burlingame, CA, USA). The linker hydrazide-polyethylene glycol-
dithiol (SPT-014B) was a product of Sensopath (Bozeman, MT, USA).  
8.2.1 Gemcitabine-Thioamide Prodrug Synthesis and Characterization 
Several strategies for thiolation of Gem were considered and tested.7 After several 
failed attempts, it was deduced that the primary amine on Gem is a very weak 
nucleophile. Successful thiolation of Gem was only achieved using SATA when pyridine 
was used as the solvent. The basic nature of pyridine helped facilitate nucleophilic attack 
by the primary amine on Gem. Specifically, a thiolated version of Gem was synthesized 
in a two-step reaction as shown in Fig 8.1. Gem (25 mg, 0.0834 mmol) was placed in a 
small glass vial with 0.8 ml of pyridine and allowed to stir at room temperature. Then 
SATA (15.43 mg, 0.0667 mmol) was added. Nitrogen was bubbled into the stirring 
mixture for 1 min and then the reaction was sealed in the nitrogen environment while 
stirring for 3 hr. Aliquots of the crude mixture were taken for direct analysis by 
electrospray ionization mass spectroscopy (ESI-MS). For H1 Nuclear Magnetic 
Resonance (NMR) analysis at 600 MHz, the reaction was performed under N2 in 
deuterated pyridine and transferred directly to a NMR glass tube for analysis of the crude 
mixture. NMR analysis of the split doublets in the CH6 and CH5 positions on Gem were 
used to determine yield of the Gemcitabine acetylthioamide (Gem-ATA) prodrug.  
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To complete Step 2 of the reaction shown in Fig 8.1, 5.332 µl of the mixture from 
Step 1 was placed in 944.668 µl of a sodium phosphate buffer (50 mM, pH = 8.0) while 
stirring. Then 50 µl of a 1 mg/ml solution of hydroxylamine (0.72 µmol – 2x the moles of 
SATA present) was added and the solution was stirred at room temperature for 2 hr. 
During those 2 hr, the acetyl group was removed from Gem-ATA, creating the final 
Gemcitabine Thioamide (Gem-TA) prodrug. Analysis of the crude final product was 
attempted through ESI-MS following desalting and purification using C-18 Ziptips (a 
product of Millipore).  
8.2.2 CIT-NpS Synthesis and Characterization 
 Using the thiolated version of Gem (Gem-TA), described above, the CIT-NpS 
can be built. Three molecules were surface grafted to Ag nanoplates via thiolate bonds8, 9 
in the following order: the antibody to EGFR, Gem-TA, and mPEG-SH. The antibody to 
EGFR (a-EGFR) was added first because it is the largest molecule and therefore has the 
least mobility in solution. If it were not grafted first, it is likely that a-EGFR would not 
bind in significant quantities. The Gem-TA prodrug was grafted second to afford as much 
space for binding on the surface of silver as possible. Finally, mPEG-SH was added to fill 
in any available surface spaces, adding stability to the nanoplate.  
The steps for bioconjugation of the three moieties are described below. Any 
desired batch (S1 through S4, based on the desired optical properties) of the as prepared 
nanoplates (see Chapter 7) were placed in a 50 kDa MWCO Millipore centrifugal filter 
directly after synthesis and spun at 1500 rcf for 3 min at 20°C. The nanoplates were then 
resuspended in 1 ml of DIUF water, placed in a 2 ml tube, wrapped in foil, and allowed 
to sit overnight at room temperature. Then 200 µl of a 2 wt% PEG solution was added 
(poly(ethylene glycol) bisphenol A epichlorohydrin Mn = 14 kDa). Adding the PEG 
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solution helped limit aggregation of the nanoplates during the bioconjugation process. An 
ultraviolet to visible (UV-vis) spectrum from 300 nm to 1100 nm was measured using a 
Beckman Coulter DU 640 spectrophotometer with a 1 cm pathlength cuvette containing 7 
µl of the nanoplate solution in 400 µl of DIUF water. Then, enough of the as prepared 
antibody-linker (AB-linker) solution (see Chapter 7) was added to account for 0.05 mg of 
antibody-linker. The exact volume of the AB-linker solution varied based on the final 
concentration of the AB-linker in HEPES as determined by a Thermo Scientific 
Nanodrop read at a wavelength of 280 nm with an assumed extinction coefficient of 
210,000 M-1cm-1. The AB-linker and nanoplates were allowed to shake at room 
temperature in the dark for 20 min, after which the UV-vis spectrum was determined. 
Slight red shifts (5-10 nm) in peak resonance of the nanoplates were observed after 
conjugation of the AB-linker to the nanoplates.  
The Gem-TA prodrug was conjugated after the AB-linker. Specifically, 40 µl of 
the as prepared Gem-TA solution (see section 8.2.1) was added to the silver 
nanoplate/AB-linker solution and allowed to shake at room temperature in the dark for 20 
min, after which the UV-vis spectrum was measured. Again, slight red shifts (4-6 nm) in 
peak resonance of the nanoplates were observed after conjugation of the Gem-TA to the 
nanoplates. 
To limit opsonization in the bloodstream, the surface area of the silver not 
covered by antibody or Gem-TA was passivated by attachment of mPEG-SH. 
Specifically, after allowing the AB-linker/Gem-TA/Ag nanoplate solution to react, 40 µl 
of 50 mM mPEG-SH (5 kDa) was also added to react with the Ag nanoplates. After 
shaking in the dark for 20 min, the nanoplates were cleaned using a 50 kDa MWCO 
Millipore centrifugal filter spun at 1500 rcf for 5 min at 4°C. Supernatants were collected 
for analysis. Then, the nanoplates were resuspended in 500 µl of DPBS and sent through 
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a 0.22 µm filter into another 50 kDa MWCO Millipore centrifugal filter in 5 ml total of 
DPBS. The nanoplates were again spun at 1500 rcf for 5 min at 4°C. The sterile 
nanoplates (the final CIT-Nps) were suspended in 500 µl of DPBS in a sterile 2 ml tube 
for future use.  
Several analytic techniques were used to prove that Gem-TA attached to the 
nanoplates. To enhance the accuracy of these methods, a set of nanoplates conjugated to 
Gem-TA, without a-EGFR or mPEG-SH was created. Briefly, an S3 batch of the as 
prepared nanoplates (see Chapter 7) was placed in a 50 kDa MWCO Millipore 
centrifugal filter directly after synthesis and spun at 1500 rcf for 3 min at 20°C. The 
nanoplates were then resuspended in 1 ml of DIUF water, placed in a 2 ml tube, wrapped 
in foil, and allowed to sit overnight at room temperature. Then, 40 µl of the Gem-TA 
solution (see section 8.2.1) was added to the silver nanoplate solution and allowed to 
shake at room temperature in the dark for 20 min, after which the UV-vis spectrum was 
taken. Then the plates were washed twice using a 50 kDa MWCO Millipore centrifugal 
filter (1000 fold dilution). For analysis using energy-dispersive X-ray spectroscopy 
(EDS) on a scanning transmission electron microscope (STEM), nanoplates were drop 
casted onto formvar/carbon 200 mesh Cu TEM grids. For analysis using X-ray 
photoelectron spectroscopy (XPS), nanoplates were drop casted onto a silicon wafer and 
dried in a vacuum oven overnight at 60°C. Lastly, to ensure that Gem-TA was grafting 
specifically to the nanoplates, Step 2 of the reaction shown in Fig 8.1 was replicated with 
and without the hydroxylamine reactant. The supernatants after nanoplate attachment for 
both reactions were analyzed using UV-vis spectroscopy.  
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8.2.3 In Vitro Characterization with Pancreatic Cancer Cells 
The human pancreatic cancer cell line L3.6pl and the non-cancerous pancreatic 
line HPNE were incubated with bioconjugated silver nanoplates and tested for cell 
viability. Since several different conditions were tested using the same assay, the 
procedure for culturing the cells and the general assay protocol description are 
consolidated in this section. Specifics of each test are then provided in the following 
sections 8.2.3.1 through 8.2.3.4.  
The L3.6pl cell line was cultured in vitro using Dulbecco’s Modified Eagle 
Medium (DMEM) (with 4500 mg glucose/L, L-glutamine, NaHCO3 and pyridoxine HCl) 
supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin 
(Pen/Strep) while maintained at 37°C and 5% CO2 in a humidified incubator. The 
DMEM and the FBS were purchased from Sigma and the Pen/Strep from Invitrogen. The 
non-cancerous pancreatic cell line, HPNE, was cultured in vitro using Medium D that 
contained one volume of medium M3, three volumes of glucose-free DMEM (with L-
glutamine, phenol red, and pyridoxine HCl), 5% FBS, 5.5 mM glucose, 10 ng/ml EGF, 
and 50 µg/ml gentamycin. Medium M3 is a proprietary formulation optimized for the 
growth of neuroendocrine cells (InCell Corp., San Antonio, TX, USA). For cell viability 
studies, cells were seeded in a 96 well plate (each well had 5,000 cells per 100 µl of 
media for the L3.6pl line and 10,000 cells per 100 µl of media for the non-cancerous, 
HPNE line). The cells were allowed to attach and grow in the 96 well plate for 24 hr, 
after which the cell media was removed and replaced with suspensions of bioconjugated 
Ag nanoplates or drugs (at least 5 wells were seeded for each concentration). After 48 hr 
of incubation, the media was removed and replaced with fresh media containing no 
nanoplates or drugs. The absorbance of each well in the plate was measured at 490 nm 
using a Synergy HT Multimode Microplate Reader from BioTek.  To perform the assay, 
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20 µl of a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and an electron 
coupling reagent (phenazine methosulfate) PMS from the CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (a Promega product) was added to each well. Over a 
period of 1 hr in the incubator, the MTS was bioreduced by cells into a formazan product 
that had an absorbance peak at 490 nm. Dehydrogenase enzymes found in metabolically 
active cells were responsible for the conversion of MTS into the soluble formazan 
product. Therefore, the absorbance of each well at 490 nm was directly proportional to 
the number of viable cells. The absorbance of each well at 490 nm taken before adding 
MTS was subtracted from the post MTS incubation value. Cell viability was determined 
by comparing the resulting absorbance of wells containing no nanoplates or drugs to that 
of wells containing nanoplates or drugs using an F test for a one-way ANOVA. 
8.2.3.1 Cytotoxicity of the Gemcitabine-TA Prodrug 
The efficacy of the Gem-TA prodrug was compared with that of native Gem 
using the MTS assay on L3.6pl pancreatic cancer cells. Details describing how the MTS 
assay was performed can be found above (section 8.2.3). For this particular test, Gem was 
suspended in cell media at 300 nM, sterilized using a 200 nm filter, and mixed with the 
cells. Dilutions of 1:10 in media were prepared to create all of the Gem conditions tested 
(30 nM and 3 nM). Similar concentrations of Gem-TA were obtained differently. First, 
265 µl of the Gem-TA solution obtained from Step 2 in Fig 8.1 (see section 8.2.1) was 
added to 1.735 ml of sterile DPBS. The solution was sent through a sterile 200 nm filter. 
Then 48.9 µl of that sterile solution was added to 1.7511 ml of media to create a 300 nM 
concentration of Gem-TA in media. Dilutions of 1:10 in media were prepared to create 
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all of the Gem-TA conditions tested (30 nM and 3 nM). Cells were incubated with drugs 
in media for 48 hr prior to performing the MTS assay.  
8.2.3.2 CIT-NpS Therapeutic Efficacy and Cytotoxicity 
Using the CIT-NpS as a vehicle capable of carrying and delivering drugs to 
pancreatic cancer cells was evaluated against the efficacy of the free Gem-TA prodrug in 
solution using the MTS assay. Details describing how the MTS assay was performed can 
be found above (section 8.2.3). For this particular test, the CIT-NpS was obtained as 
prepared and described in section 8.2.2. However, in the last wash step instead of 
resuspending in 500 µl of DPBS, the particles were suspended in 5.5 ml of cell media. 
This dilution makes ~1.5x1011 nanoplates/ml at a Gem-TA concentration of 300 nM. 
Dilutions of 1:10 in media were prepared to create all of the CIT-NpS conditions tested. 
The Gem-TA samples were prepared as described in section 8.2.3.1.  
8.2.3.3 CIT-NpS Toxicity and Stability under Pulsed Laser Exposure 
Cell viability tests using pancreatic cancer L3.6pl cells were performed to 
determine if the pulsed laser irradiation associated with photoacoustic imaging would 
cause either (1) damage to nanoparticle labeled cells or (2) extensive drug release from 
the silver nanoplates. Details describing how the MTS assay was performed can be found 
above (section 8.2.3). For this particular test, the CIT-NpS was prepared exactly as 
described in section 8.2.3.2. Nanoplates with only a-EGFR and mPEG-SH were also 
created using the same procedures described in sections 8.2.2 and 8.2.3.2 except Gem-TA 
was excluded. Unlike the first two MTS assays described in sections 8.2.3.1 and 8.2.3.2, 
no dilutions of the particles were performed. Instead, every well was filled with ~1.5x1011 
nanoplates/ml in media at a Gem-TA concentration of 300 nM where appropriate. The 
nanoplates were incubated with cells for 4 hr prior to laser exposure. The condition that 
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was varied was the fluence of the laser exposed to the particles. Laser light at the peak 
resonance wavelength of the nanoplates was irradiated in a 0.2 cm2 circular spot 
corresponding to the area of each well in the 96 well black plate. The light was generated 
using a SpectraPhysics optical parametric oscillator (OPO) system operating at a pulse 
repetition frequency of 10 Hz and pulse duration of 4-6 ns. Each well received 1000 
pulses of light. The MTS assay was performed at 48 hr post laser exposure.  
8.2.3.4 CIT-NpS Toxicity under Continuous Wave Laser Exposure  
Cell viability tests using pancreatic cancer L3.6pl cells were also performed to 
determine if a continuous wave laser could be used in combination with silver nanoplates 
to induce photothermal cell damage. Details describing how the MTS assay was 
performed can be found above (section 8.2.3). For this particular test, nanoplates with 
only a-EGFR and mPEG-SH were created using the same procedures described in 
sections 8.2.2 and 8.2.3.2 except Gem-TA was excluded. Similar to the test performed in 
section 8.2.3.3, no dilutions of the particles were prepared. Instead, every well was filled 
with ~1.5x1011 nanoplates/ml in media. The nanoplates were incubated with cells for 4 hr 
prior to laser exposure. The condition that was varied was laser irradiation time. Laser 
light at the peak resonance wavelength of the nanoplates was irradiated in a 0.2 cm2 
circular spot corresponding to the area of each well in the 96 well black plate. The 
measured power of the continuous wave diode 808 nm laser was kept constant at 1.3 
W/cm2. The MTS assay was performed at 48 hr post laser exposure. 
8.3 RESULTS AND DISCUSSION 
Other researchers have attached Gem to gold nanoparticles and targeted 
pancreatic cancer6. Presented here is the synthesis of a new Gem prodrug and its 
subsequent attachment to silver nanoplates for pancreatic cancer treatment. These 
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preliminary results demonstrate that the CIT-NpS can be synthesized and used as a drug 
carrier with multifunctional properties.  
8.3.1 Gemcitabine-TA Prodrug Synthesis and Characterization 
Thiolation of Gem was performed to create the prodrug Gem-TA that was 
successfully grafted to silver nanoplates. The thiolation was achieved using the reactant 
SATA that had been previously used for protein thiolation.7 The two-step reaction 
scheme for Gem-TA synthesis is shown in Fig 8.1. In the first step, Gem-ATA was 
formed by reacting Gem and SATA in pyridine. Surprisingly, pyridine was the only 
solvent that allowed for favorable formation of Gem-ATA. Other aqueous solvents such 
as basic phosphate and carbonate buffers were tried, but ultimately failed to produce 
Gem-ATA. Interactions between the pyridine solvent and Gem likely increase the 
nucleophilicity of Gem’s primary amine, allowing the reaction with SATA to proceed. 
However, more investigation would be required for a detailed reaction mechanism to be 
fully elucidated. ESI-MS results shown in Fig 8.2 demonstrate the presence of both Gem 
and Gem-ATA in the crude reaction mixture after Step 1. NMR of the crude mixture also 
confirmed this result where peaks associated with the CH6 and CH5 hydrogens on Gem 
are still present in the Gem-ATA spectrum (Fig 8.3). Comparing the integrated peak 
values of the split doublets associated with native Gem at 8.38 ppm and the doublet 
associated with Gem-ATA at 8.73 ppm, the reaction yield was calculated at only 15%. 
For the second reaction step, ESI-MS was used to analyze the mixture after reaction with 
hydroxylamine in aqueous phosphate buffer. After purification and desalting using C18 
Ziptips, the ESI-MS did not detect Gem-TA in the sample. Moreover, Gem, NHS, and 
SATA were also not detected, so it is possible that the desalting using the C18 Ziptips 
actually filtered out the compounds of interest. Thus, even though confirmation of the 
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Gem-TA prodrug was difficult; notable changes in the nanoplate properties and 
supernatants were found, which indicate that Gem-TA must have been formed. Details of 
these tests are provided in the next section.  
8.3.2 CIT-NpS Synthesis and Characterization 
Results here indicate that the CIT-NpS was formed. Chapter 7 already showed 
that Ag nanoplates could be created with a-EGFR and mPEG-SH grafted. In this Chapter, 
Gem-TA was formed and grafted in succession with a-EGFR and mPEG-SH to Ag 
nanoplates. The most convincing evidence that Gem-TA was formed and did attach to 
silver came from supernatant analysis. As described in section 8.2.2, the reaction in Step 
2 of Fig 8.1 was set up as a test with and without the hydroxylamine (HA). After those 
reactions were run for 2 hr in phosphate buffer, 40 µl of each was reacted with different 
batches of silver nanoplates. The nanoplates were then washed twice and the supernatants 
analyzed using a spectrophotometer. The UV spectrums from the first supernatant washes 
are shown in Fig 8.4a. Unfortunately, pyridine, Gem, Gem-TA, and NHS all contribute to 
the collective peak at 255 nm shown in Fig 8.4a. However, a noticeable change in peak 
height is visible for the supernatant collected for the nanoplates reacted with HA and 
without HA in Step 2. Therefore, even though absorption in the UV range for multiple 
reactants did not allow for precise quantification of Gem-TA attachment to Ag 
nanoplates, the decrease in the overall absorbance for the supernatant captured when HA 
was used, shows that Gem-TA must have attached to the nanoplates. 
Analysis of the Ag nanoplates after conjugation of a-EGFR and Gem-TA also 
confirmed grafting. As shown in Fig 8.4b, the resonance peak for the Ag nanoplates right 
shifted with each subsequent grafting step. These small shifts in resonance are consistent 
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with findings from other researchers who attached molecules to gold using thiolate 
bonds.9, 10   
Further qualitative demonstration of Gem-TA attachment to the nanoplates was 
provided by EDS and XPS analysis. For EDS analysis, nanoplates were washed and drop 
casted on TEM grids for analysis in the STEM. Figure 8.5 shows the resulting EDS 
elemental mapping for Ag, F, and S for the single silver nanoplate shown in Fig 8.5a. The 
colored maps for the various elements show overlap in the signals for the three elements, 
illustrating that Ag is present and that F and S atoms associated with the Gem-TA 
prodrug are also present. Lastly, XPS analysis further confirmed the presence of F on the 
surface of Ag nanoplates. As shown in Fig 8.6, a peak for F 1s was located at a binding 
energy of 688 eV. That peak was integrated and compared with the corresponding peak 
for silver. XPS analysis indicated that a Ag:F ratio of 40:1 was calculated from the 
integrated peak values. However, without having known standards for the XPS 
measurement, this ratio could not be used quantitatively to determine the exact amount of 
Gem-TA on the surface of Ag. Thus, though the results are only qualitative, both XPS 
and EDS showed that Gem-TA was grafted to the surface of Ag nanoplates.   
8.3.3 Cytotoxicity of the Gemcitabine-TA Prodrug 
Once a prodrug like Gem-TA is built, it is important to first test its efficacy in 
vitro in comparison to the native drug Gem. A cell viability test was performed using the 
MTS assay on the pancreatic cancer cell line L3.6pl, and the results are shown in Fig 8.7. 
The concentration dependent loss in cell viability is comparable for the two versions of 
the drug. As discussed in Chapter 5, previous studies11, 12 have shown that prodrug 
versions of Gem are more effective than Gem. Most references site the stability of the 
prodrug forms in plasma as the main reason for increased therapeutic efficacy.11, 12 The 
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tests performed in the literature measured inhibition of protein synthesis and used 
different cells lines than those used here. The MTS assay, which assesses the function of 
active mitochondria, is a cell viability study only. The results shown in Fig 8.7 indicate 
that Gem-TA and Gem have toxic effects proportional to concentration. However, for this 
MTS assay performed on L3.6pl pancreatic cancer cells, there is no evidence of enhanced 
cytotoxicity for Gem-TA. Instead, these results indicate that Gem-TA and Gem are 
equally effective. The contradiction between these results and the literature might stem 
from either the type of cytotoxicity tests performed or the differences between individual 
cells lines. Protein inhibition testing would need to be performed on the L3.6pl cell line 
to further elucidate the reason for this difference. 
8.3.4 Therapeutic Efficacy of the CIT-NpS 
As explained above (Section 8.3.3), Gem-TA was proven at least as effective as 
Gem in inhibiting cell growth; now the therapeutic efficacy of the entire CIT-NpS 
complex was preliminarily assessed. Again, an MTS assay was performed on pancreatic 
cancer L3.6pl cells, this time with the CIT-NpS mixed in media as compared with Gem-
TA free drug mixed in media. Surprisingly, the CIT-NpS did not perform as well as the 
free Gem-TA drug. This finding is in contrast to a study from Patra et al.6 They used the 
same EGFR antibody (C225) and native Gem loaded on gold nanospheres. Both their in 
vitro and in vivo data showed that the bioconjugated gold carriers were significantly more 
effective than the antibody or Gem used alone or in combination against pancreatic 
cancer. One possible explanation for the contradictory results is that in the data presented 
here, the concentration of drug on the surface of the CIT-NpS could be in error. None of 
the analytical techniques used (EDS, XPS, or UV-vis) could quantitatively determine 
drug attachment. Another reason for the variation in the studies could be use of different 
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pancreatic cells lines. Patra et al used AsPC-1, MIA Paca-2, and PANC-1 cell lines, while 
the L3.6pl pancreatic cancer line was used here. Finally, another explanation is that silver 
is actually having a survival benefit for cells. This explanation may seem incredible given 
the body of literature claiming that silver is toxic.13, 14 However, in most of the MTS 
assays run to date (data not shown) in which cells were mixed with PEGylated or 
antibody conjugated silver nanoplates, the cells were up to 20% more viable than 
controls. This observation appeared to be within experimental error and was thus ignored 
for years. However, research done by Dr. Levi of Wake Forrest University seems to 
support the conclusion. Dr. Levi was using silver nanoplates to help prevent infection 
while sealing wounds. She induced slight hyperthermia in the wound region using 
continuous wave lasers in conjunction with silver nanoplates. Her unpublished in vitro 
tests also showed a survival benefit when silver nanoplates were present. Ongoing 
investigation into this topic is underway to determine if these results are credible, but 
they could indicate that silver is (1) stressing the cell and causing increased activity or (2) 
having a strong antimicrobial effect that relieves the cell and allows for increased 
proliferation. Regardless of the cause, the CIT-NpS was not as effective a drug carrier as 
expected and more tests are required to understand this phenomenon.   
8.3.5 CIT-NpS Cytotoxicity under Pulsed Laser Exposure 
Another reason that the CIT-NpS was not as effective as the free Gem-TA drug 
could be that drugs were so tightly bound to silver that they did not interact with cells in 
the same way as free drugs. To test this theory, again MTS assays were run on L3.6pl 
cells that were mixed in separate wells with the CIT-NpS and a-EGFR/mPEG-SH 
conjugated silver nanoplates in media. Light energy of various fluences, 1000 pulses of 
laser irradiation at peak nanoplate resonances, were exposed to the wells to determine if 
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photoacoustic laser pulses could be used to trigger drug release from the silver nanoplates 
and enhance therapeutic efficacy. Unfortunately, cell viability at 48 hr post laser exposure 
remained constant for all conditions tested, as shown in Fig 8.9. This result raises three 
considerations. First, it is inconclusive whether these laser pulses enhanced drug delivery. 
The same MTS assay was repeated for an incubation period of 24 hr (data not shown), 
and losses in cell viability were only barely apparent at that early stage. Thus, since Gem 
takes so long (at least 48 hr) to exhibit anti-proliferative effects, this test likely cannot 
accurately measure if drugs were dropped in the 48 hr period by the laser in the beginning 
or by cell activity slightly later. Conjugation of a fast-acting drug to silver nanoplates and 
using them in combination with a different assay that can measure cell death would be a 
better way of testing whether laser pulses can trigger drug release. Secondly, 
photoacoustic laser pulses had no cytotoxic effect. For example, the cells exposed to only 
a-EGFR/mPEG-SH conjugated silver nanoplates in media were at least as viable as 
controls regardless of laser energy. Lastly, for the cases where a-EGFR/mPEG-SH 
conjugated silver nanoplates were used, they were all more viable than controls. This 
observation gives credence to the discussion in section 8.3.4 about how silver is 
somehow enhancing cell viability relative to controls. Therefore, while this test did not 
show triggered drug release, it did prove that photoacoustic pulsed irradiation of 
nanoplates had no toxic effect on cells.  
8.3.6 CIT-NpS Cytotoxicity under Continuous Wave Laser Exposure 
Even though the CIT-NpS was not as effective a drug carrier as expected, it was 
an excellent photothermal agent. In this test, the MTS assay was used on pancreatic 
cancer L3.6pl cells after incubation with a-EGFR/mPEG-SH conjugated silver nanoplates 
in media. The MTS assay measured cell viability 48 hr post continuous wave laser 
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exposure. As shown in Fig 8.10, significant hyperthermic effects were prevalent starting 
at 2 min of laser exposure. Therefore, a-EGFR targeted silver nanoplates interacted with 
cells, continuous wave lasers were used to heat the area surrounding the nanoplates, and 
this heat caused significant cell damage. When targeted to cancer cells, this photothermal 
damage strategy can be highly effective using silver nanoplates.  
8.3.7 CIT-NpS Stability 
Using Ag nanoplates for any type of biological or imaging contrast agent 
application requires that they are stable in saline solutions. While Ag has excellent optical 
properties for use as a sensor, it is silver’s lack of stability in salt solutions that has 
largely limited its use in biomedical applications. As shown previously,15 when Ag 
nanoplates are built, the face of the plate takes on the lowest possible energy surface, the 
(111) plane. A high resolution transmission electron micrograph (TEM) of a silver 
nanoplate face is shown in Fig 8.11a. The electron diffraction pattern from that same 
nanoplate face is shown in Fig 8.11b where the first ring of intense spots can be attributed 
to the (220) Bragg reflections with a lattice spacing of 1.44 Å. This nanoplate surface is 
most unstable at the tips where its electromagnetic field enhancements are greatest.16 
Usually it is the loss of these tips that causes the longitudinal surface plasmon resonance 
(LSPR) peak to left-shift (to lower wavelengths, also termed blue-shift), even when Ag 
nanoplates are suspended in water over time. Therefore, the synthesis technique 
employed for silver nanoplates synthesis purposefully did not generate perfect Ag 
nanoplates tips, but instead allowed for rounded tips as shown in Fig 8.11a to be 
produced. The loss of the tips happened twice in the protocols presented. The first 
rearrangement of atoms on the silver surface happened during the wash step when Ag 
nanoplates were removed from their growth media. Centrifuging is a technique known to 
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left-shift the resonance peak of Ag nanoplates.17 Secondly, the nanoplates are kept in foil 
at room temperature overnight in water prior to use. The nanoplates do left-shift ~40-50 
nm while sitting overnight in water. However, they stabilize after that and can be kept in 
water without shifts in resonance for up to two weeks at 4°C.   
 Employing a synthetic method that generated rounded nanoplate tips was only 
the first step to solving the stability issue. Even Ag nanoplates with rounded tips will 
degrade and dissolve in salt solutions without additional passivation. Fortunately, grafting 
molecules like antibodies and PEG to the surface of silver further passivated the 
nanostructure. As shown in Fig 8.12, silver nanoplates can be kept for days in media at 
37°C in a humidified incubator with little change in resonance. Comparing the data from 
Figs 8.12a and 8.12b, silver nanoplates with Gem-TA conjugated were less stable than 
silver nanoplates with only a-EGFR and mPEG-SH. Thus, drug conjugation can make the 
nanoplates less stable.  
Interactions with cells strongly affected nanoplate stability. In the graphs shown 
in Figs 8.12c and 8.12d, two different cell lines were mixed with ~1.5x1011 nanoplates 
per ml in media. These wells were not exposed to laser irradiation. They were left to 
incubate with the cells for up to 96 hr; UV-vis spectra of the wells were taken at various 
time points. Interestingly, the L3.6pl cells caused a 100 nm left shift in the spectrum, 
indicating that silver was degrading and the aspect ratio of its longitudinal to transverse 
dimensions was decreasing. Correspondingly, the peak at ~400 nm in Fig 8.12c at 46 hr 
indicates that formation of silver nanospheres increased over time. Conversely, the non-
cancerous HPNE pancreatic cell line caused no such left shift in the spectrum (Fig 8.12d). 
Instead, the significant loss in the longitudinal peak was caused by cell induced 
aggregation of silver. Correspondingly, no increase in the peak at 400 nm associated with 
formation of silver nanospheres was observed. These results suggest that (1) silver can be 
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degraded by cells and (2) that silver could be used as a sensor for cell interaction. The 
cells that overexpress a-EGFR, such as L3.6pl cells, will interact with the silver, 
ultimately causing a left shift in the spectrum that can be detected using photoacoustic 
techniques. Thus, silver nanoplates could be used to sense cellular interactions non-
invasively, in vivo.  
Using silver nanoplates as a sensor will only be possible if photoacoustic laser 
pulses do not also induce shape changes in the silver. Photoacoustic laser pulses last 4-6 
ns and can deposit so much energy in a nanoparticle that it transiently heats to hundreds 
of degrees Celsius.18 Since nanoparticle melting temperatures can be hundreds of degrees 
lower than the bulk metal’s melting temperature, nanoparticles can melt and change 
shape in response to photoacoustic laser pulses. To test the structural stability of Ag 
nanoplates to these laser pulses, PEGylated silver nanoplates were suspended in media 
and placed in a black 96 well plate. The wells were subjected to 1000 pulses of varying 
laser fluences. Unfortunately, even the smallest laser fluence tested (2.5 mJ/cm2) had a 
left-shifting effect on the silver nanoplates as shown in the UV-vis spectra in Fig 8.12e. 
Furthermore, two sizes of silver nanoplates were tested in this manner, one S3 batch and 
one S4 batch corresponding to Figs 8.12e and 8.12f, respectively. Both batches 
demonstrated instability in response to laser irradiation (note that the 5 mJ/cm2 plot in Fig 
8.12f is not missing, but directly under the 10 mJ/cm2 plot). Therefore, silver nanoplates 
should be stabilized if they are to be used for photoacoustic imaging in vivo. One method 
of stabilization already proposed for gold nanorods is silica coating. The connection 
between silica and gold makes it more difficult for the surface atoms to rearrange under 




A thiolated version of Gemcitabine, Gemcitabine-Thioamide, was synthesized 
and successfully grafted to silver nanoplates. By grafting a-EGFR, Gem-TA, and mPEG-
SH in sequence, the final CIT-NpS was built. Surprisingly, the CIT-NpS’s performance 
as a drug carrier was seemingly not as effective as that for the free drug. Methods for 
accurate quantification of drug on the nanoplate surface are needed to allow for direct 
comparison with free drugs; however, the CIT-NpS showed slightly less therapeutic 
efficacy in the cell viability assay performed. Cell viability assays performed with cells 
exposed to silver nanoplates and photoacoustic laser pulses showed that photoacoustic 
pulses caused no toxicity to cells. However, silver nanoplates exhibited instability under 
pulsed laser irradiation. Therefore, techniques to stabilize their structure, such as silica 
coating, are needed. Finally, silver nanoplates were excellent photothermal agents, 
causing cell death after 2 min of continuous wave laser exposure. Overall, the nanoplates 
have potential since they can interact with cells for photothermal therapy applications as 
well as sensor applications. The LSPR of silver nanoplates left-shifted in response to 
interactions with pancreatic cancer cells; while normal pancreatic cells caused a decrease 
in resonance, but no left or right shift. These shifts are indicative of cellular interactions 
with nanoparticles that can be detected non-invasively in vivo using photoacoustics. 
Therefore, silver nanoplates can be employed as a degradable, cellular sensor. In 
summary, though the CIT-NpS is moderately effective as a drug carrier; the 
multifunctional aspects of its design make it an excellent nanoplatform with possible uses 
as a photothermal agent and degradable sensor.  
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Figure 8.1: Reaction scheme for thiolating Gemcitabine to create Gemcitabine-






Figure 8.2:    Mass Spectroscopy results showing formation of the Gem-ATA prodrug. 
The large peaks at 496.25 and 518.17 m/z are unreacted Gem and SATA 









Figure 8.3:    NMR of Gem (top) and the Gem-ATA prodrug (bottom). The H shifts that 
are most noteworthy for Gem-ATA formation are the CH6, CH5, and CH1 
as labeled in blue, green, and purple, respectively. The Gem-ATA spectrum 
shows major shifts in the doublet peaks associated with the CH6 and CH5 
hydrogens. The CH1 position shows two overlaid triplets in the Gem-ATA 





Figure 8.4:    UV-vis spectrographs showing (a) the difference in the supernatant after 
conjugation to Ag nanoplates for a Gem-ATA reaction staged with HA and 
without HA, and (b) Ag nanoplates after conjugation of antibodies and 
Gem-TA prodrugs. 
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Figure 8.5:    Energy-dispersive X-ray spectroscopy results captured using a scanning 
transmission electron microscope showing a silver nanoplate (a) with an 
elemental map of the elements Ag (b), F (c), and S (d). The coregistry of F 
and S with the location of the silver nanoplate in the image shows that Gem-





Figure 8.6:   X-ray photoelectron spectroscopy results showing the detection of F 1s at a 
binding energy of 688 eV on the surface of a silver nanoplate sample 





Figure 8.7:   A comparison of L3.6pl cell viability after 48 hr of incubation with various 






Figure 8.8:    A comparison of L3.6pl cell viability after 48 hr of incubation with various 
drug concentrations either attached to silver nanoplates (Ag-Gem-TA) or 






Figure 8.9:    A comparison of L3.6pl cell viability after 1000 laser pulses at various light 
fluences. Cell viability was measured 48 hr after pulsed laser exposure for 
cells mixed with nanoplates conjugated to EGFR (Ag-EGFR) or nanoplates 
conjugated to EGFR and Gem-TA (Ag-EGFR-Gem-TA, 300 nM Gem-TA). 
The concentration of Ag nanoplates was kept constant for each condition at 





Figure 8.10:  Cell viability results for L3.6pl cells mixed with EGFR conjugated silver 
nanoplates (1.5x1011 nanoplates per ml of media) at 48 hr after exposure to a 





Figure 8.11:  High-resolution transmission electron microscope of one Ag nanoplate (a) 






Figure 8.12: Ultra-violet to visible (UV-vis) spectrophotometry results depicting various 
aspects of silver nanoplate stability with either time or pulsed laser 
exposure. The UV-vis with time for drug loaded (a) versus non-drug loaded 
nanoplates (b) kept in media at 37°C for 96 hr; the UV-vis with time for 
non-drug loaded, but EGFR conjugated nanoplates mixed with either L3.6pl 
cells (c) or HPNE cells (d); the UV-vis directly after 1000 laser pulses at 
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Chapter 9: Conclusions and Future Work 
9.1 MOTIVATION 
Pancreatic cancer remains an unsolved health problem, with conventional cancer 
treatments having little impact on disease course. In the United States, pancreatic cancer 
represents the fourth leading cause of cancer-related deaths.1 In fact, for all stages of 
pancreatic cancer combined, the 5 year survival rate remains at a low 5%, making it 
arguably the most lethal of all solid tumors.2 Chemotherapy is a common treatment for 
pancreatic cancer, but survival benefits from those treatments are measured only in 
months.2, 3 The most effective drugs that have formed the basis of chemotherapeutic 
treatment for pancreatic cancer have been 5-fluorouracil (5-FU) and the more recently 
approved gemcitabine (Gem).2 As with most chemotherapeutic regimens, treatment 
involves systemic intravenous injections. The concentration of Gem used per session is 
dose-limited by its cytotoxic effect on healthy bone marrow and epithelial tissue.4 Some 
hypothesize that the systemic approach is ineffective for most patients because drug 
concentrations accumulated within the tumor itself are not high enough to realize their 
estimated therapeutic potential.5  
The objective of this thesis was to create tools to improve and better understand 
chemotherapeutic treatment of pancreatic cancer. Thus, nanosystems were designed with 
a dual purpose: to carry Gem and act as imaging contrast agents for photoacoustic 
imaging. The strategy is that packaging drugs into nanosystem delivery vehicles will 
make treatment more effective. Furthermore, synthesizing the nanosystems to be 
multifunctional imaging contrast agents also facilitates visualization of drug delivery, 
allowing clinicians to assess whether proper doses of drug arrived at the diseased site. 
Toward this end, the combined imaging and therapy nanocage system (CIT-NS) and the 
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combined imaging and therapy nanoplate system (CIT-NpS) were designed, synthesized, 
and characterized in this work. Specifically, Chapters 2 and 6 explained the design of 
each nanosystem in depth. Chapter 3 and 7 demonstrated that both nanosystems could act 
as imaging contrast agents for photoacoustic imaging in ex vivo and in vivo scenarios. 
Finally, Chapters 4, 5 and 8 demonstrated that synthesis of these nanosystems as drug 
carriers and imaging contrast agents was possible. Throughout each chapter, discussions 
of the advantages and limitations of each respective system was presented; additionally, a 
critical overview and comparison of these nanosystems from a clinical perspective is 
provided below.  
9.2 THE CIT-NS VERSUS THE CIT-NPS: CLINICAL RELEVANCE  
The CIT-NS and the CIT-NpS are complex nanosystems built as drug carriers and 
photoacoustic imaging contrast agents. The clinical advantage of these systems could be 
the ability to visualize drug delivery to pancreatic cancer in vivo, non-invasively. 
Furthermore, the nanosystems can act as both photothermal therapy agents and as IR-
sensitizing agents, providing clinicians even more therapeutic options.  
The ideal CIT-NS consisted of a polymer core of poly(lactic-co-glycolic) acid 
(PLGA) with encapsulated drugs covered with a nanocage of silver. Targeting and 
stabilizing agents were grafted to the exterior of the nanosystem (Chapter 2, Fig 2.1). The 
CIT-NS incorporating the model drug doxorubicin (DOX) was successfully synthesized 
(Chapter 4). Analysis of the in vitro properties of the system, such as control over the 
drug release profile and broad extinction in the near infrared spectrum, indicate that the 
nanosystem has potential for in vivo applications. However, encapsulation of gemcitabine 
(Gem) or a Gem prodrug (Gemcitabine-N4 Oleoyl Amide) in PLGA was unsuccessful 
(Chapter 5). Therefore, different encapsulation methods will be required for successful 
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encapsulation, or a different chemotherapeutic drug for treatment of pancreatic cancer 
can be used. One such drug, paclitaxel (Taxol), is known to be effective against 
pancreatic cancer and has been shown to encapsulate in PLGA nanoparticles.6 Other 
solutions to this problem could involve updating the CIT-NS design. For instance, the 
polymer used for encapsulation could be changed to one unaffected by Gem, or 
liposomes7 could be used as the core of the CIT-NS. New designs for the CIT-NS could 
also be considered that incorporate silver and Gem without the polymer, such as the CIT-
NpS.  
The CIT-NpS consisted of a silver nanoplate with a targeting antibody, a Gem 
prodrug, and poly(ethylene glycol) (PEG) molecules grafted to its surface (Chapter 6, Fig 
6.1). Preliminary results indicated that silver nanoplates were excellent photoacoustic 
imaging contrast agents (Chapter 7). They were easily synthesized to absorb light from 
the visible to the near infrared spectrum. Finite difference time domain (FDTD) modeling 
confirmed that they have absorption cross-sections comparable to, and in some cases 
greater than, conventional gold contrast agents. Silver nanoplates bioconjugated to 
antibodies showed effective cell labeling and uptake in a subcutaneous tumor model of 
pancreatic cancer in vivo. Surprisingly, the performance of CIT-NpS as a drug carrier was 
seemingly not as effective as that for the free drug (Chapter 8). Methods for accurate 
quantification of drug on the nanoplate surface are needed before a precise comparison 
can be made; however, the CIT-NpS showed slightly less therapeutic efficacy in the cell 
viability assay performed. Cell viability assays performed with cells exposed to silver 
nanoplates and photoacoustic laser pulses showed that photoacoustic pulses caused no 
toxicity to nanoparticle-labeled cells. Finally, silver nanoplates were excellent 
photothermal agents, causing cell death after 2 min of continuous wave laser exposure. 
Overall, though the CIT-NpS is moderately effective as a drug carrier, the multifunctional 
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aspects of its design make it an excellent nanoplatform with possible uses as a 
photothermal agent and degradable sensor.  
9.2.1 Nanosystem Size and Drug Loading  
 The CIT-NpS may be superior to the CIT-NS since it has the advantages of 
higher absorption cross section per particle, sharper and more defined LSPR peaks, 
simplified synthesis, and smaller size that allows for better accumulation and intracellular 
trafficking at a tumor site. However, the large disadvantage of the nanoplate system is its 
reduced drug loading capacity compared to the CIT-NS. Achieving a clinically effective 
dose using the CIT-NS is feasible; while the loading of Gem-TA in the CIT-NpS at 300 
nM concentrations for ~1.5x1011 nanoplates/ml cannot provide a similar dosage without 
the injection of excessive amounts of silver. However, the use of other drugs such as 
Taxol, that require much lower clinical dosages, should be considered for both 
nanosystems to enhance clinical relevance. Furthermore, the CIT-NpS is more difficult to 
stabilize due to its high-energy surface that is prone to dissolution and side reactions if 
not properly passivated. Therefore, a critical design consideration for drug carrier 
nanosystems in general is the tradeoff between size, drug loading, and stability.  
9.2.2 Triggered Drug Release 
Triggered drug release was not definitely proven for either nanosystem. The cell 
viability assays used in combination with the CIT-NpS were not definitive. Furthermore, 
inducing shape change of the CIT-NS system using pulsed lasers was attempted (data not 
shown) and no shape change was observed. However, using different tests, it is still 
possible to drop drugs using lasers as has been shown with other nanosystems.8-10 For 
instance, it is likely that the pulsed laser used for these tests did not facilitate drug release 
from the CIT-NpS or shape change of the CIT-NS. Continuous wave lasers that create 
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sustained heating of the nanosystems could create considerable drug detachment, 
however. Conjugating dyes or other fast-acting drugs to the nanosystems could provide 
better experimental conditions for drug release testing. Performing the pulsed laser tests 
again with those molecules in the nanosystems would provide more definitive proof of 
triggered drug release.    
9.2.3 Nanosystem Stability 
Nanosystem stability in biological solutions is a critical parameter for clinical 
application of the investigated system. The CIT-NS shape and optical properties were 
stable under all conditions tested; however, the CIT-NS has a short shelf life because its 
large size leads to aggregation in solution. The nanoplate system has longer shelf life (up 
to two weeks), but suffers from other types of instability. The CIT-NpS exhibited shape 
instability under pulsed laser irradiation; therefore, techniques to stabilize nanoplate 
structure, such as silica coating11, are needed. A preliminary experiment was performed 
to assess the feasibility of coating PEGylated silver nanoplates with silica. The silica 
coating was performed using the addition of tetraethyl orthosilicate under basic 
conditions as previously reported.12 Energy-dispersive X-ray spectroscopy (EDS) 
mapping measurements of a silica-coated silver nanoplate is shown in Fig 9.1. Signals for 
Si and Ag map onto the nanoplate, however, the nanoplate was unstable under the 
electron beam and was degraded during the measurement. This degradation likely 
happened because the particles were not sufficiently cleaned from the buffer before drop 
casting on TEM grids. Nonetheless, this preliminary experiment showed that silica 
coating is possible. Testing of enhanced stability of silica-coated silver nanoplates under 
pulsed laser irradiation is a next step for future work.   
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In addition to instability under pulsed laser irradiation, the CIT-NpS was also 
unstable upon prolonged cell exposure. This instability is an exciting finding since it 
infers that silver nanoplates could be used as a cellular biosensor (Chapter 8). For 
example, the LSPR of silver nanoplates left-shifted in response to interactions with 
pancreatic cancer cells; while normal pancreatic cells caused a decrease in resonance, 
with no left or right shift. These shifts are indicative of cellular interactions with 
nanoparticles and can be detected in vivo, non-invasively using photoacoustics. 
Therefore, silver nanoplates can be employed as a cellular sensor.  
Nanoplate instability with prolonged exposure to cells in vitro also indicates that 
silver is degradable. Silver nanoplates as a non-toxic, biodegradable sensor could be an 
exciting discovery for imaging diagnostics applications. However, in vivo tests using 
silver showed significant accumulation of silver after systemic injection in the tumor, 
liver, spleen, and feces. Thus, organ specific toxicity associated with degradation of silver 
in the liver and spleen must be addressed prior to widespread adoption as a photoacoustic 
imaging contrast agent. Accumulation of silver in feces following systemic injection 
suggests that this is one mechanism of clearance.  
Overall, instability of the nanoplate system presents both advantages and 
disadvantages. Instability in response to pulsed laser irradiation could degrade 
photoacoustic signals. However, future work on silica coating of the nanoplates could 
alleviate this concern. Instability in response to the cellular environment could provide 
significant opportunities such as using the nanoplates as exogenous, biodegradable 
sensors.   
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9.2.4 Silver versus Gold 
Finite difference time domain (FDTD) simulations performed using Lumerical 
software corroborates earlier fidnings13 that longitudinal surface plasmon resonances 
(LSPR) of silver are stronger and sharper than gold (Fig 9.2). However, for photoacoustic 
imaging enhancement, it is the absorption cross section of the nanoplate that is most 
important. For plate sizes with aspect ratios below 90 nm edge length by 12 nm 
thickness, the absorption cross-section of silver nanoplates exceeds that of gold. 
However, as illustrated in Fig 9.2, as the plate aspect ratio increases, the absorption cross-
section for the gold nanoplates exceeds that of silver. Therefore, at higher resonance 
wavelengths, gold is more advantageous to use as a photoacoustic contrast agent 
(assuming a nanoplate shape). Since the absorption cross section of silver and gold vary 
with respect to size, the best metal to use for nanosystems like the CIT-NS and CIT-NpS 
will partially depend on the spectral range in which imaging will be conducted.  
An even more important factor than the optical properties of silver versus gold, is 
the biological reaction to one metal or the other. The biocompatibility of gold has been 
well documented.14-16 However, complete clearance of gold from the body is unlikely. 
Silver has been documented as toxic17, 18 in the form of a salt (silver nitrate) or small 5 
nm spherical shapes. Results presented here contradict those findings for silver. In fact, 
for the five cell lines tested (2 pancreatic cancer lines, 1 breast cancer line, and 2 normal 
pancreatic lines), silver nanoplates could not be concentrated to a level that showed 
cytotoxic effects using the MTS assay. Therefore, a size dependent toxicity of silver 
nanoparticles might exist; but the topic requires further exploration. Assuming that silver 
is not as toxic in nanoplate form, the real difference between silver and gold is 
biodegradability. The instability of silver in the body could be used to advantage in 
cellular sensor applications with this metal. Therefore, using silver versus gold in 
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nanosystems like the CIT-NpS is not a clear choice. Nanosystem stability, LSPR effects, 
and biocompatibility should all be considered in the design.   
9.3 FUTURE DIRECTIONS FOR NANOSYSTEMS TO TREAT AND IMAGE PANCREATIC 
CANCER 
This thesis focused on packaging Gem in or on nanosystems for treatment of 
pancreatic cancer with some success. Drugs like Taxol are several times more effective in 
killing pancreatic cancer cells in vitro than Gem. However, Taxol has never been 
approved for pancreatic cancer treatment because the dose required for systemic 
injections is overly toxic to healthy tissue. A potent drug like Taxol that shows promise 
therapeutically in cell culture is a perfect candidate for nano-vehicle delivery. 
Nanosystems have the potential to deliver drugs to diseased tissue while leaving healthy 
tissue largely unaffected. Therefore, testing this potential using nanosystems like the 
CIT-NS or CIT-NpS with encapsulated Taxol would be an excellent topic for future 
work. 
A major contributor to the lack of chemotherapeutic efficacy in pancreatic cancer 
is the tumor’s underdeveloped vascular system. Drugs do not reach the tumor in high 
enough concentrations to be beneficial since the vasculature is not robust. Furthermore, a 
pancreatic cancer mass actually has very few pancreatic cancer cells. Pancreatic cancer 
cells induce the formation of stromal cells in the tumor area, and these stromal cells form 
the bulk of most pancreatic cancer masses. Therefore, a two-pronged strategy might be 
needed to achieve a therapeutic benefit using nanoparticles as drug delivery vehicles to 
fight pancreatic cancer.  
Nanosystems still have to use the existing vasculature to be delivered in large 
quantities to the tumor. Ultrasound can assist in this process. Therefore, the first part of 
the strategy would employ highly focused ultrasound to create pores in the existing 
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vasculature of the tumor after systemic nanoparticle injection. This procedure will allow 
for increased accumulation of the nanosystem in the tumor. The second part of the 
strategy would use nanosystems with grafted antibodies meant to target receptors on the 
surface of stromal cells in the mass, rather than upregulated receptors on the surface of 
pancreatic cancer cells. No such antibody target for stromal cells has been created that 
would be specific to the stromal cells generated in pancreatic cancer, but researchers in 
the Pancreatic Cancer Research Group at M.D. Anderson Cancer Center are actively 
searching for them.  
Lastly, accurate animal models of pancreatic cancer are needed to test if these 
nanosystems have potential in humans. The best model available to date is an orthotopic 
pancreatic cancer mouse model. The work presented here showing in vivo uptake of 
silver nanoplates in a mouse model of pancreatic cancer was a subcutaneous model. The 
vasculature formed in subcutaneous models is different than that formed in orthotopic 
models.  Therefore, future work using orthotopic pancreatic cancer mouse models to test 
the efficacy of Taxol loaded nanosystems targeted to stromal cells is an excellent future 
project. Attempts to deliver gold nanospheres to orthotopic pancreatic tumors in mice has 
shown some success,19 so this approach is promising.  
9.4 SUMMARY OF CONTRIBUTIONS TO THE FIELD 
The originality of this thesis is given by the study of the CIT-NS and CIT-NpS, 
which represent compositions of matter never before tested nor designed. The methods of 
synthesis and characterization outlined in this work will allow future researchers to 
recreate or build upon the current designs. Although explanations provided here focus on 
applicability of these nanosystems for pancreatic cancer, the nanosystems are platform 
technologies, from which several types of cancer could be treated and imaged. Also 
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introduced here is the idea of using nanotechnology to help visualize drug delivery. The 
combination of photoacoustic imaging with these nanosystems presents a new tool for 
clinicians. Better imaging of the tumor and quantification of drug delivery are both 
possible with this technique.  
Also described in this thesis were steps towards understanding silver 
nanostructures, which revealed several new findings that contradict current literature. For 
instance, passivated silver nanostructures are non-toxic to several cancerous and non-
cancerous cell lines. Furthermore, silver is biodegradable and could be considered instead 
of gold for applications such as photothermal therapy and noninvasive cellular sensing. 
Although future research is required to fully investigate the clinical potential of these 
systems for pancreatic cancer, the work presented in this dissertation is a significant step 
towards creation of multifunctional nanosystems that will enable photoacoustic imaging 






























Figure 9.1: Energy-dispersive X-ray spectroscopy results captured using a scanning 
transmission electron microscope showing a silica-coated silver nanoplate 
(a) with an elemental map of the elements Si (b) and Ag (c). The coregistry 
of Si and Ag with the location of the silver nanoplate in the image shows 





Figure 9.2:   Finite difference time domain (FDTD) modeling of the extinction, 
scattering, and absorption cross-sections for 90x12 nanoplates (a), 128x12 
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